Drug, bio-affecting and body treating compositions inventions 06/06

20060140856 - Skeletal-targeted radiation to treat bone-associated pathologies: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such...

20060140857 - Method of the administration of drugs with binding affinity for plasma protein and preparation to be used in the method: A method of the administration of drugs with binding affinity for plasma protein and drugs regulating the effective ingredient dose of drugs with binding affinity for plasma protein; and a preparation whereby the effective ingredient dose of drugs with binding affinity for plasma protein is regulated. The above administration method...

20060140858 - Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s): The present invention relates to targetable constructs which may be bound by a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds the targetable construct. The targetable construct comprises a carrier portion which comprises...

20060140859 - Imaging agents for early detection and monitoring of cardiovascular plaque: The present invention relates in part to a method of imaging cardiovascular plaque formation in a mammal comprising administering to the mammal an effective amount of 18F-2-fluorodeoxy-D-glucose and then detecting the 18F-2-fluorodeoxy-D-glucose....

20060140860 - Computational knowledge model to discover molecular causes and treatment of diabetes mellitus: In one aspect, the invention comprises a method of developing an immunosuppressant drug with reduced propensity to induce type II diabetes mellitus symptoms by assaying candidate molecular entities for binding preferentially to leukocyte isoform calcineurin and less preferentially to muscle cell isoform calcineurin. In another aspect, the invention comprises a...

20060140861 - Method for diagnosing lactose intolerance and diagnostic kit for performing the method: The method for diagnosing lactose intolerance in patients by the oral administration of defined amounts of lactose, followed by assaying metabolites of lactose, is performed in a way where the lactose administered contains 99% 13-labeled lactose, preferably from 5 to 30 mg, and after the administration of the 13C-lactose, the...

20060140862 - Fish hatching method and apparatus: The invention is a method and kit for conducting a rapid toxicity test. Methods and kits according to the invention include an animal or plant species in diapause....

20060140867 - Coated stent assembly and coating materials: A high magnetic susceptibility nanomagnetic material that may be attached to recognition molecules and other therapeutic biological materials so as to be targeted to specific biologic tissues, thereby enabling the presence of the targeted tissue to be detected under magnetic resonance imaging with much greater sensitivity. Also a stent coated...

20060140868 - Method of preparation of biomagnetic nanoparticles coated with a noble metal layer: A method for the preparation of magnetic nanoparticles coated with a noble metal is described. The method includes providing a first mixture containing a first non-polar organic solvent and uncoated magnetic nanoparticles. The first mixture is mixed with a second mixture containing a second non-polar organic solvent and ions comprising...

20060140869 - Polymeric contrast agents for use in medical imaging: A contrast agent comprising a polypeptide is provided. The polypeptide contains lysine residues and optionally, one or more types of amino acid residues selected from the group consisting of glutamic acid residues and aspartic acid residues, wherein the lysine residues are substituted with a group derived from a steric hindrance...

20060140871 - Magnetic resonance imaging of prostate cancer: Paramagnetic or superparamagnetic nanoparticle-ligand conjugates that include a recognition ligand that interacts with a component on the surface of a prostate cancer cell. Nanoparticle-ligand conjugates of the invention may be used for magnetic resonance imaging of prostate cancer, or for treatment of tumors by targeted thermal ablation....

20060140870 - Method for assessing tumor response to cancer treatment: A method for measuring tumor response to a cancer therapy is provided. The method comprises the steps of injecting a polymeric contrast agent in a subject; obtaining a series of magnetic resonance image signals of the contrast agent in the tumor for up to about 60 minutes; and determining a...

20060140866 - Agents for treating neurodegenerative disorders: m

20060140865 - Nano-micelle carrier used in near infrared image detection and detection method thereof: A nano-micelle carrier used in near infrared image detection. The carrier includes a nano-micelle comprising a plurality of block copolymers having critical micelle concentration (CMC) and a near infrared dye grafted onto the micelle surface, wherein the carrier has a hydrophobic interior and a hydrophilic surface. The invention also provides...

20060140864 - Oral contrast and method of producing the oral contrast: Oral contrast compositions are used as an aid for CAT scans and are ideally fast-flowing and good tasting for assisting in quick preparation of a patient in today's extremely active and busy emergency rooms. An oral contrast used for CAT scans of the esophagus, stomach, duodenum, jejunum, small intestines, colon...

20060140863 - Production of a dye agent for colouring cells in the human or animal body: Use of a biocompatible dye, for example patent blue V or brilliant blue R, for the production of a dye agent for non-cytotoxic visualisation of cells, in particular delimiting or separating membranes in the human or animal body, in particular in the eye....

20060140873 - Aerosol pharmaceutical compositions: A suspension aerosol composition suitable for use in pressurized metered dose inhalers has improved post-shaking suspension stability and comprises predetermined amounts of an active pharmaceutical ingredient (API) insoluble in the composition, a propellant comprising a hydrofluoroalkane (HFA), and a pharmaceutically acceptable non-aminated C1-6 organic acid....

20060140872 - Novel signaling pathway for the production of inglammatory pain and neuropathy: This invention relates to a remedy for treating allergic contact dermatitis containing a substance having MEK inhibitory action as its effective component....

20060140875 - Semi-soft c-class immunostimulatory oligonucleotides: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C....

20060140874 - Stable aerosol formulations of peptides and protein with non-cfc propellants: Glycosidicaily stabilised macromolecules, such as proteins and peptides, have substantially greater stability in the presence of hydrofluoroalkane propellants for dispensing from metered dose inhalers, when formulated with polyhydroxylated polyalkenes such as PVA....

20060140876 - Buccal cavity treatment composition and corresponding uses thereof: Composition for treatment of the oral cavity and corresponding uses. The composition comprises the combination of a chlorhexidine derivative, for example chlorhexidine digluconate, with triclosan and a zinc salt, for example zinc lactate or citrate. Preferably the chlorhexidine digluconate is present in a concentration of between 0.01 and 0.2%, the...

20060140878 - Classified silica for improved cleaning and abrasion in dentifrices: A method of making precipitated silica abrasive compositions having excellent cleaning performance and lower abrasiveness with post-reactor sizing of the abrasive particles being performed via air classification techniques is provided. By targeting a specific particle size range, it has been determined that higher pellicle film cleaning levels may be achieved...

20060140877 - Methods of producing improved cleaning abrasives for dentifrices: A method of making precipitated silica abrasive compositions having excellent cleaning performance and lower abrasiveness with post-reactor sizing of the abrasive particles being performed via air classification techniques is provided. By targeting a specific particle size range, it has been determined that higher pellicle film cleaning levels may be achieved...

20060140881 - Oral care compositions containing flavonoids and flavans: Oral care compositions containing: a free-B-ring flavonoid and a flavan; as well as at least one bioavailability-enhancing agent are provided. Methods of using the oral compositions are also provided....

20060140880 - Oral compositions containing biphenol antibacterial compounds: Antiplaque oral compositions are provided that contain an orally acceptable carrier and an antibacterial effective amount of the compound of formula (I). In various embodiments, the compositions contain from about 0.001% to about 10% by weight of the compound of formula (I)....

20060140879 - Two phase toothpaste composition: An oral care composition having a first phase of clinically efficacious 2,4,4′-trichloro 2′-hydroxydiphenyl ether admixed in a first orally acceptable aqueous vehicle, and a second phase having a stannous salt (such as stannous fluoride) admixed in a second orally acceptable aqueous vehicle. The second phase has no less than 10...

20060140882 - Two phase whitening oral care composition: An oral care (toothpaste) amalgam composition has first and second aqueous phases. The first phase has a measured pH of from about 7 to about 9 and contains 2,4,4′-trichloro-2′-hydroxydiphenyl ether and a methylvinyl ether-maleic anhydride copolymer antibacterial-enhancing agent for the ether. The second aqueous phase has a measured pH of...

20060140885 - Method of reducing oral tissue inflammation using magnolia extract: A method for treating a mammal having oral tissue inflammation is provided, where the inflamed oral tissue is contacted with a safe, efficacious, non-irritating oral composition having an anti-inflammatory agent comprising a magnolia extract. The magnolia anti-inflammatory active ingredient reduces one or more mediators of inflammation and reduces inflammation in...

20060140883 - Oral care compositions containing a eucalyptus extract: Oral care compositions comprising an antibacterial effective amount of an antibacterial system comprising a substantially water insoluble, noncationic antibacterial agent and Eucalyptus extract and an orally acceptable carrier. Methods of inhibiting oral bacteria in the oral cavity of a human or other animal subject are also provided....

20060140884 - Oregano oral care compositions and methods of use thereof: A multi-benefit oral composition is provided. The oral composition is efficacious as an antibacterial, antiplaque, anti-inflammatory, anti-oxidant, and anti-halitosis oral composition. The active ingredient has one or more active compounds from an extract of oregano. The oral composition can be in the form of a mouth rinse; a dentifrice, including...

20060140887 - Hair conditioning composition: The present invention is related to a conditioning composition for hair comprising flavone derivatives and particularly on enhanced deposition of flavone derivatives onto hair. Accordingly, the compositions comprise at least one conditioning agent, at least one organic solvent, at least one flavone derivative and at least one hydroxycarboxylic and/or dicarboxylic...

20060140886 - Tanning aids: The invention relates to tanning aids comprising a polymethylmethacrylate moulded body, which contains between 0.1 and 1.5 wt. % of a UV-stabiliser comprising a 2,2,6,6 tetraalkyl piperidyl group, said stabiliser having a transmission of at least 95% when dissolved in MMA with a concentration of 1 wt. % at 330...

20060140888 - Whitening agent containing crystalline molecular complex of hydroquinone and surfactant: There are provided a hydroquinone-containing whitening agent having high storage stability and sustained release of hydroquinone, a process for production of the whitening agent, and a whitening method for skin which employs the whitening agent. The whitening agent of the invention comprises a crystalline molecular complex composed of hydroquinone or...

20060140889 - Affinity proteins for controlled application of cosmetic substances: Provided are means and methods for applying a cosmetic substance to a desired target. The method comprises providing a conjugate of a proteinaceous substance having a specific affinity for the target molecule linked to a cosmetic substance, whereby the resulting connection between the cosmetic substance and the target molecule can...

20060140890 - Oily solid cosmetic and method for production thereof: An oil-based solid cosmetic comprising (A) vitamin A and/or a fatty acid ester thereof, (B) silicic anhydride, (C) an oil-soluble antioxidant, and (D) an oily ingredient existing as paste and/or liquid at room temperature is disclosed. The aforementioned oil-based solid cosmetic, wherein the ingredient (B) is aerosol silicic anhydride, and...

20060140891 - Cosmetic composition: The invention provides a cosmetic composition, particularly a cosmetic composition for antiperspiration. The invention relates to a cosmetic composition comprising surface-hydrophobated water-absorbing polymer particles and an anti-perspiring component, as well as a cosmetic composition comprising water-absorbing polymer particles, an anti-perspiring component, and at least one member selected from the group...

20060140896 - Cosmetic compositions comprising at least one silicone copolymer in a aqueous emulsion and at least one thickener, and uses thereof: Cosmetic compositions comprising, in a cosmetically acceptable medium, at least one aqueous emulsion of at least one silicone copolymer with a dynamic viscosity ranging from 1×106 to 100×106 cP and at least one non-cellulose thickener. This combination can give cosmetic properties, such as at least one of smoothness, lightness, and...

20060140894 - Olefin wax, silicone-modified olefin waxes, silicone-base cold-setting compositions made by using the same, and cosmetics containing the same: An olefin wax (A) is (i) a copolymer (A1) obtained by copolymerizing ethylene and at least one diene or a copolymer (A2) obtained by copolymerizing ethylene, at least one olefin selected from α-olefins of 3 to 12 carbon atoms and at least one diene; wherein (ii) the content of unsaturated...

20060140895 - Two-part cosmetic product: There are provided two-part cosmetic products and methods for imparting a filling and swelling effect to skin, lips, hair, eyelashes, and/or eyebrows. The two-part cosmetic product has an anhydrous liquid or semi-solid first part composition with a water absorbent polymer, and a water-based second part composition with a water soluble...

20060140900 - Method for enhancing chroma of hair: There is provided a method for enhancing a chroma of hair which comprises the steps of shampooing the hair with a water-based shampoo containing (A) 5 to 20% by weight of an anionic surfactant, (B) 0.1 to 5% by weight of a water-insoluble modified silicone containing at least one of...

20060140897 - Biphasic inducing agent for aqueous cleansing compositions: The invention relates to the use of specifically defined agents that induce the formation of biphasic liquid cleansing compositions. In particular the biphasic inducing agents include water soluble, high-gel-point polysaccharides having a molecular weight greater than about 10,000 Daltons; fatty ester or fatty ether ethoxylates of intermediate ethoxylation; and mixtures...

20060140898 - Use of a combination of at least one associated polymer and at least one amphiphilic diblock copolymer for thickening cosmetic compositions: at least one associative polymer comprising at least one hydrophilic part and at least one C8-40 fatty chain, and at least one linear diblock block copolymer composed of a hydrophobic block and a hydrophilic block, with the proviso that the at least one linear diblock block copolymer is not chosen...

20060140893 - Assay of hair proteins: A process for detecting previous treatment of keratinous fibers with alkaline technology for hair straightening or smoothing includes: bringing the keratinous fibers into contact with an extraction solution under conditions effective to cause dissolution of keratin proteins; and conducting a qualitative and/or quantitative assay of the keratin proteins dissolved in...

20060140892 - Method for generation of memory effects on hair: Disclosed is a method for achieving a recallable hair deformation. A composition is applied onto hair, comprising at least one active agent, which, alone or in combination with further compounds, is able, after application to the hair and after carrying out the treatment of hair in accordance with the present...

20060140899 - Skin cleansing system comprising an anti-adherent formulation and a cationic compound: Cleansing systems and methods are disclosed for improving the cleaning of skin. The cleansing systems comprise a first product comprising an anti-adherent formulation and a second product comprising a cationic compound capable of binding contaminants located on the skin. The first product is wiped across the skin of a user...

20060140901 - Articles: An article for sequential dispensing of vapours, notably evaporable fragrances, comprises separated first and second liquids (22, 24). Liquid (22) issues first. Its evaporation may be assisted by a wick (26). The simultaneous evaporation of the second liquid is prevented by an intermediate liquid phase (20). As liquid (22) issues...

20060140902 - Odor control substrates: An odor control substrate that contains a plurality of fibers oriented in the z-direction is provided. At least some of the fibers contain portions that are exposed on an outer surface of the substrate. An odor control coating is applied to the substrate so that a majority of the coating...

20060140903 - Diagnoses and treatment of disorders using an alternative glucose pathway: This invention proposes the existence of an alternate glucose pathway different from that presently accepted and offers different methods of proving this. The proposed alternate glucose pathway considers the cerebral spinal fluid as a major component of the pathway. Based on this, a diagnostic tool for detecting mental disorders and...

20060140904 - Random alkylene oxide copolymers for medical and surgical utilities: Medical and surgical uses for random alkylene oxide copolymers have been discovered. Preferably, this is a biocompatible, non-metabolizable, non-toxic, and/or readily eliminated compound that has a viscosity which is adjustable for different utilities (e.g., from runny oil to thick grease). It is also preferable to formulate the compound as an...

20060140905 - Chemokine beta-7 variants: The present invention relates to deletion and substitution mutant polypeptides of human chemokine β-7 (Ckβ-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ckβ-7,...

20060140906 - Composition comprising cysteamine for improving immunity of animals: There is provided a new use of cysteamine, a salt thereof, or a composition containing cysteamine or a salt thereof, for improving immunity of animals....

20060140907 - Central airway administration for systemic delivery of therapeutics: The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of...

20060140909 - Method of using adenoviral vectors with increased persistence in vivo: The invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises slowly releasing into the bloodstream a dose of replication-deficient or conditionally-replicating adenoviral vector having reduced ability to transduce mesothelial cells and hepatocytes. The normalized average bloodstream concentration of the adenovirus over 24 hours...

20060140908 - Methods for inducing an immune response via oral administration of an adenovirus: The present invention provides a method for inducing an immune response to an adenovirus in a subject which has been pre-exposed to an adenovirus or adenoviral vector. The invention further provides a method for inducing a mucosal immune response to an antigen. The methods of the invention are carried out...

20060140910 - Recombinant adenoviral vectors and methods of use: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also...

20060140920 - Adenoviral vectors encoding an antibody fused to a cd4 extracellular domain: Genetically modified cell implant comprising an exogenous nucleotide sequence coding for all or part of an antibody, method for the preparation of such an implant and its therapeutic use for the treatment or prevention of an acquired disease. The invention also concerns an adenoviral vector for the expression of one...

20060140921 - Disimmortalizable mammalian chromaffin cell lines for cell therapy for pain: Cloned disimmortalizable mammalian chromaffin cell lines that express chromaffin cell phenotype/genotype are disclosed....

20060140922 - Universal gm-csf expressing bystander human k562 cell line: The present invention provides a universal immunomodulatory cytokine-expressing bystander cell line, a composition comprising such a cell line and a cancer antigen, a method of making such a cell line, and a method of using such a composition....

20060140911 - Bacteriophage for the treatment of bacterial biofilms: The present invention provides a composition for treating a bacterial biofilm, comprising a first bacteriophage that is capable of infecting a bacterium within said biofilm, and a first polysaccharide lyase enzyme that is capable of degrading a polysaccharide within said biofilm. The composition preferably further comprises a pharmaceutically-acceptable antimicrobial agent,...

20060140918 - Bioartificial device for propagation of tissue, preparation and uses thereof: The present invention relates to a device and corresponding methods for its use, in the propagation of tissue. The device comprises a bioartificial composite comprised of a substrate having at least one surface capable of the reception and growth promoting retention of a cellular preparation, and a first layer of...

20060140917 - Compositions and methods for selective dissolution of nascent intravascular blood clots: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots, which are capable of selective dissolution of pathological nascent clots formed intravascularly, with minimal risk of unwanted dissolution of pre-existing hemostatic clots, are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell...

20060140916 - Methods and compositions for treating congestive heart failure: Compositions and methods for treating congestive heart failure are provided herein....

20060140912 - Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients: This invention provides a method of achieving a higher rate of allogeneic hematopoietic stem cell engraftment by either (i) matching the major histocompatibility complex class I K locus between donors and recipients or (ii) identifying how class I K on HSC interact with FC (CD8/33Kd receptor complex) works thus allowing...

20060140919 - Methods for selectively stimulating proliferation of t cells: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors...

20060140913 - Regeneration initiating cells: Methods and compositions for treating hyperglycemia and pancreatic damage as well as stimulating the repair or regeneration of islet cells are disclosed....

20060140914 - Repairing or replacing tissues or organs: In general, this invention provides methods and compositions for stabilizing, repairing, or replacing damaged or diseased tissues or organs by engineering blood vessels in such tissues or organs. In addition, the invention further provides methods and compositions for producing functional microvascular networks useful in tissue engineering....

20060140915 - Veterinary protocol for cellular regeneration: A medicament and corresponding treatment protocol for in-vivo cellular regeneration within a mammal is described. Applications include the treatment of injuries to bone, cartilage, ligaments and tendons in humans and animals. Treatment includes the step of administering one or more therapeutically effective doses of medicament into an injured, living mammal....

20060140923 - Semi-synthetic platelet gel and method for the preparation thereof: A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. A method for preparing a semi-synthetic platelet gel comprising the steps of...

20060140924 - Composition and wipe for reducing viscosity of viscoelastic bodily fluids: The present invention provides a topical composition for application to the perianal and/or labial areas of the skin which helps prevent viscoelastic fluids, such as menses and feces, from attaching to the skin and aids in the reducing the viscoelastic properties of the fluid so that the fluid can flow...

20060140925 - Composition of biochemical compounds involved in bioenergy metabolism of cells and method of use: A composition of biochemical compounds involved in bioenergy metabolism of cells and a method of use in prevention and therapy of diseases are disclosed....

20060140926 - Mss4 as an antifungal target: The invention provides 1-phosphotidylinositol-4-phosphate 5-kinase (MSS4) as a novel antifungal target, screening methods for MSS4 inhibitors and their use as antifungal compounds, pharmaceutical compositions containing them and their use in medicine....

20060140927 - Cytochrome p450 enzyme complexes and methods of treatment using the same: The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture....

20060140928 - Use of heparinases to decrease inflammatory response: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized...

20060140929 - Modified hirudin proteins and t-cell epitopes in hirudin: The invention concerns hirudin and in particular modified forms of hirudin with improved properties. The improved proteins contain amino acid substitutions at specific positions. The invention provides modified hirudin with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in...

20060140930 - Promotion of central nervous system remyelination using monoclonal autoantibodies: Monoclonal IgM antibodies which promote central nervous system remyelination when given to a mammal afflicted with a demyelinating disease are disclosed. These antibodies show multi-organ autoreactivity, and recognize both surface and cytoplasmic determinants on glial cells....

20060140937 - B7-related nucleic acids and polypeptides useful for immunomodulation: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated...

20060140931 - Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment: The invention provides a bispecific molecule comprising an antibody that binds a C3b-like to one or more antigen-binding antibody fragments, each of which binds an antigenic molecule. The invention also provides methods of producing such bispecific molecules and to therapeutic uses of such bispecific molecules. The invention further provides bispecific...

20060140933 - Compositions and methods for treating rage-associated disorders: Fusion proteins comprising a Receptor for Advanced Glycation End Products Ligand Binding Element (RAGE-LBE) and an immunoglobulin element are disclosed. Also disclosed are fusion proteins comprising a RAGE-LBE and a dimerization domain. Also disclosed are nucleic acids encoding such fusion proteins and methods for using disclosed nucleic acids and proteins...

20060140932 - Human il-1 beta antagonists: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low kooff values), reduced deamidation compared to the native antibody, and can be used to treat various diseases such as rheumatoid arthritis,...

20060140936 - Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer: Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a...

20060140934 - Modified fc molecules: The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one peptide that modulates the activity of a protein of interest;...

20060140935 - Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof: The present invention provides compositions and methods for treating or preventing vascular-associated disorders....

20060140940 - Anti-hgf-r antibodies and their use: The present invention relates to monoclonal antibodies which recognize the chain of the HFG receptor with the agonist activity of the natural ligand. The invention also relates to the hybridoma which secretes said antibodies and to their therapeutic and diagnostic use....

20060140941 - Growth differentiation factor-3: Growth Differentiation factor-3 (GDF-3) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-3 polypeptide and polynucleotide sequences....

20060140942 - Human g-protein coupled receptor (hetgq23): Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed were methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat...

20060140939 - Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury: A method for preventing or treating tissue damage associated with ischemia-reperfusion injury and thoraco-abdominal aortic aneurysm (TAAA) repair by administering a tissue damage preventing or treating amount of a complement inhibitor to a patient likely to suffer from or suffering from tissue damage associated with ischemia-reperfusion injury or TAAA repair....

20060140938 - Monoclonal antibody specific for ppar gamma, hybridoma cell line producing the same, and method for detecting regulator related to diseases, including inflammation, cancer and metabolic diseases, using the same: The present invention relates to a hybridoma cell line producing a PPAR gamma-specific monoclonal antibody, and a method for detecting a PPAR gamma ligand related to the progression of difficult diseases, such as cancer, inflammation and metabolic diseases obesity and diabetes), using the PPAR gamma-specific monoclonal antibody. This PPAR gamma-specific...

20060140943 - Immunotherapy using modulators of notch signalling: There is provided a use of a modulator of Notch signalling for the preparation of a medicament for treatment of Graft Versus Host Disease (GVHD) and diseases and conditions caused by or associated with transplants such as organ, tissue and/or cell transplants (e.g. bone marrow transplants), wherein the modulator is...

20060140944 - Novel polypeptides involved in immune response: Novel polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders....

20060140946 - Anti-tnf chimeric antibody fragments: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays...

20060140948 - Fully human monoclonal antibodies to il-13: The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding...

20060140949 - Human anti-tnf antibodies and peptides: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of...

20060140947 - Method for treating diseases associated with abnormal kinase activity: Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced...

20060140945 - Nephropathy-associated gene: A nephropathy-associated gene which encodes a transcription repressor; and a nonhuman transgenic animal suffering from nephropathy which is constructed by transferring the above gene and allows the observation of increases in urinary volume, urinary albumin and urinary NAG, pyelectasis, enlargement in kidney tubule and glomerular swelling at the early stage...

20060140951 - Tumour necrosis factor binding ligands: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues His73-Val74-Leu75-Leu76-Thr77-His78-Thr79-Ile80-Ser81-Arg82-Ile83-Ala84-Val85-Ser86-Tyr87-Gln88-Thr89-Lys90-Val91-Asn92-Leu93-Leu94 (peptide 309) of mature human TNF-α. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-α of amino acid resides 73-94. Antibodies or fragments...

20060140952 - Tumour necrosis factor binding ligands: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues Ala22-Glu23-Gly24-Gln25-Leu26-Gln27-Trp28-Leu29-Asn30-Arg31-Arg32-Ala33-Asn34-Ala35-Leu36-Leu37-Ala38-Asn39-Gly40 (peptide 307) of mature human TNF-α. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-α of amino acid resides 22-40. Antibodies or fragments...

20060140950 - Uses of mammalian cytokine; related reagents: Provided are methods of treatment for inflammatory and autoimmune disorders of the central nervous system and gastrointestinal tract. Also provided are methods of diagnosis....

20060140954 - Novel human protein kinases and protein kinase-like enzymes: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the PTK's and STK's have been identified and...

20060140953 - Systems and methods for treating human inflammatory and proliferative diseases and wounds, with ucp and/or fas antibody or other inhibitor, optionally with a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination...

20060140955 - Specific isotype antibodies of secretion-excretion anti-antigens of leishmania sp of promastigote or amastigote forms used as protection, resistance and curing markers of mammals to leishmaniases and to intracellular pathogenic micro-organism infections,: The invention concerns immunoglobulins characterized in that they include immunoglobulins of IgG2 classes and corresponding sub-classes, specific of secretion-excretion antigens of the prosmatigote and asmatigote forms of Leishmania sp, capable of lyzing Leishmania sp amastigotes and promastigotes in vitro, and neutralizing their proliferation....

20060140960 - Biomarkers for pre-selection of patients for anti-igf1r therapy: The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small...

20060140962 - Combination treatment of pancreatic cancer: A combination for use in the treatment of pancreatic cancer comprising: (i) an anti-gastrin effective immunogenic composition; and, (ii) one or more chemotherapeutic agents suitable for inhibiting cancer growth....

20060140961 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same....

20060140963 - Cytotoxicity mediation of cells evidencing surface expression of cd59: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The...

20060140957 - Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis: Methods and compositions for modulating ephrin/Eph receptor-mediated cell adhesion and/or cell repulsion are provided, particularly in relation to preventing, inhibiting or delaying tumour cell metastasis through modulation of Eph receptor-ephrin binding interactions and subsequent Eph receptor signalling. Particular agents useful according to the invention are agents which interfere with a...

20060140956 - Method and compounds for inhibiting hec1 ativity for the treatment of proliferative diseases: The present invention provides methods and compounds for inhibiting HEC1 activity for the treatment of diseases involving cell hyperproliferation, e.g. cancer. The present invention also provides methods of identifying compounds for inhibiting HEC1 activity....

20060140959 - Old-35, a gene associated with senescence and terminal cell differentiation, and uses thereof: The present invention relates to the old-35 gene, its encoded protein, and its promoter sequence. The old-35 gene is associated with terminal differentiation and senescence of cells, and as such the gene and its related molecules may be used in the control of cell proliferation and in the modulation...

20060140958 - Tag-1 and tag-2 proteins and uses thereof: The present invention is directed to a newly discovered gene family with multiple isoforms, designated TAG-1, TAG-2a, TAG-2b, TAG-2c, and TAG-3, nucleic acid sequences encoding those proteins, and antibodies generated against said proteins. The genes, proteins, and peptides described herein may be used as diagnostic indicators of the presence of...

20060140964 - Human igm antibody lysing activated lymphocytes under mediation by homologous complement: A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM...

20060140969 - Hypoallergenic polypeptides based on fish parvalbumin: The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination....

20060140966 - Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins: The present invention relates to complexes and fusion proteins comprising an acute phase protein and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides for complexes comprising an acute phase protein noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The...

20060140965 - Immunogenic compositions comprising a xenogenic prostate protein p501s: The present invention relates to pharmaceutical/immunogenic compositions and methods for inducing an immune response against tumour-related antigens. More specifically, the invention relates to non-human prostate-specific antigens, more precisely to the non-human prostate-specific P501S, which can be used as xenogeneic antigen in prostate cancer vaccine therapy and as diagnostic agents for...

20060140967 - Immunogenic peptides for the treatment of prostate and breast cancer: Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1....

20060140968 - Novel tumor antigen protein sart-3 and tumor antigen peptides thereof: A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided....

20060140970 - Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis: This invention encompasses proteic binding partners of Translationally Controlled Tumor Protein (TCTP), which can modulate tumor reversion or cell apoptosis. Methods of screening for compounds useful for treating, preventing or managing cancer, an inflammatory disorder, or a neurodegenerative disorder and use of these compounds are also encompassed....

20060140971 - Cell surface expression vector of sars virus antigen and microorganisms transformed thereby: The present invention relates to a surface expression vector of SARS coronavirus antigen containing a gene encoding an antigen of SARS inducing coronavirus and any one or two or more of genes pgsB, pgsC and pgsA encoding poly-gamma-glutamic acid synthase complex, a microorganism transformed by the surface expression vector, and...

20060140972 - Staphylococcus saprophyticus nucleic acids and polypeptides: Isolated nucleic acid molecules which encode proteins from Staphylococcus saprophyticus are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated proteins, mutated proteins, fusion proteins, antigenic...

20060140974 - Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract: A yeast extract or yeast-derived bioactive peptide having an activity of selectively inhibiting reuptake of serotonin and norepinephrine, which can be effectively used in preventing or treating various diseases related to reuptake of serotonin and norepinephrine, especially depression, anxiety, stress, fatigue and obesity are provided. Also, a yeast extract or...

20060140973 - Method for treating weight loss in patients suffering from inflammatory bowel diseases: The present invention relates to a method of treating or preventing weight loss of patients with inflammatory bowel diseases comprising administering to said patients an effective amount of Saccharomyces boulardii....

20060140975 - Regulated bacterial lysis for gene vaccine vector delivery and antigen release: The present invention generally relates to regulated host-vector systems for delivery of genetic vaccine vector or desired gene products to a eukaryotic host, preparations of bacterial genetic vaccines, genetically engineered microorganisms that are useful for delivery of genetic vaccine vectors or desired gene products, and methods of use for the...

20060140976 - Trivalent vaccine with material antibody transfer via the milk: Embodiments of the present invention generally relate to novel multivalent vaccines and methods of vaccinating. In an embodiment, the present invention is a trivalent vaccine for canine herpesvirus (CHV), canine rotavirus (CRV), and Minute virus of canine (MVC) or other canine parvovirus delivered to pups of a whelp through colustrums...

20060140977 - Methods for assaying inhibition of hiv-1 envelope glycoprotein-mediated membrane fusion: This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T...

20060140978 - Genetic constructs and compositions comprising pre and cte and uses thereof: Genetic constructs that comprise a coding sequence for HIV-1 Rev, and a coding sequence for a desired protein are disclosed. Compositions that comprise at least two nucleic acid molecules in which at least one nucleic acid molecule comprises a coding sequence for HIV-1 Rev, and at least one nucleic acid...

20060140979 - Antigenic polypeptides: The invention relates to a method for the identification of antigenic polypeptides expressed by pathogenic microbes; vaccines comprising said polypeptides; recombinant methods to manufacture said polypeptides; and therapeutic antibodies directed to said polypeptides....

20060140980 - Immunization of non-human mammals against streptococcus equi: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. Equi and subsp. Zooepidemicus and use thereof for immunization of non-human mammals against...

20060140981 - Intranasal delivery of pneumococcal polysaccharide vaccines: The invention relates to a method for preventing against diseases induced by Streptococcus pneumoniae infections, which comprises mucosally administering to a patient in need of a S. pneumoniae capsular polysaccharide. This latter may be conjugated or not and is preferably mixed with a mucosal adjuvant such as cholera toxin, E....

20060140982 - Tuberculosis nucleic acids, polypeptides and immunogenic compositions: The present invention provides transcriptionally active Mtb polynucleotides, recombinant Mtb peptides and polypeptides, and immunogenic Mtb antigens. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides diagnostic kits for Mtb....

20060140983 - Dendritic cells loaded with heat shocked melanoma cell bodies: The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells....

20060140986 - Anesthetic composition for topical administration: It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpynrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase;...

20060140987 - Aqueous compositions with poorly water soluble compounds: There is provided an aqueous composition comprising at least one poorly water soluble compound and at least one pH-sensitive dispersed polymer. Also provided is a method of preparing an aqueous composition, comprising the step of preparing a mixture by mixing such ingredients, where the viscosity of the mixture is less...

20060140990 - Composition for topical treatment of mixed vaginal infections: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for...

20060140984 - Cosmetic and pharmaceutical foam: The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable...

20060140985 - Lansoprazole formulations and related processes and methods: The invention provides novel liquid lansoprazole formulations comprising lansoprazole and an excipient system, wherein: (a) the concentration of lansoprazole in the formulations ranges from about 0.3 mg/mL to about 50 mg/mL; (b) the excipient system comprises either a single excipient, or a combination of two to four compositionally distinct excipients;...

20060140989 - Pharmaceutical formulations: New and improved antihistaminic syrups are disclosed....

20060140991 - Pharmaceutical preparations having an improved solubility: The present invention provides a method for producing a pharmaceutical preparation having an improved solubility, which comprises the steps of forming a micelle by dissolving a poorly-soluble drug having the ability to form the micelle into water; and fixing the micelle structure which is formed with the poorly-soluble drug, by...

20060140988 - Visco-supplement composition and methods: The present invention relates to methods and depot emulsion compositions for delivery of visco-supplements....

20060140992 - Cosmetics excellent in texture and oil-dispersibility: A cosmetic material with an excellent feeling which contains a crosslinked product of poly-γ-glutamic acid and/or a crosslinked product of a poly-γ-glutamic acid salt having a particle size of 0.1 to 100 μm and an average particle size of 1 to 50 μm, exhibits a less stickiness upon use, a...

20060140993 - Hair and scalp ointment: Abies Balsamea Resin, Beeswax, Carmel Color, Cetyl Alcohol, Disodium Edta, DMDH Hydantoin, Fragrance, Gelatin/Keratin Amino Acids/Lysine Hydroxypropyltrimonium Chloride, Glycerin, Stearate, Propylene Glyco and Imidazolidinyl Urean and Methyl Paraben and Propyl Paraben, Hydrolyzed Collagen, Microcrystalline Wax, Octoxynol-9, Panthenol (Pro Vitamin B5), Petrolatum, Propylene, Sodium Salt of Carbomer 940, Vitamin A, Vitamin...

20060140994 - Application of an antimicrobial agent on an elastomeric article: An elastomeric article having reducing microbe affinity and transmission and methods for applying and immobilizing antimicrobial compounds to the elastomeric substrate surface are disclosed. The elastomeric article has a body formed of a natural or synthetic polymer latex having an outer surface and an inner surface. The body has a...

20060140998 - Agricultural disinfectant composition:

20060140997 - Avermectin and avermectin monosaccharide derivatives substituted in the 4\"-or 4'-position having pesticidal properties: What is described are a compound of the formula (I) Wherein U is —N(R2)OR3 or —N+(O−)═C(RE)RZ); n is 0 or 1; X—Y is —CH═CH— or —CH2—CH2—; R1 is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; R2 and R3 are, for example; independently from each other, -Q, —C(═O)-Z-Q or —CN; RZ and RE are,...

20060140995 - Methods for treating ectoparasite infections on the mammalian body: Methods for treating ectoparasites, their nymphs, and their egg infestations on animal skin and hair, wherein the compositions used in the methods contain at least one monohydric aralkyl alcohol in a quantity sufficient to provide pesticidal activity; the compositions are applied to the infected areas in a quantity sufficient to...

20060140996 - Vermin-repellant compositions and compounds: Compounds of formula (I) are described for deterring vermin, wherein R is unbranched or branched C1-C15 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; R1 and R2 are unbranched or branched C1-C12 alkyl, preferably C1-C6 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; and...

20060141003 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building...

20060141002 - Coated implants and methods of coating: A method including forming a first coating layer derived from an alkoxide on a substrate having a dimension suitable for an implant and forming a second coating layer on the first coating layer that promotes osseointegration. An apparatus comprising a substrate having a dimension suitable as a medical or dental...

20060141001 - Pharmaceutical product: A pharmaceutical and pharmaceutical-like product is provided. The product provides a plurality of components having active agents that are delivered in a single delivery entity or vehicle. The product allows for selective control of the release rates of each of the active agents while still being delivered in a single...

20060141000 - Porous biodegradable polymeric materials for cell transplantation: Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted...

20060140999 - Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect: The present invention relates to drug release systems which employ shape memory materials....

20060141004 - Compositions and medical devices utilizing bioabsorbable polymeric waxes: The present invention is directed to medical devices, pharmaceutical or agricultural compositions, and seeds, each containing a synthetic, bioabsorbable, biocompatible polymeric wax that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the polymeric wax having a melting point less than about...

20060141005 - Compositions and medical devices utilizing bioabsorbable polymeric waxes: The present invention is directed to medical devices, pharmaceutical or agricultural compositions, and seeds, each containing a synthetic, bioabsorbable, biocompatible polymeric wax that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the polymeric wax having a melting point less than about...

20060141006 - Methods and apparatus for treatment of aneurysmal tissue: The present invention encompasses methods and apparatus for aiding aneurysm repair....

20060141007 - Agent with a retarded release of substances: The present invention relates to a composition for producing a satiation effect and for weight reduction comprising at least one compound which is swellable and comprises nutrients....

20060141008 - Over-coated product including consumable center and medicament: Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes one or more coatings having a medicament or agent. The coatings can further comprise one or more fat-based confectioneries to provide a coated product that...

20060141010 - Coated preparations that contain at least one hydroformate: t

20060141011 - Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health: This invention is directed to compositions for animal consumption (including foods, treats, etc.), particularly compositions that tend to improve kidney function, and particularly compositions that comprise enhanced antioxidants and reduced quantities of protein and/or phosphorus. This invention also is directed generally to methods for using such compositions....

20060141013 - Lysine mixture and apparatus and method for administering lysine: A mixture is described comprising L-lysine and a base substance palatable to cats. Also described is a improved method and apparatus for administering L-lysine using an oral syringe....

20060141009 - Novel compositions and processes for delivering an additive: Embodiments of the present invention generally relate to novel compositions and processes for the delivery of an additive to an organism in a form suitable for consumption....

20060141012 - Tissue scaffold: A tissue scaffold includes a first film having a plurality of cell openings and a second film adjacent the first film and having a plurality of cell openings larger than the cell openings of the first film. The cell openings of the first film interconnect with the cell openings of...

20060141015 - Antimicrobial material: The present invention relates to an antimicrobial material comprising sheet of fabric and- metallic salt crystals embedded in an adhesive material covering the sheet of fabric....

20060141014 - Skin treatment articles and methods: The present invention relates to skin treatment articles, particularly cleansing articles, and methods for delivering multiple skin treatment formulations to the skin....

20060141016 - Enzyme inhibiting adhesives: An adhesive composition including an adhesive component and an enzyme inhibiting component for use in ostomy and wound care applications. The enzyme inhibitors are derived from tubers, such as potatoes. In ostomy, the adhesive composition helps to secure the collection bag or pouch to the skin. In wound care application,...

20060141018 - Hemostatic compositions and methods for controlling bleeding: The invention provides hemostatic compositions useful to promote hemostasis at active bleeding wound sites. The hemostatic compositions typically include an article containing cellulose, e.g., cotton gauze, and a polysaccharide covalently linked to the cellulose, or a polysaccharide ionically cross-linked and in association with the article. Methods of making and using...

20060141017 - Zinc-based compositions and methods of use: The invention relates generally to zinc-based compositions for topical use in humans and animals, and methods therefor. The invention further relates to the use of zinc-based compositions in wound treatment, cleaning and other therapeutic applications....

20060141019 - Liposome: The present invention provides a liposome to which a polyalkylene glycol and albumin are bonded having an excellent retention in blood....

20060141020 - Liposomes containing oligonucleotides: It is possible to radiosensitize tumor cells by administration of compositions containing the Human antisense c-raf-1 oligodeoxyribonucleotide (ODN/oligo) sequence: 5′-GTGCTCCATTGATGC-3′ (SEQ. ID. NO: 1) wherein only the end bases are phosphorothioated is a preferred embodiment. Antisense sequences of up to 40 bases which contain this sequence, such as 5′-CCTGTATGTGCTCCATTGATGCAGC-3′ (SEQ...

20060141021 - Polymeric microspheres and method for preparing the same: A polymeric microsphere. The polymeric microsphere comprises a first polymer, a layer formed on the surface of the first polymer, and a second polymer formed on the layer. The invention also provides a method for preparing the polymeric microphere by an aqueous-two-phase emulsion process....

20060141026 - Imprinted paintball and apparatus and method for manufacturing same: A gel capsule has embossed surface configurations that form, in relief, an imprinted design over the entire extent of its exterior surface. An apparatus and method for producing and/or manufacturing an imprinted gel ribbon that is useful in forming the gel capsule. The apparatus includes a spreader box and a...

20060141025 - Methods and compositions for delivery of catecholic butanes for treatment of tumors: The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such...

20060141023 - Pharmaceutical compositions containing abiguanide-glitazone combination: The present invention relates to an orally administered pharmaceutical composition that is a combination of two or more antidiabetic agents in which one of the antidiabetic agents is present in an extended release form and the other antidiabetic agent is present in an immediate release form....

20060141022 - Soft capsule preparation: A soft capsule preparation which comprises a dispersion of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid in a vegetable oil filled in a soft capsule comprising a shell having a light blocking effect. The soft capsule preparation preferably comprises polyoxyethylene sorbitan monooleate and glycerol monostearate and the like as surfactants. As the vegetable oil, soybean...

20060141024 - Synergistic combination kit of alpha,beta-arteether, sulfadoxin and pyrimethamine for treatment of severe/multi-drug resistant cerebral malaria: The present invention relates to a method for preparation of synergistic combination kits of α,β-arteether, sulfadoxin and pyrimethamine for the treatment of severe/multi-drug resistant cerebral malaria....

20060141028 - Cyclosporin formulations: The present invention relates to compositions comprising solutions of drugs in menthol, especially drugs that are poorly soluble in water, and to methods for making such compositions....

20060141030 - Method and composition for stable and controlled delivery of (-)-hydroxycitric acid: The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable...

20060141029 - Methods and compositions for delivery of catecholic butanes for treatment of diseases: The present invention provides kits, methods and compositions for the treatment of diseases, such as, for example, non-cancer proliferative diseases, neurodegenerative diseases, diabetes and hypertension. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA Compounds in a pharmaceutically acceptable carrier or...

20060141031 - Orally disintegrating pharmaceutical compositions with sensory cue agents: The present invention relates to pharmaceutical compositions that disintegrate in the mouth and include at least one systemically active pharmaceutical ingredient in a therapeutically effective amount and at least one sensory cue agent in a sensory effective amount....

20060141027 - Sublingual administration of non-steroidal anti-inflammatory pharmacological substances: The present invention relates to a sublingual administration method of non-steroidal ant-inflammatory, referred as FANS, which allows to considerably reduce the therapeutic dose, with the additional advantage of increasing the quickness of the effects and improving the tolerability....

20060141032 - Effervescent formulations comprising apomorphine: An effervescent formulation comprising apomorphine, preferably comprising multilayer effervescent microspheres containing an acidic substance, a basic substance and water-soluble isolating agent. An effervescent formulation comprising apomorphine wherein dissolution in water of the multilayer effervescent microspheres leads, after almost immediate effervescence, to a solution or a homogeneous dispersion of the apomorphine....

20060141034 - Gaba analog prodrug sustained release oral dosage forms: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective....

20060141035 - Hmg-coa reductase inhibitor extended release formulation: Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug...

20060141036 - Hmg-coa reductase inhibitor extended release formulation: Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug...

20060141033 - P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient: The present invention relates to a new use of octylonium bromide as p-glycoprotein inhibitor to increase cellular uptake of drugs. More particularly, the present invention provides octylonium bromide as a p-glycoprotein inhibitor to increase cellular uptake of drugs such as anticancer drugs by taking octylonium bromide simultaneously with or proceding...

20060141037 - Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof: Bilayer tablet comprising an immediate release first layer comprising an effective amount of oxcarbazepine and at least one pharmaceutically acceptable excipients and a controlled release second layer comprising an effective amount of oxcarbazepine and pharmaceutically acceptable excipients wherein the total amount of oxcarbazepine impurities is less than or equal to...

20060141038 - Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof: The present invention describes how to obtain composite products comprising an active substance supported by a carrier, in which the carrier is the linear copolymer of N-vinyl-2-pyrrolidone with vinyl acetate. The composite products are obtained by co-grinding of the dry mixture of the active substance and of the aforesaid carrier....

20060141040 - Injectable non-aqueous suspension: The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions....

20060141039 - Oral compositions containing oxidized camellia: Oral composition comprising a Camellia extract of semi-oxidized tissue from a member of the genus Camellia and an enhancing agent....

20060141048 - (polyalkoxy)sulfonate surface modifiers: The present invention is directed to novel compounds, methods of manufacture and methods of use. The present invention is also directed to solid drug/active agent particles having one or more of the compounds of the present invention associated with the surface thereof. The compounds of the present invention are comprised...

20060141043 - Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides: e

20060141050 - Drug microparticles: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them....

20060141051 - Drug microparticles: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them....

20060141052 - Drug microparticles: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them....

20060141042 - Hollow nanoparticle having modified cysteine residue and drug with the use thereof: The invention provides hollow nanoparticles of a protein with the ability to recognize specific cells such as the hepatocytes and to form particles (for example, hepatitis B virus surface-antigen protein), wherein the protein has a cysteine residue substituted to a different amino acid. The hollow nanoparticles have a stable particle...

20060141045 - Isolation of cells or the like from bodily fluids: Spheroidal beads present an exterior surface of a hydrophilic hydrogel, which is an isocyanate-functional polymer that is polymerized by urethane bonds and cross-linked by urethane and urea bonds. Sequestering agents present at the surface are covalently bound to isocyanate groups or to intermediate linkers that are so bound. These beads...

20060141047 - Methods and compositions for delivery of catecholic butanes for treatment of obesity: The present invention provides kits, methods and compositions for the treatment of obesity. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered...

20060141041 - Methods and compositions for the targeted delivery of biologically active agents: The present invention relates to a sustained release composition for the targeted delivery of biologically active agents to specific tissues and cells. The composition comprises microparticles containing a biocompatible polymer, a water-soluble polymer and a biologically active agent. In one embodiment, the biologically active agent is an antigen or an...

20060141046 - Particles for the delivery of active agents: Formulations of active agent particles of less than 100 microns in a droplet of dispersant, which is coated with a matrix of cationic and anionic polymers, are efficient vehicles for delivering active agents to tissues such as skin and mucosal membranes. Such formulations are able to deliver compounds to skin...

20060141044 - Pharmaceutical compositions based on diclofenac derivate: The present invention relates to particles comprising the drug 2-[2-(nitrooxy)ethoxy]ethyl{2-[(2,6-dichlorophenyl)amino]phenyl}acetate, optionally mixed with one or more surfactant(s) and to a new drug delivery composition comprising said particles optionally in combination with a second drug. Furthermore, the invention relates to processes for preparing said particles and drug delivery composition as well...

20060141049 - Triamcinolone compositions for intravitreal administration to treat ocular conditions: Triamcinolone compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps...

20060141053 - Pharmaceutical composition for improving palatability of drugs and process for preparation thereof: The present invention discloses compositions, comprising a lipid-polymer matrix to mask the bitter or unpleasant taste of the medicament. The lipid or a blend of lipids, are used in combination with the pH dependent polymer where the said polymer is acid soluble or swellable The process for the preparation of...

20060141054 - Metal coordinated compositions: A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof....

20060141055 - Cardiac development promoting activity of perivitelline fluid of embryos of indian horseshoe crab, tachypleus gigas (muller): The present invention relates to a method for cardiac development activity in a subject comprising administering to the subject an appropriate amount of perivitelline fluid obtained from fertilized eggs of horseshoe crab....

20060141056 - Antimicrobial resin composition: A resin composition having excellent dispersibility, discoloration resistance and antimicrobial properties by blending a resin (A) with an antimicrobial agent (B) in which at least one kind of metal ion selected from the group consisting of silver, copper, zinc and tin is supported on zeolite, and an antimicrobial agent (C)...

20060141058 - Methods and compositions for weight management and mood enhancement: The present invention provides nutritional supplement compositions and processes for treatment using nutritional supplements that assist in weight management. One aspect of the invention comprises the inclusion in a single supplement constituent(s) that assist in reduction of a subject's cortisol level, thermogenic constituent(s), and constituent(s) that assist in stabilizing blood...

20060141057 - Methods of treatment of inflammatory diseases: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or...

20060141059 - Self-preserved ophthalmic pharmaceutical compositions containing tobramycin: Self-preserved, multi-dose ophthalmic compositions containing tobramycin are described. The compositions do not contain a conventional antimicrobial preservative, such as benzalkonium chloride. Rather, the compositions are self-preserved as a result of the inherent antimicrobial activity of tobramycin. The compositions preferably also contain either boric acid or, more preferably, a borate/polyol complex...

20060141060 - Molecular sieve materials having increased particle size for the formation of blood clots: A composition for clotting blood comprises a molecular sieve material. The molecular sieve material is in the form of particles, the particles having an average diameter of about 0.2 millimeters (mm) to about 10 mm. The molecular sieve material may be a zeolite, the zeolite being an aluminosilicate comprising at...

20060141067 - Anti-allergic herbal formulation: The invention provides a novel herbal preparation useful in treatment of allergy. Formulation(s) comprises of plant preparation or active component of plant extract together with conventional additives to form the oral dosage forms, which includes tablets, capsules and liquid dosage forms viz. syrup and suspension as anti-allergic. Formulation(s) comprises of...

20060141061 - Anti-arthritic herbal composition and method thereof: The invention provides a novel herbal composition for treatment of arthritis and inflammation. The herbal composition comprises a therapeutically effective combination of extracts obtained from the plants Terminalia chebula, Pluchea lanceolata, Desmodium gangeticum, Vitex negunto and Zingiber officinale, optionally along with pharmaceutically acceptable additives. The invention further comprises methods of...

20060141063 - Health promoting functional foods fortified with herbs: The present invention provides a novel herbal composition, which promotes the proven pharmacological activities such as anti-oxidant, anti-stress and adaptogenic activities. Composition(s) comprises of plant juices or extracts together with the conventional recipients to form paste/jelly/jam/cake/cream puff/chocolate forms fortified with plants like Mangifera indica, Evolvulus alsinoides, Withania somnifera and Asparagus...

20060141068 - Herbal formulation as memory enhancer in alzheimer condition: The invention provides a novel herbal formulation used to improve the memory and in treatment of senile and presenile dementia as a brain tonic. Formulation(s) comprises of alcoholic extract of Tinospora cordifolia, Centella asiatica, Withania somnifera, Mucuna pruriens and Curcuma longa. The formulation can be used as an emulsion or...

20060141065 - Herbal formulation for the treatment of piles: The present invention provides a novel herbal formulation for use in treatment of piles. Formulation(s) comprises of leaves of Moringa oliefera, tender leaves of Pongaemia pinnata, whole plant of Cassia occidentalis and leaves of Albizia lebbeck. The formulation can be used as an emulsion or as a soft gelatin capsule...

20060141064 - Herbal formulation useful as local anesthetic: The invention provides a novel herbal formulation useful as local anesthetic in topical surgical operations, nerve block conduction, extradural and infiltration anesthesia. Formulation(s) comprises of extract(s) of Spilanthus calva and Spilanthus oleraceae with Gymnema sylvestre, Urtica dioica and Piper longum. The formulation can be used as topical application as ointment...

20060141066 - Herbal nutritious chocolate formulation and process for preparation thereof: The present invention provides a novel herbal chocolate composed of Tinospora cordifolia, Glycyrrhyza glabra, Adhatoda vasica, Madhuca indica and Cassia occidentalis. The solid or semisolid nutritious composition is rich in protein/mineral fortified with standardized herbs with proven pharmacological activities such as anti-oxidant, anti stress and adaptogenic property and relief the...

20060141062 - Herbal prepration for joints: The present invention is an extract of the herb Brachystemma calycinum for the amelioration or treatment of pain or discomfort due to, or associated with, osteoarthritis. The extract is obtained by a multi-step extraction process wherein the temperatures of each step never reaches boiling point....

20060141069 - Synergistic antipyretic formulation: The present invention relates to a synergistic antipyretic formulation comprising extracts of plants Berberis aristata, Tinospora cordifolia, Alstonia scholaris, Andrographis paniculata and Hedychium spicatum, optionally along with pharmaceutically acceptable additives; its use in treating fever, and lastly, a process for the preparation said synergistic antipyretic formulation....

20060141071 - Compositions and methods for treating gynecological disorders: A composition for treating or alleviating a symptom resulting from a gynaecological disorder, comprising the herbs Chi Shao (Paeonia obova, Root), Dang Gui (Angelica Polymorpha, Root), Chuan Xiong (Ligusticum Wallichii, Root), Xiang Fu (Cyperus Rotundus, Rhizome), Yan Hu Suo (Corydalis turtschanninovii, Rhizome), Tao Ren (prunus persica, Seed) or parts thereof....

20060141070 - Notoginseng saponin intravenous injection and the method for preparing this injection: The invention shows the saponins family of Radix notoginshen intravenous injection, a method for preparation thereof. The object is to provide an intravenous injection for prevention and treatment of cardiac and cerebral vascular disease and its sequelae. This injection has stable pH, could be used in large dosage, and with...

20060141074 - Composition for neutralizing house dust mite feces: Methods for neutralizing dust mite feces are disclosed. In one embodiment, a botanical extract having a BAPNA-Trypsin Inhibition (IC50×10−3 (%, v/v or w/v) of from about 0.01 to about 500 and a sufficient solubility in water is introduced into water to form an aqueous botanical extract solution. The aqueous botanical...

20060141075 - Methods and compositions for weight management and mood enhancement: The present invention provides nutritional supplement compositions and processes for treatment using nutritional supplements that assist in weight management. One aspect of the invention comprises the inclusion in a single supplement constituent(s) that assist in reduction of a subject's cortisol level, thermogenic constituent(s), and constituent(s) that assist in stabilizing blood...

20060141073 - Oral care composition containing extract of unoxidized camellia: e

20060141072 - Oxidation resistant dentifrice compositions: Low water tooth pastes contain a variety of plant extracts. The oral or dentifrice compositions containing humectants, abrasive compounds, and a variety of plant extracts, such as rosemary and green tea extracts, along with an additional antioxidant component. Examples of antioxidants include stannous compounds, sodium meta-bisulfite, BHT, ammonium sulfate, and...

20060141076 - Morinda citrifolia based compositions and methods for inhibiting xanthine oxidase: The present invention relates to the inhibition of xanthine oxidase. In particular, the present invention relates to systems and methods for utilizing Morinda citrifolia L. based compositions and methods to inhibit xanthine oxidase activity....

20060141077 - Pest controlling composition and the use thereof: The invention relates to a composition and method for controlling a pest population, in particular an aphid population. The composition comprises menthol of 1,8-cineole and methyl salicylate....

20060141078 - Composition comprising a rice protein hydrolysate and an agent for increasing glycosaminoglycan synthesis: The present invention relates to a process for preventing and/or reducing the signs of ageing of the skin, in particular for remodelling the face and/or limiting the age-related hollowing of the face, by applying to facial skin a composition containing, in a physiologically acceptable medium, at least one rice protein...

20060141079 - Supplement foods and pharmaceuticals: The present invention provides effective supplement foods and safe pharmaceuticals, each having a hypotensive effect and anti-diabetic effect and no adverse effects. The supplement foods and pharmaceuticals of the present invention comprise squash extract mixed with onion extract. Synergistic effect of the two extracts can be expected by mixing the...

20060141080 - Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof: e

20060141082 - Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity: The invention provides hops (Humulis lupulus) extracts or derivatives thereof for use in treating a patient prophylactically and/or therapeutically for ulcerogenic-type disorders of the stomach and/or intestines. The ulcerogenic disorders can be of the type chemically induced, environmentally-induced, infection-induced, and/or stress-induced. The invention also provides a pharmaceutical composition comprising an...

20060141081 - Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity: The invention provides hops (Humulus lupulus) extracts or derivatives thereof for use in treating a patient prophylactically and/or therapeutically for ulcerogenic-type disorders of the stomach and/or intestines. The ulcerogenic disorders can be of the type chemically induced, environmentally-induced, infection-induced, and/or stress-induced. The invention also provides a pharmaceutical composition comprising an...

20060133995 - Method for determining suitability of various contrast agents for the imaging examination of the patient and uses of the ligand contained in a selected contrast agent: A method is for determining suitability of various contrast agents for the imaging examination of the. In this case, a tissue sample is taken from the patient, it is divided into a plurality of individual samples and a contrast agent which binds to a particular target structure in the tissue...

20060133994 - Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis: The present invention relates to antibodies with sub-nanomolar affinity specific for a characteristic epitope of the ED-B domain of fibronectin, a marker of angiogenesis. Furthermore, it relates to the use of radiolabelled high affinity anti ED-B antibodies for detecting new-forming blood vessels in vivo and a diagnostic kit comprising comprising...

20060133997 - A method of demonstrating draining activity of a cosmetic and/or dermocosmetic treatment on the superficial dermis and/or the epidermis: The present invention concerns a method of demonstrating the draining activity of a cosmetic and/or dermocosmetic treatment, said method comprising: prior to the treatment, acquiring at least one first datum representative of the water content in the superficial dermis and/or in the epidermis, using an MRI imaging technique having high...

20060133996 - Method and apparatus for determining effectiveness of sunscreens and other skin preparations in shielding human skin from uva radiation: The present invention provides a method and apparatus for measuring the effectiveness of a sunscreen composition or other skin preparation in reducing the exposure of human skin to UVA radiation, wherein differential electron spin resonance spectroscopy is used to quantify the extent of UVA-induced ascorbate or other measurable radical production...

20060133999 - Method for the diagnosis of helicobacter pylori infection, and a diagnostic kit for performing the method: e

20060133998 - Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled amides using metal amides and photo-induced free radical carbonylation: Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using weakly nucleophilic amines and alkyl/aryl iodides are provided. The resultant carbon-isotope labeled amides are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits for PET studies are also provided....

20060134000 - Method for producing a computed tomography display of tissue structures by applying a contrast medium: A method is disclosed for producing a computed tomography display of tissue structures by applying a contrast medium. A contrast medium is applied to a patient for better visualization of the tissue structure to be examined. An X-ray scan is performed during the presence of the one contrast medium, and...

20060134001 - Conjugated infrared fluorescent substances for detection of cell death: One aspect of the invention is an infrared fluorescent reagent that may be useful to provide images of regions of cell death. The reagent may comprise a fluorescent substance, preferably an infrared fluorescent substance, conjugated to a targeting moiety that selectively localizes or binds to cells or tissue undergoing cell...

20060134002 - In vivo flow cytometry system and method: The present invention provides methods and systems for performing in vivo flow cytometry. In one embodiments, selected circulating cells of interest of a subject are labeled with fluorescent probe molecules. The labeled cells are irradiated in vivo so as to excite the fluorescent probes, and the radiation emitted by the...

20060134005 - In-vivo monitoring of circulating apoptotic cells: The present invention provides methods and systems for performing in vivo flow cytometry. In one embodiments, selected circulating cells of interest of a subject are labeled with fluorescent probe molecules. The labeled cells are irradiated in-vivo so as to excite the fluorescent probes, and the radiation emitted by the excited...

20060134004 - Methods and apparatus for detection of carotenoids in macular tissue: Methods and apparatus are provided for the noninvasive detection and measurement of macular pigments such as carotenoids in macular tissue. In one technique, lipoftiscin autofluorescence spectroscopy is utilized for macular pigment measurements. In autofluorescence spectroscopy, the emission of lipoftiscin is excited at two wavelengths: one wavelength that overlaps both the...

20060134003 - Systems and methods of light-scattering based in vivo flow cytometry: The present invention provides methods and systems for performing in-vivo flow cytometry to obtain desired information regarding one or more cell types of interest flowing through a subject's circulatory system. In one embodiment of the invention, a portion of the subject's circulating blood is illuminated with radiation having multiple wavelength...

20060134006 - Chemical carrier based on a beta-limit dextrin: A formulation, especially a pharmaceutical formulation, comprises an active agent and a carrier for the active agent, wherein the carrier comprises a beta-limit dextrin. The formulation may be a bioadhesive pharmaceutical formulation in which the beta-limit dextrin acts as a mucoadhesive agent. The active agent is a pharmaceutically active agent...

20060134007 - Blister for inhalers: The invention relates to a blister for charging an inhaler with a pharmaceutical preparation, characterised in that the blister is at least partially manufactured from a dehydrating plastics material. The invention also relates to blisters according to the invention which are filled with a pharmaceutical preparation....

20060134010 - Chemical composition and process: The invention concerns an aqueous slurry comprising thermally expandable microspheres comprising a thermoplastic polymer shell and a propellant entrapped therein, said slurry further comprising an at least partially water soluble polymer selected from the group consisting of gums, celluloses, chitins, chitosans, glycans, galactans, pectins, mannans, dextrins, polyacrylic acid, esters and...

20060134008 - Compositions and methods for pulmonary conditions: Compositions and methods for the treatment of pulmonary conditions, especially pulmonary conditions characterized by persistent cough, are disclosed. The compositions and methods employ at least one muscarinic receptor antagonists and at least one local anesthetic administered pulmonarily either simultaneously or in sequence. The compositions may be in powder or liquid...

20060134009 - Low dose corticosteroid powders for inhalation: The invention relates to a method of treating a corticosteroid-responsive condition of the air passage ways and lungs by delivering a corticosteroid to the pulmonary system of a patient, comprising administering a particle mass comprising a corticosteroid from an inhaler characterized in that the corticosteroid is not substantially deposited in...

20060134013 - Coated natural calcium carbonate oral care toothpowder composition: Toothpowder comprising natural calcium carbonate with a flavor oil coating is derived by agitating a particulated calcium carbonate bed and by spraying a nebula of flavor oil into the bed. The spray rate is controlled to preclude formation of agglomerated particles of the coated natural calcium carbonate....

20060134014 - Method to promote oral health in companion animals: A method for promoting oral health in a companion animal comprises causing the animal to ingest a composition comprising an oral health-promoting effective total amount of at least one antioxidant....

20060134015 - Methods for use of oral care compositions containing free-b-ring flavonoid anti-oxidants: The present invention relates to a method for providing an anti-oxidant to an oral cavity of a mammalian subject. An oral composition comprising an anti-oxidant active ingredient comprising a free-B-ring flavonoid and an orally acceptable carrier is contacted with oral tissue in the oral cavity. The anti-oxidant active ingredient reduces...

20060134011 - Oral and dental composition: The invention provides an oral and dental composition comprising an effective antibacterial amount of a combination of a physiologically acceptable divalent metal ion; a quaternary ammonium compound; chitosan or a chitosan derivative in a form to facilitate interaction with the other two components of the combination; and a physiologically acceptable...

20060134012 - Temporary pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing: Topical application of a pharmacologically-inactive, inert polymeric solution to teeth affords a temporary, protective barrier for pharmacologically-active compounds that have been previously applied topically to the tooth surfaces for caries reduction. In a method of use, an aqueous dispersion polymethylmethacrylate (PMMA) and a suitable plasticizer are applied topically to the...

20060134016 - Drug to be introduced tooth or periodontal tissue and apparatus for introducing drug to tooth or periodontal tissue: Disclosed are a medical material for use in therapeutic agent delivery to a tooth or periodontal tissue, and an agent delivery apparatus for delivering a therapeutic agent to a tooth or periodontal tissue, by means of ultrasonic energy with less damage to the tooth or periodontal tissue. The medical material...

20060134018 - Oral compositions for prevention and reduction of bacterial adhesion to oral surfaces: The present invention encompasses an oral composition containing an anti-adhesion agent, preferably a cysteine protease and most preferably ficin. In another aspect, the cysteine protease is in combination with one or more ingredients, such as antibacterial agent and surfactant. The anti-adhesion agent mitigates interaction between a subject oral cavity and...

20060134017 - Oral treatment compositions containing an anti-adhesion agent, antibacterial agent and incompatible compound: The present invention encompasses an oral treatment composition containing an anti-adhesion agent, preferably a cysteine protease and most preferably ficin. In another aspect, the cysteine protease is in combination with one or more ingredients, such as antibacterial agent and surfactant. The anti-adhesion agent mitigates interaction between a subject oral cavity...

20060134020 - Anti-caries oral care composition with a chelating agent: An oral care compositions comprises a water-soluble calcium salt, a fluoride-providing agent, and a chelating agent. Methods of treating or preventing dental caries are also provided....

20060134019 - Oral preparation system: An oral preparation of the present invention contains a multi-composition system including a calcium ion supplying compound; a fluoride ion supplying compound a polyolphosphate ion supplying compound; and, a monofluorophosphate ion supplying compound, wherein the calcium ion supplying compound and the fluoride ion supplying compound are separated within the oral...

20060134021 - Mouth rinse with enhanced oxygenating activity: There are provided oral mouth rinse compositions, consisting essentially of: a) 1-20 wt % of an orally acceptable peroxide, b) 0.5-15 wt % of an orally acceptable sulfate, bisulfate, pyrosulfate salt of an inorganic cation or mixtures thereof, and c) water to 100 wt %. There are further provided methods...

20060134022 - Salivary stimulatory compositions and method of use thereof: Effective stimulation of oral salivary activity in the oral cavity is achieved by the introduction thereinto of a warm aqueous solution, containing 0.5-15 wt % of an inorganic cation salt of a sulfate, bisulfate pyrosulfate or mixture thereof, having a temperature of at least 103° F. (39.4° C.)....

20060134024 - Antibacterial and anti-inflammatory oral care composition: An efficacious antibacterial and anti-inflammatory oral composition is provided having an active ingredient combination comprising one or more active compounds from an extract of magnolia and an extract of hops. Preferably, the active compounds from magnolia extract comprise honokiol and magnolol, and the active compounds from hops extract comprise hexahydrogenated...

20060134023 - Oral care malodor composition: An oral odor control agent admixture of generally equivalent proportions of thymol, anise, fennel, basil, and juniperberry essential oils shows efficacy as an odor control agent in oral care for control of garlic odor....

20060134025 - Oral compositions containing extracts of rosmarinus and related methods: Addition of rosemary extract to various dentifrice compositions results in tooth paste, mouth rinses, and other compositions that are suitable for treating and preventing a variety of oral disease including gingivitis, plaque build-up, and the like. Rosemary extract, containing major amounts or ursolic acid and camosic acid, is added to...

20060134030 - Cosmetic composition: The present invention is related to enhance deposition of UV filters especially anionic water soluble ones onto hair from conditioning composition comprising UV filter, especially anionic water soluble ones, at least one conditioning agent and having a pH below 4.5....

20060134028 - Moisturizing compositions: The present invention relates to compositions useful for moisturizing keratinous materials which contain at least one polyol and a solid wax capable of stabilizing the at least one polyol in an anhydrous solid composition....

20060134029 - Personal care compositions comprising semiconductor nanocrystals and methods of making and using the same: A personal care composition that includes a personal care ingredient and semiconductor nanocrystals. A method of protecting at least a portion of a body against ultraviolet radiation by applying a personal care composition is also provided....

20060134031 - Phototherapy compositions and methods: Compositions containing a photoactivable agent and an agent that absorbs or blocks extraneous radiation during phototherapy are useful and used in methods to treat leukocyte mediated autoimmune diseases such as psoriasis, CTCL, and vertiligo....

20060134027 - Sunless tanning products and processes: Aqueous sunless tanning formulations employed for automatic spray systems with enhanced tanning and skin moisturization properties....

20060134026 - Sunscreens: A UV sunscreening composition suitable for cosmetic or topical pharmaceutical use which comprises an amount of one or more organic components which are photosensitive and/or which are degraded and/or in which degradation is induced by another ingredient of the composition, and an amount of TiO2 and/or ZnO which has been...

20060134032 - Nail varnish composition comprising a sequenced polymer: The present invention relates to a nail varnish composition comprising, in a cosmetically acceptable medium, at least one particular block polymer, the said composition being free of nitrocellulose and having a mean gloss greater than 50 out of 100. A subject of the invention is also the use of such...

20060134033 - Cosmetic composition with a lightening effect: The present invention relates to a cosmetic composition for making up and/or caring for the skin and/or the lips, comprising, in a physiologically acceptable medium, at least interference particles with a volume-average size of less than 40 μm and at least one filler such that the said composition also has...

20060134035 - Long wear topical composition having improved glossy appearance: There are provided compositions and methods for imparting a long-wear and glossy effect to skin, lips, eyelashes, hair, and/or fingernails and toenails. The composition has hydrogenated polycyclopentadiene and a liquid gloss agent having a refractive index of at least 1.47. Preferably, the composition has phenylpropyldimethylsiloxysilicate, and is in a lipstick,...

20060134034 - Non-transfer cosmetic composition comprising a dispersion of a grafted ethylene polymer: The invention provides a cosmetic lipcare and/or lip makeup composition comprising at least one cosmetically acceptable organic liquid medium and a dispersion of a grafted ethylenic polymer, the said polymer being such that, when dispersed in sufficient amount in the composition, the composition is able to form a deposit having...

20060134036 - Antiperspirant/deodorant compositions and methods: An antiperspirant composition comprising at least one antiperspirant or deodorant active and at least one retentive filler, where the active is solubilized in a polar solvent and contained within the at least one retentive filler and a method for treating skin....

20060134037 - Antiperspirant or deodorant compositions: Segregation of antiperspirant actives suspended in anhydrous compositions employing ester oils or non-volatile silicone oils having a refractive index of at least 1.5, preferably together with an alcohol oil, gelled with a fibre-forming amide gellant can be inhibited by including a segregation inhibitor, especially an arylene-alkylene block copolymer, such as...

20060134041 - Conditioning composition for hair comprising optical brightener: The present invention is related to a conditioning composition for hair comprising optical brightener. The conditioning composition of the present invention can be in the form of a shampoo, cleansing-conditioning composition, or in the form of a conditioner used after use of cleansing compositions. The preferred optical brightener is disodium...

20060134038 - Make-up composition for keratin fibres such as eyelashes: The invention relates to a cosmetic make-up composition for keratin fibres. The inventive composition comprises at most 20 wt.-% of water and/or water-soluble solvent in relation to the total weight of the composition. Said composition is characterised in that it comprises at least 3 wt.-% of at least one wax...

20060134039 - Nail restructuring compositions for topical application: The present invention is directed to compositions containing a combination of a herb from the genus Equisetum together with one film forming agent and its use as a nail topical formulation, like nail varnish, cream, gel, lotion or foam. The present invention is further directed to the use of a...

20060134040 - Pest protection method and composition: A method and composition for the method for preventing insect infestation that comprises applying to the area to be protected an effective amount of solid material coated with by treatment with a composition comprising a silicone polymer, and an essential oil. A protective effect by reducing the population of harmful...

20060134044 - Cosmetic composition comprising a sequenced polymer and a plasticizer: the plasticizer is a compound, the nature and the amount of which are such that the composition is capable of forming a film having a hardness of less than or equal to 35 seconds, the hardness of the film being measured using a Persoz pendulum according to Standard NF-T-30-016, and...

20060134047 - Personal care and household compositions of hydrophobically-modified polysaccharides: A conditioning composition is used in functional systems (personal care and household care compositions) that has a nonionic hydrophobically modified cellulose ether (HMCE) having a weight average molecular weight (Mw) with a lower limit of 400,000 and an upper limit of 2,000,000 and a hydrophobic substitution lower limit of 0.6...

20060134045 - Personal care compositions comprising plant fiber: Personal care compositions having plant fiber such as tapioca fiber, and methods of applying those formulations. The addition of fiber to personal care formulations can provide performance improvement such as cleansing, exfoliation, irritation reduction, suspending, foam enhancement, and rheological property modification....

20060134048 - Reduction of hair growth: A method of reducing hair growth includes topical application of a heat shock protein inhibitor and/or a compound that promotes apoptosis in conjunction with heat....

20060134046 - Skin nourishing and moisturizing cream: A very rich, all natural nourishing, super-moisturizing and anti-aging cream. The composition comprises a water in oil emulsion blended to a creamy texture. The cream is produced by blending specific quantities of spermacetti, anhydrous lanolin, pure beeswax, sweet almond oil and coconut oil with glycerin, rose water, hydrolysed collagen, hyaluronic...

20060134049 - Hair styling compositions: The present invention relates to compositions and methods for treating and modifying hair. More particularly, this invention is directed to styling and conditioning compositions for modifying and fixing hair comprising one or more rheology modifiers and one or more hair styling resins and a method of using the compositions to...

20060134050 - Bio-synthetic matrix and uses thereof: A bio-synthetic matrix comprising a hydrogel which is formed by cross-linking a synthetic polymer and a bio-polymer is provided. The matrix is robust, biocompatible and non-cytotoxic and is capable of supporting cell in-growth in vivo. The matrix can be tailored to further comprise one or more bioactive agents. The matrix...

20060134053 - Composition for cosmetic or dermatological use containing a triblock polymer: The present patent application relates to a cosmetic and/or dermatological composition comprising at least one aqueous phase including at least one water-soluble or water-dispersible polymer, of triblock structure B-A-B in which A is an ionic water-soluble polymer block and B is a hydrophobic polymer block, the amount of polymer block...

20060134052 - Compositions comprising polymeric emulsifiers and methods of using same: Provided are compositions comprising a polymeric emulsifier, a hydrophobic agent, a wetting agent having at least one sulfonate group and at least one base-neutralizable carboxylic acid group, and a hydrophilic particulate material. Also provided are methods of mitigating diaper dermatitis using the composition, and methods of promoting the benefits associated...

20060134051 - Glossy non-transfer composition comprising a sequenced polymer: The present invention relates to a cosmetic composition containing a cosmetically acceptable organic liquid medium and a film-forming linear ethylenic block polymer, the said polymer being such that, when it is in sufficient amount in the composition: the mean gloss at 20° of a deposit of the said composition, once...

20060134054 - Polymer composition for ph dependent dissolution behavior and process for preparation thereof: The present invention relates a novel pH sensitive polymer which exhibits pH dependant swelling/dissolution behavior. The composition is useful for taste masking of bitter drugs and also for the gastric delivery of the drugs. The said polymer comprises a hydrophobic monomer polymerized along with a basic monomer or a hydrophobic...

20060134042 - Hair shaping composition comprising at least one tetramethylguanidine: The present disclosure relates to a ready-to-use composition for permanently shaping keratin fibers comprising, as permanent shaping agent, at least one tetramethylguanidine, a kit comprising compartments comprising the contents of the ready-to-use composition, and also to a process for using this composition....

20060134055 - Clobetasol propionate shampoos for the treatment of seborrheic dermatitis of the scalp: Seborrheic dermatitis is effectively/safely treated by topically applying a corticosteroid shampoo, notably a clobetasol propionate shampoo, onto the scalp of a human subject afflicted therewith....

20060134056 - Use of alkylguanidines as cationic emulsifiers: b

20060134057 - Cosmetic composition comprising a polyol ether and an ester: Disclosed herein is a composition comprising, in at least one physiologically acceptable medium, at least one fatty phase comprising at least one polyol ether and at least one neoacid ester. The polyol ether may be, for example, a pentaerythritol ether. This composition may, for instance, constitute a stick and may...

20060134043 - Makeup composition: An oil-in-water makeup composition containing (A) from 1 to 40% by weight of a component selected from the group consisting of a carboxylic acid having from 23 to 100 carbon atoms, a salt form thereof, and mixtures thereof, (B) from 1 to 30% by weight on a solid basis of...

20060134059 - Compositions and methods of their use for improving the condition and appearance of skin: The present invention relates to compositions and methods for treating, preventing and improving the condition and aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include natural plant constituents which increase expression levels genes associated with the dermatological signs...

20060134058 - Hair treatment lotion: A hair treatment lotion comprising green tea, gentian and geranium mixed with at least one solution medium and adapted to be used for hair loss prevention treatments and/or to facilitate the growth of new hair....

20060134060 - Ophthalmic compositions comprising aloe vera: Disclosed herein are new formulations containing Aloe Vera. These formulations are useful as eye drops that provide high patient compliance as well as carriers for pharmaceuticals such as steroids and anti-allergy ophthalmic drugs....

20060134061 - Bisacyloxypropylcysteine conjugates and the use thereof: The invention relates to novel lipopeptide conjugates, in which a cysteine that is double-substituted by a fatty acid is bonded by means of the carboxyl group to a highly soluble, physiologically compatible and non-immunogenic, polymeric conjugate group. The novel conjugates exhibit an excellent macrophage stimulant action and do not require...

20060134062 - Polymeric boronic acid derivatives as lipase inhibitors: Human obesity is a health problem affecting a significant proportion of the American population. Numerous methods of treating obesity have been developed, but all have serious drawbacks. The present invention discloses a novel class of polymers with either a sulfur atom or an electron withdrawing group between a polymer backbone...

20060134063 - Agents for proliferating pancreatic beta-cells of the islets of langerhans, agents for suppressing apoptosis of said cells, and screening of candidate compounds for these agents: The present invention provides agents for proliferating pancreatic β-cells of Langerhans' islets, agents for suppressing apoptosis of the cells, and methods of screening for candidate compounds for these agents. The combined use of an inflammatory mediator IL-6 and glucocorticoid remarkably induces the expression of Reg gene in β cells and...

20060134064 - Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and IFNα combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy....

20060134065 - Composition comprising the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors including the corresponding nucleic sequences and their therapeutic use: The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The...

20060134067 - Loading of cells with antigens by electroporation: Methods for loading an antigen-presenting cell with one ore more antigens are disclosed. Methods for the treatment and prevention of a disease in a subject using an antigen-presenting cell that has been electroporated with a composition of one or more antigens. Composition of one or more antigens comprises one or...

20060134066 - Localization of vectors and other agents: Methods are disclosed to enhance controlled localization and/or release of an agent at an anatomical and/or physiological site where the agent is desirable. In one embodiment, the method localizes vector transfected with a gene(s) that enhances neovascularization (i.e., genes encoding angiogenic agents). In another embodiment, the method localizes genes that...

20060134068 - Treatment of cancer by simultaneous inhibiton of braf and restoration or mimicry of p16ink4a activity: Provided is a method for inhibiting growth of a tumor cell which comprises oncogenically activated BRAF and defective p16INK4A by inhibiting activated BRAF and restoring functional p16INK4A. Also provided is a method for sensitizing the foregoing tumor cell to cytotoxic or cytostatic effect of a chemotherapeutic agent or radiation by...

20060134077 - Electronic commerce system including customized catalog having encoded information: The invention features methods for the treatment of diabetes by administering a IAP nucleic acid sequence to a subject. One method includes the steps of (a) providing one or more insulin-producing cells or one or more precursor cells capable of producing progeny cells that produce insulin; (b) transducing the cells...

20060134079 - Implantable medical devices comprising isolated extracellular matrix: Implantable devices containing extracellular matrix and methods of using the devices are provided....

20060134078 - Method for culturing neural stem cells using hepatocyte growth factor: A medium containing hepatocyte growth factor (HGF) was shown to induce neurosphere formation. Furthermore, the addition of HGF to a culture medium containing FGF-2, EGF, or both increased both the size and number of newly formed neurospheres. Thus, the present invention relates to a growth medium comprising HGF for culturing...

20060134081 - Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system: The present disclosure relates to a method for introducing a hematopoietic cell into the brain of a mammal, by administering bone marrow-derived progenitor cells into the body of the mammal by intravenous injection. The bone marrow-derived cell is preferably a cell that differentiates into a glial cell. The disclosure also...

20060134080 - Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics: The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1+...

20060134083 - Compositions comprising sclareol or derivatives thereof and uses thereof: The present invention provides a composition which includes a sclareol or a derivative thereof, wherein the sclareol or a derivative thereof is bound by a glycoprotein matrix. The composition of the invention provides improved potency, stability and bioactivity characteristics of sclareol, or its derivatives....

20060134082 - Mammalian animal compositon: The present invention relates to the use of probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal Camplylobacter infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal, the method...

20060134075 - Composition and method for improving function of embryonic kidney transplants: Methods and compositions are disclosed for use with embryonic metanephric tissue so as to increase the functioning renal mass obtained upon transplantation into a recipient....

20060134073 - Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using analogues of camp and cgmp: The present invention relates to ex vivo methods for preserving/maintaining blood vessels that are to be used as vascular grafts. The present invention also relates to compositions comprising an analogue of cAMP and/or an analogue of cGMP for use in the methods of the invention, which compositions are free of:...

20060134074 - Compositions and methods for promoting hair growth: The present disclosure provides compositions and methods for promoting the growth of hair for cosmetic purposes as well as for treating disorders of hair growth. The compositions are conditioned media obtained from a three dimensional tissue that produce a combination of cellular factors effective to induce, promote, or enhance hair...

20060134069 - Erythrocytic cells and method for preserving cells: A dehydrated composition is provided that includes freeze-dried erythrocytic cells. Alcohol (e.g., sterol or cholesterol) is at least partially removed from erythrocytic cells including erythrocytic membranes. After removal of at least part of the alcohol, the erythrocytic cells have a low phase transition temperature range, an intermediate phase transition temperature...

20060134072 - Self-assembling protein matrix prepared from natural extracellular matrices: The present invention provides a method for preparing a biomaterial involving extracting Collagen Type I (Col I) protein from small intestine submucosa (SIS) under conditions that preserve the native helical configuration. The extract of the present method contains a substantial amount of the alpha helical form of Col I. Further...

20060134076 - Three dimensional bioengineered smooth muscle tissue and sphincters and methods therefor: This invention relates to a three dimensional bioengineered sphincter such as a bioengineered internal anal sphincter (IAS) and three-dimensional physiological models of smooth muscle cells. The invention also related to methods for generating a bioengineered sphincter and smooth muscle rings in culture. In addition, the invention provides for methods of...

20060134070 - Tissue regeneration: A method including positioning a delivery device at a location in a vessel within a mammalian body, introducing a first treatment agent including a cellular component through the delivery device, and introducing a different second treatment agent disposed in a carrier through the delivery device. A method including identifying an...

20060134071 - Use of extracellular matrix and electrical therapy: The invention provides methods and devices useful for cardiac repair....

20060134084 - Therapeutic platelets and methods: A dehydrated composition is provided that includes freeze-dried platelets. The platelets are loaded with trehalose which preserves biological properties during freeze-drying and rehydration. The trehalose loading is conducted at a temperature of from greater than about 25° C. to less than about 40° C., most preferably at 37° C., with...

20060134085 - Compositions containing coenzyme q10: A coenzyme Q10-containing composition comprising a coenzyme Q10 and a hydrophilic fatty acid ester of a polyhydric alcohol; a coenzyme Q10-containing composition comprising a coenzyme Q10, a lipophilic fatty acid ester of a polyhydric alcohol and a hydrophilic fatty acid ester of a polyhydric alcohol; and a food or beverage...

20060134086 - Targeted enzymes: The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes....

20060134087 - Iti-d1 kunitz domain mutants as hne inhibitors: Mutants of Kunitz domain 1 (ITI-D1) of human inter-α-trypsin inhibitor (ITI), are useful as inhibitors of human neutrophil elastase. Mutants characterized by one or more of the following substitutions (numbered to correspond to bovine pancreatic trypsin inhibitor, the archetypal Kunitz domain) are of particular interest: (a) Val15 or Ile15, (b)...

20060134088 - Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit: A kit for the treatment of retinitis pigmentosa containing the enzymes glutathione peroxidase, prolidase, glucose-6-phosphate dehydrogenase and, optionally, aldose reductase in aliquot parts and interactive quantities appropriate for administering said enzymes in accordance with a predefined time sequence....

20060134089 - Nitric oxide synthase gene transfer to the atrium for vagal tone increase: High vagal tone is a positive prognostic indicator against sudden cardiac death, whereas impaired activity is a strong t predictor of mortality. NOS gene transfer to cardiac tissue has been found to increase expression of the enzyme in cholinergic ganglia, to increase the release of acetylcholine, and to enhance the...

20060134090 - Method and dietary composition for improving lipid digestibility: A method of providing a pet with a benefit relating to effective assimilation of a lipid is described wherein the pet is administered, as a part of, or in addition to its regular diet, an edible composition that contains an ingredient that maintains, promotes or enhances the capacity of the...

20060134091 - Additive for an animal feed: The present invention relates to the use of a combination of a protease and an inner salt of a quaternary amine carboxylic acid for the preparation of an agent for the treatment and/or prophylaxis of coccidiosis and bacterial infections such as necrotic enterities in animals. Preferred embodiments of the invention...

20060134092 - Method of degrading hardly degradable protein: Disclosed is an agent for digesting a protein highly resistant to denaturation and degradation, comprising as an active ingredient an enzyme exhibiting an activity of digesting a protein highly resistant to denaturation and degradation and having the following properties: (a) activity and substrate specificity: hydrolyzing a peptide bond of a...

20060134093 - Fibrin cell supports and methods of use thereof: The present invention relates to fibrin cell supports for cell cultures formed by the mixture of plasma proteins including fibrinogen and thrombin. The fibrin cell supports are preferably used for preparing a culture of cells such as keratinocytes, recovering the culture in the form of a reconstituted tissue, and transporting...

20060134094 - Fibrin material and method for producing and using the same: This invention describes a bioerodible fibrin material which is obtained by mixing fibrinogen and thrombin reconstituted or diluted with a particular high tonic strength medium, free of calcium. Such a fibrin-based biomaterial develops a tight structure with thin fibers and small pore size suitable for use as an anti-adhesion...

20060134095 - Antioxidative composition and composition for external use: As a technical means of enabling the application of a fullerene and an analogue thereof in various fields relating to biocompatibility to achieve a novel function, in particular as a means of applying the same to a cosmetic product, a formulated skin preparation for external use or the like, an...

20060134096 - Compositions and methods for medical use of graphene-containing compositions: Non-porous carbon materials that are materials other than a fullerene or a nanotube are employed for medical use, wherein the carbon material has a smallest dimension of less than 100 nanometer. In preferred aspects, the material is topically used on a wounds, orally administered as sorbent for various toxins, or...

20060134097 - Process for production of aqueous colloid of graphite silica particles emitting far-infrared rays: To prevent or treat diseases in which active oxygen is involved such as inflammatory cell injury, diabetic diseases (nephropathy, retinopathy, and neuropathy), ischemia and reperfusion injury, renal failure, rheumatoid arthritis, and myocardial infarction, a process for producing an aqueous colloid of graphite silica particles emitting far-infrared rays, the process comprising...

20060134098 - Immunoglobulin variable region cassette exchange: The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the VH and VL sequences of the reference antibody with sequences from human antibody repertoires. The invention also provides novel compositions comprising hybrid immunoglobulin variable domains containing a combination of...

20060134099 - Production of rabies antibodies in plants: Human rabies monoclonal antibodies (rabies MAbP) comprising rabies human MAb S057 heavy chain and light chain subunits are expressed and assembled in plants under the control of two strong constitutive promoters. Additionally, regulatory control elements such as alfalfa mosaic virus untranslated leader sequence and Lys-Asp-Glu-Leu (KDEL) endoplasmic reticulum retention signal...

20060134106 - Antibody composition and passive immunization against pregnancy-induced hypertension: A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds...

20060134103 - Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands: Disclosed herein are multimeric molecular complexes and compounds that are multivalent, i.e., they have two or more targeting elements directed to a ligand that confers paracellular transporting properties and/or transcytotic properties to complexes and compounds to which it is bound. The complexes and compounds have properties that are different from...

20060134100 - Dc-sign blockers and their use for preventing or treating viral infections: The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN receptor present on cells of the mammal...

20060134104 - Humanized anti-cmet antagonists: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies....

20060134105 - Igg immunoglobulin variants with optimized effector function: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes....

20060134107 - Immunoglobulins devoid of light chains: The invention relates to an immunoglobulin having determined antigen specificity, and having a variable fragment which is derived from a so-called heavy-chain immunoglobulin having two heavy polypeptide chains capable of recognizing and binding one or several antigens and which is further naturally devoid of light chains, wherein the immunoglobulin having...

20060134102 - Lymphotoxin beta receptor agents in combination with chemotherapeutic agents: This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other chemotherapeutic agents, as well as therapeutic methods and screening methods for identifying agents that in combination with a lymphotoxin-beta receptor agonist agent have a supra-additive effect on tumor inhibition....

20060134101 - Use of avian antibodies: The present invention relates to a novel method for treatment and prophylaxis of infections, especially enteric infections, in newborns, which is both safe and effective. This is achieved by using IgY directed against microbes, in particular against Enterobacter cloacae, which have been obtained by hyperimmunising birds with an antigen (microbe)...

20060134108 - Method for retarding or precluding alzheimer's dementia: A method for treating a condition related to the development of Alzheimer's disease (AD) is disclosed. The method involves the removal of circulating autoantibodies of a biochemical marker or markers, specifically human glial fibrillary acidic protein (GFAP) and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH), from the sera of a patient in an amount effective...

20060134109 - G protein coupled receptors and uses thereof: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists)...

20060134110 - Cd55-interaction partners and the uses thereof: The invention relates to the use of a binding member which binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody which binds to SCR1 and SCR2 of CD55 and neutralising CD55 and making cancer cells susceptible to...

20060134111 - Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy: The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNFα-inhibitors....

20060134113 - Preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient: A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising an interleukin-6 (IL-6) antagonist, for example an antibody directed against IL-6 receptor, an antibody directed against IL-6, an antibody directed against gp130, and the like....

20060134112 - Uses of mammalian cytokine; related reagents: Provided are methods of treatment for inflammatory and autoimmune disorders of the metabolic system. Also provided are methods of diagnosis....

20060134115 - Method of screening for sensitivity to kinase inhibitor therapy: Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of...

20060134114 - Novel human kallikrein-like genes: The invention relates to nucleic acid molecules, kallikrein-like proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules....

20060134116 - Ca 125 tumor antigen function and uses thereof: The present invention is directed to modulators of CA 125 tumor antigen, a recombinant nucleic acids, vectors, host cells, pharmaceutical compositions, uses of the foregeoing for negatively modulating CA 125 tumor antigen in mammalian cell, preventing and treating a CA 125 tumor antigen associated disease in a mammal, as well...

20060134121 - Dii4 antagonists, assays, and therapeutic methods thereof: Methods for screening for agents capable of inhibiting Dll4 are provided, as well as therapeutic methods for treating Dll4-mediated conditions. More specifically, methods are provided for identifying agents capable of inhibiting blood vessel growth and formation, such as antibodies to human DLL4....

20060134119 - Drugs containing galectin 9: Galectin 9 exerts various functions depending on its localizations. On the other hand, galectin 9 is expected as participating in various biological functions. Thus, it has been required to clarify the detailed biological activities of galectin 9 and develop galectin 9-related techniques including development of drugs. Human galectin 9 shows...

20060134118 - Methods for regulating cancer: The present invention provides methods for inhibiting cancerous growth of a cell using an antibody or an antigen-binding portion thereof which binds to an epitope of EphB4 polypeptide. Purified antibodies of EphB4 are also provided. The invention also provides methods for preventing or treating cancer. The invention also relates to...

20060134120 - Multiple marker assay for detection of ovarian cancer: Methods for diagnosing and monitoring ovarian cancer in a subject comprising measuring a plurality of kallikrein polypeptides, and optionally CA125, or nucleic acids encoding the polypeptides in a sample from the subject. The kallikrein polypeptides include kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11....

20060134122 - Peptides of syndecan-1 for inhibition of cancer: The present invention provides a novel peptide from the extracellular domain of syndecan-1 that inhibits migration, metastasis, survival and proliferation of cancer cells....

20060134117 - Preventives/remedies for cancer: A compound inhibiting the activity of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 17, SEQ...

20060134123 - Methods and means for targeted gene delivery: A method for producing viral gene delivery vehicles which can be transferred to pre-selected cell types by using targeting conjugates. The gene delivery vehicles comprise: 1) the gene of interest; and 2) a viral capsid or envelope carrying a member of a specific binding pair, the counterpart of which is...

20060134124 - Immunosuppression: The invention herein described relates to a method to improve the tolerance of a mammal, preferably a human, to a xenograft through immunisation of the recipient mammal with an immunogen comprising both a B cell epitope derived from porcine polypetides and T cell epitope. The invention also encompasses immunogenic compositions...

20060134125 - Purification of antigen-specific t cells: A new method to capture, purify and expand antigen-specific T lymphocytes has been developed using magnetic beads coated with recombinant MHC class I molecules. This method was optimized using homogenous populations of naive T cells purified from mice transgenic for the 2C T cell receptor (TCR). These T cells were...

20060134127 - Antiallergic agent: It is intended to provide an anti-allergic agent, which efficaciously relieves symptoms accompanying an allergic disease without causing any serious side effect. This object is achieved by providing an anti-allergic agent which contains, as an effective ingredient, proteins collected from royal jelly or purified royal jelly, or royal jelly or...

20060134128 - Novel adaptor protein binding to mammalian toll-like receptor 3, and gene thereof: A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors,...

20060134130 - Oral drug delivery compositions and methods: The present invention relates to an oral drug delivery system, and in particular to modified amino acids and modified amino acid derivatives for use as a delivery system of sensitive agents such as bioactive peptides. The modified amino acids and derivatives can form non-covalent mixtures with active biological agents and...

20060134126 - Peptide constructs for treating disease: This invention relates to peptides directing a CD4 related T helper cell response wherein the peptides may be used as an adjuvant provided with an antigen or as an immunomodulatory agent without an antigen and compositions comprising modification of a fifteen-mer peptide sequence from the MHC IIβ chain at positions...

20060134129 - Synthetic hla binding peptide analogues and uses thereof: The present invention is directed to immunogenic bcr-abl-based peptides, compositions and vaccines comprising same, and methods of use thereof for treating, inhibiting or reducing the incidence of a bcr-abl-expressing cancer, and methods of generating a heteroclitic immune response against, or cytotoxic T cells specifically recognizing bcr-abl-expressing cancer cells....

20060134131 - Cosmetic or pharmaceutical composition comprising a genus halopteris brown alga extract: The present invention concerns the use of an extract of a brown alga of the genus Halopteris or Sphacelaria in a cosmetic or pharmaceutical composition intended to limit the expansion of adipose tissues through its effect on pre-adipocyte differentiation....

20060134132 - Protective barriers for micronutrients, phytochemicals, and nutraceuticals: Compositions that act as a protective barrier for micronutrients, phytochemicals, and nutraceuticals such as may be found in food products, for example food additives. Also, a process for producing food additives using the compositions....

20060134133 - Mva expressing modified hiv envelope, gag, and pol genes: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes....

20060134135 - Bacterial virulence genes: An attenuated Actinobacillus pleuropneumoniae bacterium has a mutation in a gene required for bacterial virulence. Vaccines based upon the bacterium are provided, as are isolated virulence genes and polypeptides and uses thereof....

20060134134 - Method of obatining cochlear structures, vaccine compositions, adjuvants and interme- diates thereof: The present invention has applications in the field of immunology, specifically in the sphere of adjuvants and vaccines. The invention aims at obtaining cochlear structures from vesicles found in the outer membranes of microorganisms, in order to employ them in the preparation of adjuvants and vaccines. The invention also discloses...

20060134136 - Whole bacterial cells as immune modulator: An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, wherein said immune modulator composition in use modifies a cellular immune response....

20060134137 - Transduction vector based on modified hiv-2: A lentiviral vector system for gene transfer and gene therapy is disclosed. The system is based on human immunodeficiency virus type 2 (HIV-2), and uses a split-genome approach. The vector system can integrate into a host genome regardless of cell division. It may be used in terminally-differentiated cells. It has...

20060134138 - Recombinant influenza viruses for vaccines and gene therapy: The invention provides a composition useful to prepare influenza A viruses, e.g., in the absence of helper virus....

20060134139 - Dried product and a process for manufacturing the product: A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid...

20060134140 - Compositions and methods for treating tumor spreading: Pharmaceutical compositions, each consisting of a cell-permeable fusion protein conjugate of a polypeptidic cell-membrane transport moiety and a Clostridium botulinum C3 exotransferase unit, or a functional analog thereof, are provided. The compositions are useful to prevent or inhibit uncontrolled proliferation, spreading, and migration of a metastatic neoplastic cell of a...

20060134141 - Glycoconjugate vaccines containing peptidoglycan: The present invention relates to vaccines for treating bacterial infections, which vaccines comprise a glycoconjugate immunogen comprising at least one capsular polysaccharide conjugated to a carrier protein, such that the capsular polysaccharide contains an amount of peptidoglycan effective to improve the vaccine's properties....

20060134142 - Modified streptococcal polysaccharides and uses thereof: Modified streptococcal polysaccharides and methods of using the modified polysaccharides are provided herein....

20060134143 - Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli: Immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacilli are provided that include immunogenic conjugates of a poly-γ-glutamic acid (γPGA) polypeptide of B. anthracis, or of another Bacillus that expresses a γPGA polypeptide. The γPGA conjugates elicit an effective immune response against B. anthracis,...

20060134148 - Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs: The present invention relates to liquid sustained release suspension dosage forms comprising ionized forms of water-soluble drugs. In particular, the invention encompasses a liquid form controlled release drug composition comprising a dispersed phase comprising an ion-exchange matrix drug complex comprising a pharmaceutically acceptable ion-exchange matrix and a water-soluble electrolytic drug...

20060134147 - Cosmetic compositions having carnitine creatinate and methods for using: There is a topical composition having carnitine creatinate and a cosmetically acceptable vehicle. There is also provided a method for improving the aesthetic appearance of skin. There is also provided a method for inhibiting the induced lipid synthesis in skin. There is also provided a method for inhibiting the formation...

20060134149 - Methods for treatment of inflammatory diseases: An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is an oil-in-water emulsion that includes allantoin and an emulsifier system that includes at least one emulsifier that is...

20060134144 - Mucoadhesive composition and formulation for solubilization of insoluble drugs and preparation method thereof: The present invention relates to a novel mucoadhesive composition for solubilization of insoluble drugs; its formulation including pharmaceutical compounds; and the preparation methods thereof wherein said solubilizing composition comprises 4˜90% by weight of at least one selected from the monoglycerides and 0.01˜90% by weight of at least one oil. The...

20060134151 - Novel sulfamide derivatives and cosmetic use thereof: e

20060134145 - Propofol-containing fat emulsions: The present invention provides a propofol-containing fat emulsion comprising propofol, an oily component, and an emulsifier, and further comprising a predetermined amount of a stabilizer, such as phosphatidylglycerol in which a specific fatty acid is a constituent fatty acid component. The present invention also provides a pain-relieving propofol-containing fat emulsion,...

20060134146 - Stable dispersion of solid particles comprising a water-insoluble pyrazine compound: e

20060134150 - Submicron suspensions with polymorph control: The present invention provides a method for preparing a suspension of a pharmaceutically active compound, the solubility of which is greater in a water miscible first organic solvent than in a second solvent which is aqueous, The process includes the steps of: (i) dissolving a first quantity of the pharmaceutically...

20060134155 - Compositions and methods of their use for improving the condition and appearance of skin: The present invention relates to compositions and methods for treating, preventing and improving the condition and/or aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include active agents which increase expression levels of genes associated with the dermatological signs...

20060134154 - Hair treatment composition: Hair treatment compositions comprise an aqueous dispersion of water insoluble composite particles, the particles comprising: i) a clay with a net surface charge, ii) a charged organic molecule comprising at least 6 carbon atoms iii) a water insoluble hair benefit agent which is immiscible with the charged organic molecule, wherein...

20060134153 - Makeup method based on texture and texture: A texture word map is produced by selecting a plurality of texture words to express the makeup textures; classifying the plurality of selected texture words into two types; producing a texture word map by arranging one characteristic in the ordinate and the other characteristic in the abscissa and arranging positional...

20060134156 - Method for caring for the skin and associated kit: The present invention relates to a method for caring for the skin, intended to soften cutaneous signs of ageing, by the successive application to the skin, wetted beforehand, of four compositions, namely: a microdermabrasion composition, a peeling composition, a soothing composition and an anti-ageing composition having a given constitution. It...

20060134152 - Method for preparing beads containing a crosslinked mineral matrix: The invention relates to a process for the preparation of beads comprising a crosslinked inorganic matrix and to the beads obtained. The process consists in preparing gelled beads by pouring a suspension comprising a precursor of the inorganic matrix and an alginate dropwise into a solution of a polyvalent cation...

20060134166 - Absorbable biocompatible materials: Biocompatible carrier materials are described herein for enhanced delivery of therapeutic agents. Embodiments include materials and methods for making a biodegradable coating on a surface of a medical device by forming a biodegradable layer on at least a portion of the surface of the medical device, the layer comprising a...

20060134160 - Calcium phosphate coated implantable medical devices and processes for making same: This invention relates to novel calcium phosphate-coated implantable medical devices and processes of making same. The calcium-phosphate coatings are designed to minimize the immune response to the implant (e.g. restenosis in stenting procedures) and can be used to store and release a medicinally active agent in a controlled manner. Such...

20060134158 - Chitosan/acidic biopolymer hybrid fiber and culture base for animal cells: It is intended to provide a three-dimensional scaffolds appropriate for culturing animal cells such as chondrocytes and fibroblasts. These three-dimensional scaffolds which comprise a chitosan/acidic biopolymers hybrid fibers composed of chitosan or its salts in the inside of the fiber and complexes of chitosan with biodegradable acidic biopolymers coating the...

20060134157 - Co-continuous phase composite polymer blends for in-vivo and in-vitro biomedical applications: Tissue-compatible polymer composites characterized by a co-continuous, integrated multi-phase, three-dimensional microstructured network of two or more immiscible biocompatible polymers....

20060134168 - Coatings with crystallized active agent(s) and methods: The present invention relates to coatings with crystallized active agent(s) and related methods. In an embodiment, the invention includes a method for coating a medical device including selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a...

20060134159 - Device for the surgical treatment of female prolapse: A device is described having a reticular or laminar structure to be surgically implanted in uro-gynaecological treatments, useful in particular for the surgical treatment of total or partial prolapse of the female pelvic organs or of prolapse of the vaginal vault....

20060134163 - Immobilizing anti-microbial compounds on elastomeric articles: A method for modifying the surface chemistry of an elastomeric substrate and articles embodying the substrate is described. The method involves pre-treating the substrate surface to create active oxygen groups on the substrate for immobilizing securely an antimicrobial agent to the substrate. The active oxygen groups can react and bind...

20060134162 - Methods for fabricating a drug delivery device: A drug delivery device for placement in the eye includes a drug core comprising a pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent...

20060134167 - Methods of therapy with thrombin derived peptides: The present invention relates to a method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide and/or inhibiting or reducing vascular occlusion or restenosis. The invention also relates to methods of stimulating revascularization. In yet another embodiment, the...

20060134165 - Polymers of fluorinated monomers and hydrocarbon monomers: A polymer of fluorinated monomers and hydrocarbon monomers is provided. It is also provided a polymer blend that contains a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer. The polymer or polymer blend described herein and optionally a bioactive agent can form an implantable device such...

20060134164 - Th2-inducing adjuvant treatment for osteolysis: Active immunization and a formulation for treating or preventing osteolysis caused by Wear Particles, comprising: a) a Th2 -inducing adjuvant, and b) Wear Particles....

20060134161 - Water-swellable polymers: A water-swellable linear polyurethane polymer is formed by reacting a polyethylene oxide (e.g. PEG 4000 to 35,000), a difunctional compound (e.g. a diamine or diol such as 1,10-decanediol) with a diisocyanate. The ratio of the three components is generally in the range 0.1-1.5 to 1 to 1.1-2.5. The polyurethane is...

20060134171 - Agents which regulate, inhibit, or modulate the activity and/or expression of formyl peptide receptors as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of FPR....

20060134172 - Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of lysyl oxidase (LOX) or a lysyl oxidase-like protease (LOXL)....

20060134177 - Amphiphilic block copolymers and their use: The present invention relates to amphiphilic block copolymers comprising at least one block of hydrophilic units and at least one block of hydrophobic units, wherein at least one hydrophobic block contains siloxane units. The present invention may be particularly useful as a tissue adhesive or as a coating for an...

20060134175 - Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use: The present invention includes a pharmaceutical delivery system comprising a fused pyrrolocarbazole and a drug-eluting polymer matrix configured to be inserted into the eye of the patient....

20060134174 - Pharmaceutical delivery system and method of use: The present invention includes a pharmaceutical delivery system comprising a fused pyrrolocarbazole and a biodegradable polymer matrix configured to be inserted into the eye of the patient....

20060134176 - Pharmaceutical delivery system and method of use: The present invention includes a pharmaceutical delivery system comprising a fused pyrrolocarbazole and a pharmaceutical delivery device that is selected from the group consisting of reservoir device and drug infusion device. The pharmaceutical delivery systems are sized and configured to be inserted into the eye of the patient....

20060134169 - Polymerizable surfactants and their use as device forming comonomers: This invention describes the use of polymerizable surfactants as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc....

20060134173 - Polysiloxanes, method of synthesis and ophthalmic compositions: A linear polysiloxane copolymer has at least one terminal hydroxyalkyl group. The copolymer is preparable by a process comprising a combination of a base-catalysed polymerisation with an acid-catalysed redistribution, and is suitable for preparing ophthalmic compositions for forming an intraocular lens in situ....

20060134170 - Vision enhancing ophthalmic devices and related methods and compositions: Devices, methods, and compositions for improving vision or treating diseases, disorders or injury of the eye are described. Ophthalmic devices, such as corneal onlays, corneal inlays, and full-thickness corneal implants, are made of a material that is effective in facilitating nerve growth through or over the device. The material may...

20060134178 - Composition containing organic substance having double bond with improved oxidative stability: To an organic substance having a double bond such as a polyunsaturated fatty acid was added an antioxidative component containing an antioxidative sesame component and ascorbic acid or an ascorbyl fatty acid ester. The above method provides a composition containing an organic substance having a double bond exhibiting enhanced oxidative...

20060134180 - Encapsulated polyunsaturated fatty acids: The present invention relates to process for the preparation of particles comprising an oil comprising polyunsaturated fatty acids (PUFA), to particles susceptible to be obtained by the process and to a method for increasing stability of PUFAs in oils at temperatures above 70° C. The process involves the step of...

20060134179 - Health food product: The present invention provides a health food product comprising (A) proanthocyanidins, (B) ascorbic acid or a derivative thereof, and (C) L-cysteine or a derivative thereof. Preferably, proanthocyanidins containing at least 20 wt % of OPCs are used. The health food product of the present invention makes the body itself healthy...

20060134181 - Novel chocolate composition as delivery system for nutrients and medications: A novel chocolate product for use in delivering medicaments and/or nutrients to animals, particularly humans, specially formulated so that the craving for such product by animals, particularly humans, is significantly greater than the craving for chocolate conventionally used in pharmaceutical compositions and the concentration, optimization, and the addition of endogenous...

20060134183 - Pet food compositions having a defined relaxation property: Disclosed herein are pet food compositions exhibiting a defined Maximum Relaxation Force and Maximum Relaxation Stress. The pet food compositions exhibit prolonged chew time by the pet. In optional embodiments, the pet food compositions comprise one or more of water, humectant, a grain source, or a cross-linking agent....

20060134182 - Sphingolipids for improvement of the composition of the intestinal flora: The present invention relates to a method for improving the composition of the intestinal flora, to a food comprising a sphingolipid for use in such a method, to methods for the preparation of such a food and to the use of sphingolipids for the preparation of a medicine for improving...

20060134184 - At least partially degradable films containing an active ingredient and method for the production of composition comprising an active compound: A film which comprises at least one active compound and is at least partly degraded under the conditions of the site of action is suitable as a new presentation form of active compounds, in particular those having a pharmacological or biocidal action....

20060134185 - Self-adhesive reabsorbable hemostyptic: The invention relates to a reabsorbable hemostyptic self-adhering to human or animal tissue and essentially consisting of at least one polymer which carries free aldehyde groups and whose aldehyde groups are able to react with nucleophilic groups of the tissue, the hemostyptic being present in solid, in particular dry, porous...

20060134187 - Method for treating inflammation associated with acne: The present invention is directed to a method of treating the inflammation associated with acne, comprising applying a patch to an affected area of the skin, wherein said patch includes an efficacious amount of a cortisone. The patch of the present invention may be self adhesive or treated with a...

20060134186 - Oxygenating agents for enhancing host responses to microbial infections: Oxygenating agents are used in the present invention for the novel purpose of treating microbial infections. The invention takes advantage of the fact that the increase in tissue pO2 produced thereby can enhance the efficacy of the body's own antimicrobial defenses (including tissue repair), while also improving the efficacy of...

20060134188 - Transdermal pharmaceutical preparation with a progesterone a-specific ligand (prasl) as active ingredient: y

20060134189 - Sirna silencing of apolipoprotein b: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence ApoB expression and methods of using such nucleic acid-lipid particles to silence ApoB expression....

20060134190 - Formulations of bisphosphonate drugs with improved bioavailability: This invention relates to formulations of bisphosphonates such as alendronate. The formulations taught herein enhance bioavailability of bisphosphonates and reduce esophageal and gastric ulcerations associated with them. Also taught herein are methods of preparing the formulations and their clinical use in the treatment of osteoporosis and other bone diseases....

20060134201 - Collagen troches for treating mouth lesions: A soluble/erodable troche for delivering collagen in the mouth for treatment of mouth lesions. The collagen may be gelatin from animal skins. The structure of the troche may be formed with a porous network that remains solid at human mouth temperatures and slowly dissolves/erodes in saliva. In some embodiments, the...

20060134204 - Complexes made using low solubility drugs: Disclosed herein are substances that include a complex that includes a drug moiety ionically bound to a counter-ion; wherein a solubility of the complex is greater than a solubility of the drug moiety. Also disclosed are compositions and dosage forms made from such substances and complexes; methods of making compositions,...

20060134196 - Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof: A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the...

20060134194 - Formulations containing substituted imidazole derivatives: Improved formulations containing substituted imidazole derivatives of the general formula 1, formula (I) wherein Y is —CH2— or —CO—, R1 is H, halo or hydroxy, R2 is H or halo, and R3 is H or lower alkyl (e.g. C1 to C4 alkyl, preferably C1 or C2 alkyl), or a pharmaceutically...

20060134202 - Homeopathic sublingual dosage forms and methods thereof: A sublingual dosage form comprises an inert preformed tablet including at least one excipient and at least one wicking agent, with the at least one wicking agent adapted to selectively absorb at least one solvent-borne medicating ingredient from one portion of the inert preformed tablet into another portion of the...

20060134191 - Immediate-release pharmaceutical dosage form comprising polymorphous tibolone: An immediate-release pharmaceutical dosage form comprising, as the active substance, polymorphous tibolone and pharmaceutically acceptable excipients, wherein the polymorphous tibolone has a mean particle size as defined in the specification of below 22.8 μm in the dosage form....

20060134195 - Mannose-based fast dissolving tablets: Fast-dissolving pharmaceutical tablets comprising mannose are described. The mannose component imparts both structure-forming and fast-dissolution properties to the tablets. Granulation of tablet components and humidification forms strong liquid bridges at the surface interfaces of mannose particles, which leads to strengthened tablets. The mannose particles, however, remain porous following compression so...

20060134197 - Method of reducing unpleasant taste and/or unpleasant odor: The present invention has objects to provide a method of lowering the unpleasant taste and/or smell of compositions, and an agent for lowering unpleasant taste and/or smell. The objects are solved by providing a method of lowering unpleasant taste and/or smell, comprising a step of incorporating an saccharide derivative of...

20060134192 - Method of stabilizing diarylvinylene compound: The present invention provides, for example, a method for stabilization of a diarylvinylene compound such as a compound represented by the above formula (I) or the like, or a pharmaceutically acceptable salt thereof in a solid formulation containing the diarylvinylene compound or the pharmaceutically acceptable salt thereof, which comprises allowing...

20060134193 - Method to improve pharmaceutical tablets having a matrix of cellulose ether: This invention provides for a packaged tablet, which tablet has a matrix consisting of at least 55% of a cellulose ether, whereby the tablet has a water activity of at most 0.6 and is packaged such as to delay moisture uptake by the tablet in order to decrease the vulnerability...

20060134200 - Pharmaceutical composition based on agonist of benzodiazepine: The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration, including as active ingredient thereof, an agonist of the central receptor of benzodiazepinics chosen among diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam and midazolam maleate, in a mixture with a pharmaceutical excipient consisting of, at...

20060134203 - Pharmaceutical compositions: The present invention provides a pharmaceutical composition in solid form comprising a poorly water soluble drug, a solubilizing component, and a surfactant which is semisolid or solid. The poorly soluble drug may e.g. be a cyclosporin or a macrolide....

20060134198 - Pharmaceutical compositions with improved dissolution: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining...

20060134205 - Process for preparing a pharmaceutical composition: A method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, sponge-like or foam structures out of solutions and dispersions results in a favored pharmaceutical product. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid...

20060134199 - Tablet quickly melting in oral cavity: The object of the present invention is to provide, as a solid preparation for making it easy to take, thus improving patient's compliance etc., an intraorally rapidly disintegrating tablet which can be produced easily without any particular problem by a usual method of producing tablets with a usual tabletting machine,...

20060134208 - Controlled release and taste masking oral pharmaceutical composition: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution...

20060134207 - Dosage form containing diphenhydramine and another drug: A pharmaceutical dosage form which comprises diphenhydramine and/or a pharmaceutically acceptable salt thereof and at least one second drug. The dosage form provides a plasma concentration within the therapeutic range of the at least one second drug over a period which is coextensive with a substantial part of the period...

20060134206 - Oral compositions for treatment of diseases: This invention describes the use of pharmaceutical compositions, which comprise three components of which at least one is a slow release therapeutic agent. Such useful compositions are applicable for the treatment of humans suffering from diabetic, hypertensive, cardiovascular, hyperlipidemic conditions and their associated disorders thereof. Combination therapy has the advantages...

20060134209 - Sustained-release nanoparticle compositions and methods for using the same: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition....

20060134210 - Solid dosage form comprising proton pump inhibitor and suspension made thereof: A solid, rapidly gelling oral pharmaceutical dosage form, as well as an aqueous formulation prepared thereof, comprising a) an acid sensitive proton pump inhibitor as active ingredient distributed in a multitude of enteric coated pellets, and b) a suspension modifying granulate. Furthermore, the invention relates to an improved process for...

20060134214 - Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof: Disclosed is an enteric coated bead comprising at least one epothilone or epothilone analog; and a capsule comprising a multitude of the enteric coated beads. Also disclosed are a method of preparing the enteric coated bead and a method of treating cancer or other proliferative diseases using the enteric coated...

20060134216 - Enteric film coating composition containing enteric polymer micronized with detackifier: Dry, enteric, film-coating compositions and aqueous dispersions containing the same are disclosed. When applied to orally-ingestible substrates such as oral solid dosage forms, the film coatings are capable of preventing the substrates from disintegrating in media with pH values from about 1 to about 4.5 or higher values. One preferred...

20060134215 - Film coating composition, and coating and tablet of the composition: A film coating composition comprises polyvinyl alcohol and talc, and a content of the talc is 50 to 86% by mass based on 100% by mass of the total solid components of the film coating composition. A film consists of the film coating composition, and a tablet comprises the film....

20060134212 - Lercanidipine immediate release compositions: The present invention provides an immediate release composition for the low solubility drug, lercanidipine. The immediate release composition of the present invention comprises a core; a first layer, comprising lercanidipine, a surfactant and a binder, and optionally, a second layer comprising a film coating....

20060134217 - Leukotriene and integrin inhibitor combination and treatment method: The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of montelukast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms...

20060134211 - Multi-layer drug delivery device and method of manufacturing same: This application relates to a multi-layer drug delivery device and a method of manufacture. The device comprises a substrate; at least one first layer on the substrate containing the drug and a first solvent; and at least one second layer applied to the first layer to regulate release of the...

20060134213 - Stabilized ramipril compositions and methods of making: The present invention relates to ramipril compositions with improved stability. More particularly, the present invention is directed to pharmaceutical compositions comprising ramipril that are stabilized against decomposition into degradation products, namely, ramipril-diketopiperazine and ramipril-diacid, during formulation and storage conditions. The present invention also relates to methods for making and methods...

20060134218 - Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts: Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting...

20060134219 - Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs: The invention describes a new class of crystalline silica material having two levels or porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns...

20060134221 - Methods for producing block copolymer/amphiphilic particles: The invention relates to a method for manufacturing cell delivery particles, pharmaceutical component-particle dispersions, compositions comprising cell delivery particles and pharmaceutical compositions comprising pharmaceutical component-particle dispersions. The method comprises homogenization of mixtures comprising amphiphilic components and a block copolymer to form stable particles. The invention is also directed to cell...

20060134220 - Vectorization system comprising nanoparticles of homogenous size of at least one polymer and at least one positively charged polysaccharide and method for the preparation thereof: A vectorization and delivery system of therapeutic or diagnostic substances including (i) at least one polymer and (ii) at least one nontoxic positively charged polysaccharide, the nanoparticles having a substantially homogeneous distribution of size....

20060134222 - Process for encapsulating an active lipid-soluble substance by preparing a pit emulsion and emulsion obtained: The invention relates to a method of encapsulating an active lipid-soluble substance in nanocapsules, by preparing an emulsion. The inventive method is characterised in that it consists in: (a) obtaining an aqueous phase and an oil phase; (b) raising the temperature of the two phases to a temperature greater that...

20060134223 - Process for producing microparticles: An object of the present invention is to provide a solvent which is able to produce microparticles where content of the drug is still high and no initial burst takes place even when a drug having a low solubility in a halogenated hydrocarbon solvent is used. The present invention provides...

20060134224 - Engineered bone marrow: An engineered bone marrow composition, preferably comprising bone marrow cells, pulverized bone, and type 1 collagen, can be transplanted into the portal system of a patient. The engineered bone marrow provides a microenvironment, for engraftment of hematopoietic stem cells, that increases levels of chimerism while decreasing or eliminating failure of...

20060134225 - Phosphate binder with reduced pill burden: The present invention is generally directed to compositions and formulations that can be used for the treatment of diseases such as End Stage Renal Disease (“ESRD”) and Chronic Renal Insufficiency (“CRI”). Specifically, it is directed to lanthanum-based compounds that bind phosphate and that can be formulated to provide for a...

20060134226 - Compositions useful to treat ocular neovascular diseases and macular degeneration: The present invention provides a composition that includes: (a) xanthophylls; (b) vitamin C; (c) vitamin E; (d) zinc; and (e) copper. The present invention also provides a method of treating macular degeneration in a human, inhibiting angiogenesis in a human, preventing impairment of the vision or for improving impaired vision...

20060134227 - Compositions including iron: Nutritional or dietary supplement compositions that promote and/or maintain dietary iron absorption through administration of iron with an organic acid and optionally similar iron absorption promoters are provided. Also provided are methods of nutritional or dietary supplementation using one or more compositions that promote and/or maintain health through the prevention,...

20060134228 - Medicine for prevention of and treatment for amyloidosis: A pharmaceutical for the prophylaxis and/or treatment of amyloidosis such as familial amyloid polyneuropathy is provided. A pharmaceutical for the prophylaxis and/or treatment of amyloidosis that contains a compound containing the trivalent chromium ion, such as a fatty acid chromium salt, as an active ingredient, and that is capable of...

20060134232 - Herbal supplement for cognitive related impairment due to estrogen loss: Estrogen-deficiency related cognitive dysfunction may be improved by administering a composition comprising an herbal composition to a woman. In a preferred embodiment the herbal composition comprises whole plant extract of Leucojum aestivum....

20060134229 - Organic extract of geum japonicum thunb variant and use thereof: An organic extract of a Chinese herbal medicine Geum Japonicum thunb var. has been identified that displayed potent stimulatory effects on rapid agiogenesis (<24 h), myogenesis and blocking fibrosis in traumatized skeletal muscles. The extract has displayed potent dual effects on angiogenesis and myogenesis in damaged skeletal muscles leading to...

20060134231 - Use of natural plant extracts in cosmetic compositions: The present invention describes compositions and methods for treating, preventing and improving the appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating loss of subcutaneous fat in the skin, wherein the compositions include natural plant constituents that stimulate lipid synthesis. The plant extracts are preferably derived from Rhinacanthus nasutus,...

20060134230 - Weight loss composition and formulation: This invention discloses a new and unique combination of Dahurian Angelica Root extract, Polygonum multiflorum extract, Theobroma cocoa extract, Yerba mate extract, Oolong tea extract, Kohki Tea extract, Horse Chesnut extract, and Ligustrum Lucidum extract useful as a dietary supplement for increasing weight loss in humans....

20060134233 - Nitric oxide and its biomedical significance: The invention relates to nitric oxide (NO) stimulating extracts from various plants. Such extracts contain compounds known as healthin I and healthin II. Specifically, the invention provides partially purified plant extracts that have NO stimulating activity, methods of isolating and partially purifying such extracts from plant materials. In addition, the...

20060134234 - Cosmetic composition: The invention relates to a composition containing, preferably in a physiologically acceptable medium, at least one xanthine base or a plant extract containing it, at least one polyurethane powder, and at least one non-ionic dimethicone copolyol. The invention also relates to a cosmetic method for combating cellulite and/or “orange-peel” skin...

20060134235 - External preparation for improving blood flow: The present invention provides an external preparation for improving blood flow that comprises proanthocyanidins. The external preparation for improving blood flow provides an excellent effect of improving blood flow. When the proanthocyanidins that contain preferably at least 20 wt % OPCs are employed, a further excellent effect of improving blood...

20060134236 - Anti-allergy composition and related method: An composition and related method that prevents, inhibits and/or mitigates an allergic response by down regulating the production of IgE, down regulating the binding of IgE antibodies to receptors on cells, and/or inhibiting allergy mediators, for example, histamine, prostoglandin D2, or luekotriene C4 release. The composition comprises at least one...

20060134237 - Anti-microbial composition and methods of use thereof: The present invention is directed to anti-microbial compositions and methods for treating fungal and yeast infections....

20060134238 - Process of manufacturing clear juice from the leaves of the aloe vera plant: hand filleting each aloe leaf to separate the internal gel and leaving behind leaf residue; collecting the internal gel in a stainless steel container; Milling the gel in a multimill to obtain gel having particle size less than 1.5 mm; adding charcoal in the range of 1% of the mass...

20060134239 - Agents against microorganisms containing patchouli oil, patchouli alcohol and/or the derivatives thereof: This invention relates to preparations containing patchouli oil, patchouli alcohol and/or derivatives thereof, to the use of such preparations for inhibiting the asexual propagation of fungi and for preventing the adhesion of microorganisms to surfaces, and to filter media, adhesives, building materials, building auxiliaries, laundry detergents, cleaning compositions, rinse agents,...

20060134240 - Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation: Compositions and methods are provided to increase glucose uptake in a cell as well as to treat a patient suffering from a condition or disorder associated with AMPK regulation. Particularly contemplated compositions include a compound that is isolated from a plant that has AICAR-like activity. In another aspect of the...

20060134241 - Composition for effectively suppressing the growth of prostate cancer cell, suppressing the prostatic hyperplasia and its preparation method: A composition for effectively suppressing the growth of Prostate Cancer Cell, suppressing the Prostatic Hyperplasia and its preparation method, wherein this composition contains the Astragalusradix or its extracts with effective ingredients, which can either prevent or cure the Prostate cancer and suppress the Prostatic Hyperplasia as well....

20060134242 - Synergistic composition for the treatment of diabetes mellitus: The present invention relates to a synergistic composition for the treatment of diabetes in a subject in need thereof, said composition—comprising Trigonelline of concentration ranging between 20 to 30%, amino acids of concentration ranging between 20 to 60%, and soluble fiber of concentration ranging between 10 to 60%, optionally along...

20060134243 - Method of using extracts of epimedium species: Extracts of various species of the family Berberidaceae have estrogenic properties. For example, aqueous and ethanolic extracts of Epimedium species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effect include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for...

20060134244 - Breast health supplement and detoxification preparations: Novel preparations of phytochemical ingredients that are serviceable as health supplements for the body, particularly tissues susceptible to cancer, including, e.g. prostate tissue and breast tissue and, including, e.g., female breast tissue; for example, all possible combinations and permutations of member from each of the following 6 groups: 1) plant...

20060134245 - Estrogenic extracts of morus alba and uses thereof: Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Morus alba L. species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effect include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are...

20060134246 - Use of alisma orientale in cosmetics and compositions thereof: The present invention describes compositions and methods for improving the appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating excess accumulation or production of subcutaneous fat, such as cellulite, or conditions related to excess accumulation, production, or excretion of sebum, such as acne, an oily complexion, oily hair or...

20060134247 - Treatment of inflammatory bowel disease: The present invention relates to compositions (including medicaments and nutritional products) for use in the prevention or treatment of Inflammatory Bowel Disease. Such compositions comprise a therapeutically effective amount of a soluble fibre derivable from fruit of the Musa spp. The soluble fibre may in particular be derived from plantains...

20060134248 - Hop acids as a replacement for antibiotics in animal feed: A method of using hop acids for increasing food and energy uptake from feed by livestock is described which includes delivering the hop acids for oral ingestion to the animals by mixing the acids with livestock feed. The acids are mixed with the feed in an amount to inhibit certain...

20060134249 - Proteotoxin neutralizer: Proteotoxin neutralizers containing as the active ingredient proanthocyanidins obtained from hop....

20060127307 - Devices and compositions containing boron and silicon for use in neutron capture therapy: The present invention relates to a boron containing therapeutic composition comprising: (i) a boron component formed at least partly from boron-10; and (ii) a silicon component. The composition is of value in the treatment of cancers by boron neutron capture therapy or in the treatment of arthritis by boron neutron...

20060127309 - Imaging agents: The present invention provides novel compounds that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging). The present invention also provides imaging compositions for use within nuclear medicine applications. Additionally, the present invention provides methods of imaging....

20060127308 - Method to improve the efficacy of therapeutic radiolabeled drugs: Disclosed are radiolabeled drugs and methods to improve their efficacy by using a radiosensitizer such that the radiosensitizer is either part of the radiolabeled drug by directly attaching the radiosensitizer to the radiolabeled drug or by producing a mixture of the radiolabeled drug and an analogue of the drug with...

20060127306 - Radioactively labelled amino acid analogues, their preparation and use: The present invention relates to Halogenated amino acid analogues for use in diagnosis, which compounds have the genera formula (I) wherein: R is (C1-C6) alkyl optionally substituted with thioether or ether oxygen atom when n=0, or a substituted aromatic or heteraromatic ring when n=1-6; and m=0 or 1; and X...

20060127310 - Amplification of biotin-mediated targeting: The present invention relates to the delivery of drug, peptide and protein pharmaceuticals using a biotin-mediated uptake system. More particularly the invention relates to the amplification of active substance delivery with the biotin uptake system using a biotin-active substance-polymer conjugate or a biotin-nanoparticle conjugate. The invention also relates to processes...

20060127311 - Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer: Disclosed is a method for dosimetry estimation for a region of interest at or around a surgically created resection cavity in a subject. These methods enable medical practitioners to estimate the amount of administered Radioimmunotherapy (RIT) agent needed to safely and effectively achieve a final Radiation Absorbed Dose (RAD). Furthermore,...

20060127312 - Notch signaling in long-term memory formation: The present invention is directed to a method of modulating (e.g., enhanced, increased) long term memory formation in an animal comprising modulating Notch function (e.g., Notch protein expression) in said animal. In addition, the present invention is directed to a method of treating an animal with a defect in long...

20060127313 - Method and apparatus for producing contrast agents for magnetic resonance imaging: The present invention relates to an arrangement and a method for providing contrast agent for e.g. MRI (Magnetic Resonance Imaging) and NMR (Nuclear Magnetic Resonance) applications. The method according to the invention comprises the steps of obtaining (100) a solution in a solvent of a hydrogenatable, unsaturated substrate compound and...

20060127314 - Method and arrangement for producing contrast agent for magnetic resonance imaging: The present invention relates to an arrangement and a method for providing contrast agent for e.g. MRI (Magnetic Resonance Imaging) and NMR (Nuclear Magnetic Resonance) applications. The method according to the invention comprises the steps of obtaining (100) a solution in a solvent of a hydrogenatable, unsaturated substrate compound and...

20060127315 - Methods of treating humans undergoing injection of a contrast agent: A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity of the acute renal failure and/or...

20060127316 - Polyols and pvp as in vivo biocompatible acoustic coupling media: A waterless in vivo biocompatible and bio-excretable lubricant and ultrasound coupling fluid or gel produced from formulations based on polyvinylpyrrolidone (PVP) and one or more polyols such as propylene glycol, glycerol, polyethylene glycol and sorbitol....

20060127318 - Composition and method of a topical treatment of neurodermatitis: A composition for the topical treatment of dermal irritation and pain symptoms of neurodermatitis comprising a topical pharmaceutical formulation which contains a therapeutically appropriate dose of a sodium channel blocker selected from the group of ester- or amide-type local anesthetics, wherein the sodium channel blocker is released directly on or...

20060127319 - Injectables in foam, new pharmaceutical applications: The placing of a drug that is suitable for parenteral administration on bubbles formed with sterile gases produces an exponential increase in its active surface area with a decrease in the diameter of the bubble, modifies the kinetics of its distribution and, thanks to its micronisation, increases its therapeutic effect....

20060127320 - Method of delivering parathyroid hormone to a human: What is described is a method of delivering PTH to a human, comprising exposing a layer of mucosal cells to a mixture of PTH and an enhancer, wherein the enhancer is capable of modulating the barrier function of a cellular tight junction. Specifically, the method of delivering PTH to a...

20060127317 - Nasallly applicable pharmaceutical preparation and the production thereof: The invention relates to a novel pharmaceutical preparation which can be administered nasally and is based on an aqueous solution, emulsion or the like which comprises at least one mucosally absorbable and/or locally acting active pharmaceutical ingredient, at least one preservative formed by benzalkonium chloride alone or together with other...

20060127321 - Pharmaceutical foam: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In...

20060127322 - Stable pharmaceutical budesonide preparation for producing propellant-free aerosols: The invention relates to ethanol-containing pharmaceutical preparations for the production of propellant-free aerosols....

20060127323 - Formoterol and ciclesonide combination: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease....

20060127324 - Chewable oral compositions containing an anti-microbial agent and methods of formulating the compositions to have acceptable germ kill properties and taste: A method of formulating anti-microbial containing oral compositions having a targeted (P) value by selecting at least one anti-microbial agent based on the germ kill rating (R) and concentration of the anti-microbial based on the agent, the mass of the oral composition and the Q factor of the oral composition....

20060127325 - Dental formulation: This invention relates to formulations for treating or reducing dentine hypersensitivity that causes pain arising from exposed dentine in the oral cavity. The present invention seeks to provide formulations for physical blockage of dentinal tubules that have long term effectiveness and cause minimal irritation (if any at all) to the...

20060127326 - Oral hygiene product for human and animal use with a melatonin base as an active product: An oral hygiene product for human and animal use with a melatonin base as an active product is provided to be used as tooth paste, mouthwashes or animal feeds. The product includes a hydrophilic excipient, a hydrophobic excipient, and melatonin in a proportion of 0.1% to 5%....

20060127328 - Fully active alternansucrases partially deleted in its carboxy-terminal and amino-terminal domains and mutants thereof: Nucleic acid sequences of truncated or mutated alternansucrases, vectors containing these nucleic acids sequences, host cells transformed with the nucleic acid sequences encoding truncated or mutated alternansucrases are provided. Furthermore, a process to recombinantly alternansucrase with a high level of expression, while retaining the enzymatic activity is described....

20060127327 - Monoclonal antibodies specific for cariogenic bacteria: Antibodies, as well as binding fragments and mimetics thereof, that specifically bind to Actinomyces or Lactobacillus cariogenic bacteria are provided. The subject binding agents, e.g., antibodies, fragments and mimetics thereof, etc., are characterized in that they are highly sensitive and specific for their target bacteria. Also provided are methods and...

20060127329 - Tartar control oral care composition containing extract of magnolia: A stable and efficacious antiplaque, anticalculus, and antigingivitis oral composition is provided having an antibacterial ingredient comprising one or more active compounds found in an extract of magnolia combined with an anticalculus system comprising tetrasodium pyrophosphate (TSPP) about 1 to about 2.5% and sodium tripolyphosphate (STPP) about 1 to about...

20060127330 - Composition for treating and/or preventing periodontal disease: Herein disclosed are a composition used for treating and/or preventing periodontal disease, which comprises a Sasa extract and a composition used for treating and/or preventing periodontal disease, which comprises a Sasa extract and an organic acid....

20060127331 - Moisturizing compositions: The present invention relates to compositions useful for moisturizing keratinous materials which contain poly(2-hydroxyethyl methacrylate) and at least one polyol....

20060127333 - Cosmetic compositions containing very high viscosity silicone gum: A color cosmetic composition comprising at least one very high viscosity silicone gum in a cosmetically acceptable carrier....

20060127332 - Solid cosmetic composition: The present invention relates to a solid cosmetic composition comprising, as a structure agent, a combination consisting of a saturated straight-chain polymer and an agglutinating agent for this polymer. The composition of the inventions has a rigid, moldable and stable structure, being suitable for application as, for example, lipstick, blush,...

20060127334 - Lipstick comprising a sequenced polymer: The invention relates to a lip makeup composition comprising at least one organic liquid medium and at least one film-forming linear block ethylenic polymer, the said polymer being such that, when it is present in sufficient amount in the composition, the said composition is capable of forming a deposit that...

20060127335 - Deodorant fiber structure and method for production thereof: A deodorant fiber structure in which deodorant fine particles are adhered to a fiber structure through a binder resin, wherein the above-described binder resin is adhered in an approximately uniform coating film state to single fibers constituting said fiber structure; each single fiber is substantially maintained in an independent state...

20060127336 - Deodorants: A method of deodorization comprising allowing an odor-causing substance to coexist an aluminosilicate particle having the composition of a M2O.Al2O3.b SiO2.c RmQn.d H2O, wherein M is one or more members selected from the group consisting of Na, K and H, R is one or more members selected from the group...

20060127338 - Aqueous suspensions of cross-linked silicone particles, aqueous emulsions of oil containing cross-linked silicone particles, and cosmetic raw material: Aqueous suspensions of cross-linked silicone particles comprising: (A) cross-linked silicone particles with an average particle size of from 0.1 to 500 μm, (B) N-acyl-, N-hydrocarbon taurines and/or their salts, and (C) water, aqueous emulsions of oil containing cross-linked silicone particles comprising: (A) cross-linked silicone particles with an average particle size...

20060127339 - Two-coat makeup product with improved staying power, uses thereof and makeup kit comprising this product: The present disclosure relates to a cosmetic makeup product comprising at least one first and at least one second composition, wherein the at least one first composition comprises a physiologically acceptable medium, and optionally an acrylic polymer, and the at least one second composition comprises at least one silicone polymer...

20060127345 - Conditioning shampoo containing stabilized silicone particles: Shampoo compositions comprising a) a detersive surfactant, b) silicone particles, c) a protecting agent and d) an aqueous carrier provide superior conditioning. The silicone particles contain at least one amine functional silicone and optionally a non-amine functional silicone....

20060127340 - Thixotropic personal lubricant: A thixotropic personal lubricant includes a high molecular weight, thixotropic, gel-forming, naturally occurring polysaccharide extracted from algae and comprised of repeating sulfated and non-sulfated galactose and 3,6 anhydrogalactose (3,6-AG) units, and includes water....

20060127341 - Non-transfer cosmetic composition comprising a dispersion of praticles of a silicone-free grafted ethylene polymer in a liquid fatty phase: The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one dispersion of particles of a non-silicone-based grafted ethylenic polymer in a liquid fatty phase. Use for making up and caring for keratin materials, especially the skin and the lips....

20060127337 - Process for relaxing keratin fibres: The invention relates to a process for relaxing keratin fibres by applying to the keratin fibres a relaxing composition containing at least one denaturing agent with a molecular mass of greater than 18.1 g/mol, present in a molar concentration of between 1M and 8M, and raising the temperature of the...

20060127342 - Taurine-based compositions, therapeutic methods, and assays: Taurine and derivatives thereof may be used to repair the skin barrier, enhance hydration of the skin, prevent apoptosis and oxidative damage in the skin, and heal or prevent photo-induced skin damage. The presence of biogenic taurine or taurine derivatives in tissues and/or body fluids can be used as a...

20060127343 - Administration of urea compounds for combating signs of cutaneous aging: the radicals R1, R2, R3 and R4, which may be identical or different, are each a hydrogen atom, a C1-C4 alkyl radical or a C2-C6 hydroxyalkyl radical which can contain from 1 to 5 hydroxyl groups, wherein at least one of the R1 to R4 radicals represents a hydroxyalkyl radical,...

20060127344 - Novel cosmetic emulsions and emulsifiers exhibiting dilatant rheological properties: The use of novel nonionic polymeric thickeners that produce cosmetically useful emulsions of an oil phase and a water phase is described. The thickeners of choice are the urethane dimers of ethoxylated fatty alcohols. These materials were not anticipated to have emulsifying properties. Also, it has been found that the...

20060127346 - Application of volatile antibiotics and non-volatile inhibitors from muscodor spp. to control harmful microbes in human and animal wastes: This invention relates to the discovery of a novel endophytic fungus, Muscodor albus, which produces volatile antibiotics that have been shown to be effective in the treatment of human and animal waste products. Through experimentation, this invention confirms that Muscodor albus can be used in disposable bags in connection with...

20060127347 - Application of volatile antibiotics and non-volatile inhibitors from muscodor spp. to control harmful microbes in human and animal wastes: This invention relates to the discovery of a novel endophytic fungus, Muscodor albus, which produces volatile antibiotics that have been shown to be effective in the treatment of human and animal waste products. Through experimentation, this invention confirms that Muscodor albus can be used in disposable bags in connection with...

20060127350 - Dendrimer conjugates for selective of protein aggregates: Dendrimer conjugates are presented, which are formed between a dendrimer and a protein solubilising substance. Such dendrimer conjugates ar effective in the treatment of protein aggregate-related diseases (e.g. prion-related diseases). The protein solubilising substance and the dendrimer together show a protein aggregate solubilising effect higher than a physical mixture of...

20060127352 - Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds: The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments....

20060127353 - Fat-binding polymers: The present invention provides fat-binding polymers, which comprise dialkanolamine, dialkanolammonium, aminoalkylpolyol, and ammoniumalkylpolyol pendant groups for subjects in need of fat removal from the gastrointestinal tract, particularly subjects suffering from steatorrhea and/or experiencing side effects from lipase inhibitors. Patients being administered with lipase inhibitors are typically being treated for Type...

20060127351 - Process for preparing high molar mass polymers: The present invention describes processes for preparing water-compatible anionic polymers of high molar mass via water-in-oil polymerization....

20060127348 - Chemically and/or biologically reactive compounds: This disclosure provides novel compositions comprising an inorganic and organic compound, which provides a means for the indirect attachment of a reactive species, such as an organic reactive molecule, within a binder polymer matrix. Such compositions provide a hydrophilic nanoscale domain that is uniformly dispersed within the polymer matrix. The...

20060127349 - Novel of preparation hypericin bonded with poly-n-vinylamides: The invention relates to an active agent combination for diagnosing and treating tumours, comprising a water-soluble complex or a water-soluble compound of pure hypericin and a poly-N-vinylamide, especially PVP....

20060127354 - Phosphorylated polymers and conjugates thereof: The present invention is directed to absorbable polyesters comprising one or more monophosphate functionality; a conjugate comprising the foregoing polyester and a peptide and/or a bioactive agent; microparticles comprising an absorbable polyester; a conjugate comprising the microparticles and a peptide and/or a bioactive agent; an acylated or alkylated polysaccharide having...

20060127355 - Selected mixture for animal lure: The present invention is a lure optimized for a particular animal such as deer. The optimized lure is made using urine from only two animals urinating at approximately the same time. The animals can be either male or female, but preferably, females in estrus are used for optimal results. This...

20060127356 - Isolated proteins mage-4 and mage-41: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are...

20060127357 - Rapamycin and il-10 for the treatment of immune diseases: The invention discloses a combined preparation containing IL-10 and rapamucin able to induce immunosuppression and antigen-specific immune tolerance, and the use thereof in the treatment of diseases involving an excessive, dysfunctional or uncontrolled immune response mediated by T cells....

20060127361 - Compositions and methods for inducing gene expression: The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain...

20060127359 - Methods and compositions for heat activated gene therapy using cytolethal distending toxin: The invention provides compositions and methods for gene therapy using cytolethal distending toxins (CDTs). In a preferred embodiment, a gene therapy vector according to the invention includes a gene encoding a B subunit of a CDT and an antisense oligonucleotide that inhibits a DNA repair mechanism. An inducible promoter is...

20060127360 - Multi-antigen vectors of melanoma: The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma....

20060127358 - Raav expression systems and methods for enhancing transduction of mammalian neural cells: Disclosed are serotype-specific recombinant adeno-associated viral (rAAV) vectors, as well as viral particles and compositions comprising them, useful in the expression of neurotherapeutic agents (including neurotherapeutic peptides and polypeptides) in selected mammalian neural cells, as well as tissues and organ systems comprising them. In particular embodiments, rAAV serotype 1 and...

20060127376 - Methods and compositions for modulating apoptotic pathways: The present invention relates to methods and compositions for modulating apoptotic pathways. In particular, the present invention relates to methods and compositions for inducing apoptosis in cancer cells. The present invention further relates to methods and compositions for identifying drugs that modulate apoptotic pathways....

20060127377 - T cell receptors with enhanced sensitivity recognition of antigen: The present invention relates to methods of treating an infectious, proliferative, or lymphocyte-mediated disease that involve providing a T cell receptor β chain (TCR β) having higher sensitivity recognition of antigen than a wild type TCR β chain and introducing the TCR β chain directly or indirectly to a subject...

20060127363 - Antifungal methods: A composition comprising bacteria and an inert carrier is disclosed. The carrier can be porous, ceramic particles. The composition can also include a growth medium. Bacteria in such a composition can comprise a novel strain designated APM-1. APM-1 is a Gram-positive, aerobic, motile rod, and appears to be most closely...

20060127362 - Cholesterol-lowering preparation, food supplement and foodstuff, and methods for preparing same: The present invention relates to cholesterol-lowering preparations, in particular to a bacterial preparation for use as a medicament for lowering of the blood cholesterol level. The present invention provides inter alia a preparation of Rhodospirillum spp. and/or Phaeospirillum with cholesterol-lowering effects, food supplements and foodstuffs comprising said preparation and methods...

20060127378 - Composition for promoting the proliferation of lactobacillus casei subsp. casei: The present invention relates to a composition for promoting bacterial proliferation for selectively proliferating Lactobacillus casei subsp. casei, which includes a dextran. According to the present invention, a variety of biological activities originated from L. casei subsp. casei can be sustained in a living body by selectively growing-proliferating and colonizing...

20060127379 - Ginseng fermented by lactic acid bacterium, yoghurt containing the same, and lactic acid bacteria used in the preparation thereof: This invention relates to lactic fermenting products of ginseng obtained by fermentation of ginseng using lactic acid bacteria, yoghurt containing said lactic fermenting products of ginseng, and lactic acid bacteria used in the preparation of said lactic fermenting products of ginseng....

20060127380 - Lactobacillus casei bd-ii stain and used to reduce blood cholesterol: The invention disclosed a kind of lactobacillus casei Bd-II, the accession number of the deposit of which is CGMCC NO. 0849, and also disclosed a use of it for reducing blood lipid level....

20060127381 - Live bacterial preparation of bacillus coagulans for the treatment of ulcerative colitis, method for producing the same and use thereof: The present invention discloses a method for preparation of live Bacillus coagulans and the use of the bacteria in treatment of ulcerative colitis. The live bacteria are effective in the treatment of experimental ulcerative colitis in rats. They are also used in the clinical treatment of patients suffering from ulcerative...

20060127364 - Insect viruses and their uses in protecting plants: The present invention relates to an isolated small RNAvirus capable of infecting insect specifies including Heliothis species, and to the nucleotide sequences and proteins encoded thereby. The invention contemplates uses of the virus in controlling insect attach in plants....

20060127371 - Asb transcription repressor proteins and nucleic acids and their application in expansion of stem cells: The present invention relates to methods for expansion of stem or progenitor cells. These methods rely on Asb-a polypeptides or nucleic acids to temporarily suppress differentiation of the cells, thus allowing proliferation and self-renewal of the stem or progenitor cells. Abs-a polypeptides and coding sequences define a class of polypeptides...

20060127370 - Composition for culturing multipotent stem cells and utilization of the same: The invention aims to proliferate or establish undifferentiated pluripotent stem cells that retain their differentiation potency by culturing pluripotent stem cells in a medium free of a feeder cell, or a serum. The aim is attained by using a culture medium for pluripotent stem cells comprising the known ingredients, which...

20060127367 - Compositions containing macrophages and uses thereof: The invention relates to the use of macrophages for the preparation of a drug for the treatment of a disease or of a lesion involving cellular apoptosis, reduction of the survival of cells and/or destruction of cells....

20060127375 - Cryopreservation of human red blood cells: A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the...

20060127372 - Hypoxia-mediated neurogenesis: Methods are described for the production of neurons or neuronal progenitor cells. Multipotent neural stem cells are proliferated in the presence of growth factors and erythropoietin which induces the generation of neuronal progenitor cells. The erythropoietin may be exogenously applied to the multipotent neural stem cells, or alternatively, the cells...

20060127366 - Method and device for inducing biological processes by micro-organs: A method, extract, and pharmaceutical composition for inducing angiogenesis in a tissue of a mammal, and of a device for the preparation and delivery of micro-organs into a mammal, are provided....

20060127374 - Method for the in vitro production of cartilage-like tissues: A method for the in vitro production of cartilage-like tissue is disclosed. Said method comprises the cultivation of chondrogenic cells in presence of bivalent cation dependent constituents of the extracellular matrix (BCDM) and/or human serum wherein an inhibitory activity of cartilage maturation has been selectively removed from said human serum....

20060127365 - Method of cell therapy using fused cell hybrids: The present invention relates generally to the field of tissue engineering and more particularly to a method for generating tissue suitable for use in tissue replacement and/or tissue rejuvenation therapy and/or as a source of cell-derived therapeutic or diagnostic agents including proteins and hormones. Even more particularly, the present invention...

20060127369 - Spatially encoded polymer matrix: The invention relates to a spatially encoded polymer matrix in the form of a bead or a granule for combinatorial solid phase synthesis, assaying, functional proteomics and diagnostic use. Compositions of such beads or granules are also provided. Each beaded polymer matrix of the composition comprises a plurality of spatially...

20060127368 - Support for tissue regeneration and process for producing the same: The present invention provides a scaffold in which cells can be stably retained and grafted in a uniform distribution state in the culture, preferable proliferation ability and viability can be secured, and particularly in the case of cartilage, fixation treatment such as suture can be carried out in the transplantation...

20060127373 - Use of substance p for mobilization of mesenchymal stem cells or proliferation of mesenchymal stem cells and for wound healing or facilitating wound healing: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing....

20060127382 - Particle/cell separation device and compositions: A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted....

20060127383 - Pre-conditioning cells against death: Apoptosis and/or necrosis related disorders in the mammalian body, namely radiation exposure disorders, chemical exposure and ingestion disorders, neurological disorders and physical trauma disorders, are treated, and their onset is counteracted by preconditioning, by extracting from the mammalian body an aliquot of blood, subjecting the extracted aliquot, ex vivo, to...

20060127384 - Coenzyme q10 as antiapoptotic agent: The invention discloses the use of coenzyme Q10 for preventing or inhibiting apoptosis in cutaneous or adipose cells and tissues, and pharmaceutical compositions containing coenzyme Q10 for the treatment of transplanted tissues....

20060127385 - Method for sustaining enos activity: The present invention is directed to methods for sustaining eNOS activity to inhibit platelet aggregation, clot retraction, and enhance fibrinolysis. One embodiment of the invention provides methods of treating thrombosis by inhibiting the activity of the syk kinase. Another embodiment provides assays for the discovery of improved compounds to treat...

20060127386 - Antioxidant polymer nanocarriers for use in preventing oxidative injury: The present invention is a method for encapsulating active protein in a polymeric nanocarrier. The instant method employs homogenization at subzero temperatures so that enzyme activity is retained. Enzymes which can be encapsulated by the present method include, for example, antioxidant enzymes and xenobiotic detoxifying enzymes. Encapsulation of an enzyme...

20060127387 - Compositions based on polysaccharides and protein c and methods of using the same for preventing and treating sepsis and other conditions: The present invention provides pharmaceutical compositions useful for the prevention and treatment of sepsis and other conditions such as stroke, reperfusion injury and heart attacks, containing 1) at least one macromolecular polysaccharide selected from the group consisting of hydroxyethyl starch, dextran, glycogen and mixtures thereof and 2) activated protein C....

20060127388 - Variants of glycogen synthase kinase 3 and uses thereof: The present invention provides GSK3β variants, including splice variants expressed in bone or other tissues. These variants have a broad range of functional activity, from inhibiting the Wnt pathway to activating the pathway as dominant-negatives of the full-length GSK3β. These variants, as well as their modulators, can be used to...

20060127390 - Enzymatic inactivation of transmissible spongiform encephalopathy agents and dectection there of: The invention relates to a method for inactivating transmissible spongiform encephalopathy agents by contact with a subtilisin protease. The invention further relates to detection of any residual transmissible spongiform encephalopathy agents....

20060127389 - Fused protein with the function of both hemolysis and anticoagulation and use of it: This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide,...

20060127393 - Antibodies to dkk-1: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable...

20060127392 - Antibody for adcc and inducing cytokine production: The invention concerns chimeric monoclonal antibodies, humanized or human produced in selected cell lines, said antibodies exhibiting high affinity for the CD16 receptor of effector cells of the immune system and hence capable of inducing high ADCC, but also the property of inducing cytokine and interleukin secretion, in particular IFNγ,...

20060127394 - Cloning of honey bee allergen: The present invention relates to a nucleic acid encoding a polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee...

20060127391 - Methods and materials for treating inflammatory conditions: Methods and kits for treating inflammatory conditions are described that include modulating kallikrein 6 protease activity....

20060127395 - Stable liquid formulations of antibodies: The present invention provides stable liquid formulations of antibodies suitable for parenteral administration. Also, provided are aqueous solutions which have high concentrations of therapeutical antibodies which may be used to produce therapeutical liquid formulations. The present invention also relates to uses, such as medical uses, of the stable liquid formulations...

20060127396 - Peptide fragment of lyve-1 and antibody against the same: It is intended to provide a specific peptide fragment of LYVE-1 which can serve as an epitope of a lymphatic vessel-specific antibody, and an antibody recognizing the above peptide fragment. A peptide fragment comprising an amino acid sequence: Ser Lys Lys Thr Asp Lys Asn Pro Glu Glu Ser Lys,...

20060127397 - Rag polypeptides, nucleic acids, and their use: The present invention relates generally to regeneration associated genes (RAGs). More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of RAGs and RAG polypeptides. The invention further relates to methods of detecting, preventing, and treating RAG-associated disorders....

20060127400 - Activation of regulatory t cells by alpha-melanocyte stimulating hormone: The invention encompasses a method of down-regulating a T cell-mediated immune response, through activation or T cell receptor (TCR) stimulation of antigen-primed T cells in the presence of alpha-melanocyte stimulating hormone (α-MSH), which may be optionally enhanced by adding transforming growth factor-β2 (TGF-β2) approximately 4-6 hours after the start of...

20060127399 - Compositions and methods for inducing chimerism in a subject: Prevention of autoimmune disease and induction of transplantation tolerance in a recipient can be achieved by induction of mixed chimerism via bone marrow transplantation (BMT), but this procedure requires total body irradiation (TBI)-conditioning of the recipient. The toxicity of radiation and potential for graft versus host disease (GVHD) prevents its...

20060127398 - Monoclonal antibody capable of binding integrin alpha 10 beta 1: The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or...

20060127401 - Screening method: The invention relates to a screening method to determine the susceptibility of a mammal, preferably a human, to abnormal development of the nervous system and including therapeutic methods and compositions for the treatment of neurodegenerative conditions which result in abnormal expression of a family of polypeptides which induce the apoptotic...

20060127402 - Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors....

20060127405 - Antibody against tumor specific antigen as target: The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer...

20060127404 - Hinge core mimetibodies, compositions, methods and uses: The present invention relates to at least one novel human hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one hinge core mimetibody or specified portion or variant, hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants,...

20060127403 - Use of antibodies against tumor-associated antigen: The invention relates to the use of a preparation based on an antibody directed against a tumor-associated antigen, for producing a medicament for the intra-operative treatment of tumor patients, in particular for the prophylactic treatment to prevent the dissemination of tumor cells. The invention further relates to a kit for...

20060127406 - Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same: Enriched antibody population, highly specific for an antigen of a surface polysaccharide from a mycobacterium. In a related embodiment, the antibody is enriched by having been raised in an environment that maintains antigenically active antigen. These antibodies may be used in an immunoreactive environment for detecting the presence of a...

20060127407 - Anti-integrin immunoconjugates, methods and uses: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention...

20060127409 - Bcr-abl vaccines and methods of use thereof: This invention provides vaccine comprising immunogenic bcr-abl peptides and methods of treating, inhibiting the progression of, reducing the incidence of, and breaking a T cell tolerance of a subject to a bcr-abl-associated cancer....

20060127408 - Cancer immunotherapy: The invention relates to the use of polycomb group proteins as a tumour-associated antigens. Polycomb group proteins are highly involved in body architecture development, haematopoiesis and cell cycle control. Aberrant expression of polycomb proteins has been linked with haematological malignancies, mainly lymphomas. This invention relates to the use of these...

20060127410 - Naturally processed measles virus peptides eluted from class ii hla molecules: A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more...

20060127411 - Immune -modulating peptide made of s.aureus enterotoxin b: The invention relates particularly to peptides which are specifically capable of binding IgE antibodies and can be obtained from naturally occurring S. aureus enterotoxin B (SEB), for example. The immune-modulating properties thereof are substantially different from those of bacterial SEB. Surprisingly, the inventive peptides do not induce proliferation of T...

20060127412 - Aromatase activator: Drugs and cosmetics which are highly safe, and which are effective in preventing, improving, or treating various pathological conditions caused by estrogen depletion are provided. Provided are aromatase activators containing at least one member selected from plants such as Labiatae sps. including Isodon, Scutellaria (huangcen), Schizonepeta (jingjie), sage, lavender, Lamium...

20060127413 - Recombinant mva strains as potential vaccines against p. falciparum malaria: This invention relates to recombinant viruses based on MVA, which comprise at least one nucleic acid coding for a Plasmodium falciparum MSP-1 protein, a fragment or mutein of it. Furthermore, methods for the production of the recombinant viruses, virus-containing vaccines and the use of the recombinant viruses for the prophylaxis...

20060127414 - Immunogenic composition: The present invention relates to immunogenic compositions comprising a dried solid or highly viscous liquid formulation of inactivated polio virus (IPV) and a stabilising agent wherein the IPV retains its antigenicity and/or immunogenicity. Methods of producing a dried formulation of IPV which retains its antigenicity/immunogenicity are described....

20060127415 - Drying process: The present invention relates to a method of drying biological and other labile samples so that they can be preserved as a highly viscous liquid. The method involves the steps of preparing a preservation sample by dissolving/suspending an active agent in a solution of a stabilising agent, subjecting the preservation...

20060127416 - Hsp60 from arthrobacter: The hsp60 gene from a strain of Arthrobacter has been isolated and sequenced. The encoded protein is believed to be highly immunogenic, especially in fish, and also has utility as a non-specific adjuvant, and as an adjuvanting carrier for heterologous antigens....

20060127417 - Methods for treating restenosis with a botulinum neurotoxin: The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease....

20060127418 - Composition containing leishmania lip2a: The composition comprises a protein called Lip2a Leishmania formed by a sequence of amino acids coded for by a sequence of DNA that comprises the nucleotides: 1-1 of nos. 778 to 1231 of SEQ. ID NO !1-2 or formed by a sequence of nucleotides able to hybridise with the sequence...

20060127419 - Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds: The present invention relates to a process for the production of an immunogenic compound comprising inducing necrosis by temperature in tumor cells and lysing said necrotic tumor cells so as to obtain a lysate. Furthermore, the invention provides a method for the production of a pharmaceutical composition. Additionally, the invention...

20060127422 - Boron nitride particles of spherical geometry and process for making thereof: A low viscosity filler boron nitride agglomerate particles having a generally spherical shape bound together by an organic binder and to a process for producing a BN powder composition of spherically shaped boron nitride agglomerated particles having a treated surface layer which controls its viscosity....

20060127423 - Organic compounds: Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration....

20060127420 - Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof: The present invention relates to a paclitaxel composition and the preparation methods thereof for the treatment of bladder cancer wherein said paclitaxel composition comprises 4˜90% by weight of at least one selected from the monoglycerides, 0.01˜90% by weight of at least one oil, 0.01˜90% by weight of at least one...

20060127421 - Treatment using d-threo methylphenidate: Methods for treating a disease responsive to the administration of methylphenidate and/or one or more isomers thereof, said method comprising identifying a patient suffering from a disease or disorder having a family history or diagnosis of tics or Tourette's Syndrome and administering to said patient a therapeutically effective amount of...

20060127428 - Child recovery system using transfer-type tattoo: A child recovery system utilizing a transfer-type tattoo includes a laminate in series of a decal substrate material, a tattoo design (in negative) releasably disposed over the substrate material, a pressure-sensitive adhesive over and in register with the tattoo design, and a removable release sheet over the adhesive. After removal...

20060127430 - Controlled-release of cosmetic and pharmaceutical agents via osmotic nano-diffusion from zeolite cage complexes: The present invention discloses the application of cage complexes of zeolites for topical controlled delivery of organic cosmetic and pharmaceutical active agents. The treatment and protection of skin surface requires that certain organic cosmetic and pharmaceutical active agents be delivered slowly and allowed to remain on skin surface for extended...

20060127424 - Cosmetic composition: A cosmetic composition comprising a cosmetic base selected from the group consisting of liquid base, paste base and powder base, a perfume ingredient, and polyamide particles wherein the polyamide particles comprise at least either of the porous polyamide particles of the following (1) and (2) shows satisfactory shape retention on...

20060127426 - Cosmetic effervescent cleansing pillow with rupturable packet: A cleansing article is provided which includes an effervescent cleanser composition held within a rupturable packet and the packet is held within a porous receptacle. The effervescent cleanser composition is an intimate mixture of an acid material such as citric acid, an alkaline material such as sodium bicarbonate, and a...

20060127425 - Encapsulated material released to generate perceivable sensorial indicia of discrete event occurrence: Compositions (1) that provide a carrier (2) to covey a plurality of capsules (3) containing materials) (4) released to generate perceivable sensorial indicia discrete event occurrence and which can further provide perceivable sensorial reinforcers as incentives or disincentives to composition use coincident with such discrete events....

20060127431 - Regulation of mammalian hair growth: The present invention relates to a topical skin care composition containing a safe and effective amount of a skin care active comprising agmatine, and its salt; a safe and effective amount of a first additional skin care active selected from the group consisting of BHT or BHA, hexamidine, cetyl pyridinium...

20060127427 - Surface coated abrasive material for cosmetic products: Composite particle comprising a water-soluble abrasive material or core and a shell comprising a coating which is substantially insoluble in aqueous media during storage and prior to use but which becomes substantially water soluble upon activation prior to or during use. Activation may include application of substantially large quantities of...

20060127429 - Topical numbing composition for laser therapy: A method for decreasing patient discomfort and anesthetizing the skin of a patient for a dermatologic laser procedure is described. A composition is also described for topical administration of at least one anesthetic agent to the skin of a patient prior to dermatologic laser application....

20060127434 - Pest-combating compositions comprising soy methyl ester: A pest-combating composition including soy methyl ester, and methods of combating pests utilizing same. Such composition in a preferred formulation may also include 2-undecanone. The composition may be constituted as a spray composition, lotion, paste, or other compositional form. Pests that may be usefully combated with such composition include mosquitoes,...

20060127432 - Surface treatment for wood and wood products: The invention provides methods and apparatus for the surface treatment of wood using synthetic pyrethroids such as bifenthrin as well as wood products made using those surface treatments....

20060127435 - Sustained release pest control products and their applications: A method for applying a barrier to a structure to prevent the infiltration of pest species includes providing a composition and associating the coating composition with the structure. The composition is formed from a polymer component having dispersed therein beads formed from colloidal clay and adsorbed pest control agent. Colloidal...

20060127436 - System for trapping flying insects with attractant lures: The present application discloses a system for trapping flying insects, utilizing carbon dioxide in conjunction with one or more biochemical lures, visual lures or both. Preferably, a biochemical lure such as lactic acid, a salt of lactic acid, or combinations thereof, are employed in particular geometric shapes contained in specifically...

20060127433 - Wood-plastic composites: The present invention is an improved wood-plastic composite (WPC) produced from a mixture comprising, wood particles, plastic, and optionally additives. The WPC of the invention further comprises an active ingredient that acts as a biocide. The active ingredient comprises TBBA or a homologue or derivative thereof and is added to...

20060127438 - Compositions and methods for coating medical implants: Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant....

20060127440 - Drug delivery systems for the prevention and treatment of vascular diseases: Provided are drug delivery systems for the prevention and treatment of proliferative diseases, particularly vascular diseases, comprising rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents....

20060127439 - Medical assembly suitable for long-term implantation and method for fabricating the same: A process for fabricating a medical assembly having a medical device at least a portion of which is formed of inorganic material is provided. The medical assembly is suitable for substantially long-term implantation in a host animal. The process includes modifying a surface of the medical device to form a...

20060127437 - Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids: A semisolid system and combination semisolid, multiparticulate system for controlling biological fluids is provided which includes a body fluid control composition. The body fluid control composition is adapted for utilization both as an independent mixture for direct topical application to body tissue for human or veterinary application and for incorporation...

20060127444 - Antibiotic/s containing bone substitute material with sustained active substance release: Antibiotic/s containing bone substitute material is described which is characterized in that it is composed of a compacted mixture of granules of calcium sulfate dihydrate, calcium carbonate and at least one representative of the aminoglycoside antibiotics, lincosamide antibiotics, glycopeptide antibiotics, macrolide antibiotics, ketolide antibiotics, the nitroimidazoles, the fluorochinolone antibiotics and...

20060127441 - Device for stimulating the female sexual organ, packaging and dispensing member: The invention relates to a device for stimulating the female sexual organ, comprising: a carrier provided with fixing means, for fixing the carrier on the male sexual organ, and a preparation for stimulating the blood flow through a body part exposed to the preparation, wherein the preparation is combined with...

20060127443 - Medical devices having vapor deposited nanoporous coatings for controlled therapeutic agent delivery: The present invention is directed to medical devices which comprise the following: (a) an underlying region that comprises a therapeutic agent and (b) a vapor deposited nanoporous coating (e.g., a polymeric, ceramic or metallic nanoporous coating) over the underlying region, which regulates the release of the therapeutic agent from the...

20060127442 - Use of supercritical fluids to incorporate biologically active agents into nanoporous medical articles: The present invention is directed to a method in which a supercritical fluid that comprises a carrier fluid and a biologically active agent is brought into contact with medical article that comprises a nanoporous surface region. A variety of medical articles may be used in the practice of the present...

20060127445 - Anti-angiogenic compositions and methods of use: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions....

20060127446 - Apparatus and method for delivering controlled quantities of one or more agents to the eye: A flat strip of supporting material, such as filter paper, having marked reference locations on each of one or more legs, for delivering controlled quantities of one or more agents to the adnexa of the eye simultaneously upon dispensing a liquid to the strip at the appropriate reference location....

20060127450 - Composition containing higher fatty acid derivative and foods and drinks: An object of the invention is to provide a composition containing a higher fatty acid derivative, which can be easily produced at low cost, is effective as an agent for prevention and treatment of osteoporosis induced by various factors such as diet, dietary restriction, etc., is highly safe, and can...

20060127449 - Method and composition for lowering cholesterol: Compositions and methods are provided for using natural waxes or wax sub-fractions to maintain healthy blood lipid profiles, illustratively by lowering total cholesterol, lowering LDL-cholesterol, raising HDL cholesterol, and/or lowering triglyceride levels. Compositions and methods are also provided to treat symptoms of metabolic syndrome, including weight gain....

20060127447 - Poly-gamma-glutamate having ultra high molecular weight and method for using the same: The present invention relates to a poly-gamma-glutamate (PGA) having an ultra-high molecular weight greater than 5,000 kDa. The ultra-high molecular weight PGA according to the present invention has a mean molecular weight greater than 13,000 kDa, and more than 95% of its molecules have a molecular weight ranging from 3,000...

20060127448 - Use of low-glycemic sweeteners in food and beverage compositions: There is described a process for preparing a food or beverage composition having sweetness and a low glycemic index that entails incorporating in the composition a low glycemic index product comprising sucrose and an acceptor selected from the group consisting of a sugar and a sugar alcohol having free hydroxyl...

20060127451 - Coating composition: The present invention is directed to compositions containing: (i) sugar and/or a sugar substitute and (ii) microcrystalline cellulose present in an amount equal to greater than 41% of the total weight of the composition. The present invention is also directed to compositions containing: (i) sugar and/or a sugar substitute and...

20060127452 - Method and composition for reducing cravings for a craved substance: Disclosed is a composition and method for reducing cravings for a craved substance, particularly foods, with preparations containing 5-hydroxytryptophan (5-HTP). The 5-HTP is added to the same or similar substance that is actually craved to reduce the craving for the craved substance while further satisfying the craving by consumption of...

20060127454 - Feed or food product composition: The present invention relates to a feed or food product composition which comprises a mixture of bovine colostrum, comprising bioactive components, and organic particulate matter having a size between 0.3 and 7 mm in diameter. The composition is especially adapted to deliver the mixture of bioactive bovine colostrum components to...

20060127453 - Nutraceuticals and method of feeding aquatic animals: A delivery vehicle for bioactive agents and live probiotic microbes to aquatic animals protects the bioactive compounds and microbes from digestion and destruction in the animal stomach. It provides for controlled release of bioactive agents and live probiotic microbes to aquatic animals in the form of dry or wet beadlets...

20060127455 - Optimized food for expressing luminescent proteins in animals: Animal food comprises material which improves and/or optimizes the expression of luminescent proteins in animals. The animals may naturally express luminescent proteins or they may be transgenic animals transfected with a non-endogenous luminescent gene. The animal has a predetermined proteome and the luminescent protein has a predetermined composition of amino...

20060127457 - Fabrics impregnated with antimicrobial agents: The present invention provides an antimicrobial fabric comprising a fibrous material treated with an antimicrobially effective amount of an antimicrobial agent. The present invention further provides a method for preparing an antimicrobial fabric that exhibits antimicrobial properties comprising admixing an antimicrobially effective amount of an antimicrobial agent with a fibrous...

20060127456 - Novel fiber-based consumer products based on new concepts of fiber modification: Concepts for development of potentially useful fiber-based consumer products are documented. The concepts include: 1. Products in which complexes of polyvinylpyrrolidone (PVP) with iodine and/or phenol are incorporated into the fiber matrix. 2. Products in which a hydrophilic polymer such as hyaluronic acid (HYA) is deposited on the fiber's surface...

20060127458 - Single use personal care sheet: The invention relates to a single use cleansing sheet comprising: (a) a first fibrous water soluble polymer; (b) a second fibrous water soluble polymer which is different from said first fibrous water soluble polymer; wherein the ratio of (a) and (b) is effective to provide a cleansing sheet which wets...

20060127459 - Urogenital infection inhibition: There is provided compositions and methods to inhibit the adherence of pathogenic microorganisms to cells. The composition includes water soluble PEO/PEG polymers which may be hydrophilic or amphiphilic block copolymers. One example of a suitable composition is polyethylene glycol or polyethylene oxide with a chemical formula of H—(OCH2CH2)n-OH. Another example...

20060127460 - Trombin-carrying bioabsorbable synthetic nonwoven fabric: A safe and effective hemostatic is provided. The invention relates to a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient and a hemostatic comprising said bioabsorbable synthetic nonwoven fabric. The bioabsorbable synthetic nonwoven fabric holding thrombin in accordance with the present invention may be prepared by a process...

20060127462 - Wound care device having fluid transfer properties: This disclosure relates to wound care devices which are capable of one-way, directional flow of fluids and contaminants away from the wound site to the opposite side of the wound care device, which functions as a fluid reservoir. This fluid transport mechanism generally aids in reducing wound maceration by removing...

20060127461 - Wound dressings containing an enzyme therapeutic agent: The invention provides a wound dressing or implant comprising an enzymatic compound or reagent that is effective to reduce the concentration of lactate in an aqueous solution in contact with the dressing. Preferably, the compound is a lactate oxidase enzyme that converts lactate present in wound fluid as a consequence...

20060127463 - Composite structure including a low vinyl acetate layer: A composite structure suitable for making transdermal delivery devices includes in sequence: (a) a liner film layer; (b) a containment layer having from zero to 15 wt % content of vinyl acetate repeating units, the layer including either a thermal bonding copolyester resin or a combination of an ethylene-vinyl acetate...

20060127464 - Female hormone-containing patch: Provided herein is a female hormone-containing patch wherein an active ingredient is highly soluble in a pressure-sensitive adhesive layer and the active ingredient is not adsorbed to a backing, and the patch per se can follow the irregularities on the skin surface or body movements. The patch is an external...

20060127465 - Pad base for transdermal administration and needle: The object of the present invention is to provide a pad base for endermism which hardly causes bad influence on organism even if a needle fractures in the skin and remains in the MicroPatch method. It is the pad base for endermism in which a minute needle 1 is installed...

20060127466 - Method for transdermal or intradermal delivery of molecules: The present invention provides a method for transdermal delivery of molecules. The method comprises the application of electrical pulses concurrently or sequentially with application of the molecules and a lipid composition comprising negatively charged liposomal compositions. The application of the liposomal components enhances permeability of the target site for delivery...

20060127468 - Methods and related compositions for reduction of fat and skin tightening: Compositions and methods useful in the reduction of localized fat deposits and tightening of loose skin in subjects in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent...

20060127469 - Methods of delivering stable topical drug compositions: A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature....

20060127467 - Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods: The present invention relates to lipid based nanoparticles or liposomes that are sensitive to ultrasonic energy, compositions containing these particles, methods for delivering one or more active agents using the particles, and methods for preparing the particles. The nanoparticles and liposomes encapsulate active agents such as chemotoxins, genes, virus vectors,...

20060127471 - Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy: Pharmaceutical pegylated liposomal formulations for photodynamic therapy are presented. The pegylated liposomal formulation provides therapeutically effective amounts of the photosensitizer for intravenous administration. At least one of the phospholipids in the liposomes has been linked with poly ethylene glycol (PEG) as an integral part of the phospholipids. The formed pegylated...

20060127470 - Use of buckysome or carbon nanotube for drug delivery: Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and...

20060127473 - Compositions and methods for stabilizing active pharmaceutical ingredients: The present invention relates to stable pharmaceutical compositions having an unstable active pharmaceutical ingredient....

20060127475 - Nateglinide-containing preparation: The present invention provides a small-sized preparation that is easy to take, containing 26% or more of nateglinide and 28% or more of at least one disintegrant selected from the group consisting of carmellose or salts thereof, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, partly pregelatinized starch and low-substituted hydroxypropyl cellulose,...

20060127474 - Pharmaceutical compositions comprising fluvastatin: Pharmaceutical compositions comprising fluvastatin, HPMC and optionally other pharmaceutical excipients which are colour-stable upon prolonged periods of storage....

20060127472 - Taste-masked prednisolone oral formulations: An improved taste-masked pharmaceutical prednisolone composition contains prednisolone sodium phosphate taste-masked with an effective taste-masking amount of rum ether....

20060127476 - Tranexamic acid formulations with reduced adverse effects: Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release...

20060127477 - Novel preparation and administration form comprising an acid-labile active compound: Novel administration forms and preparation for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in...

20060127478 - Oral dosage formulation: A multi-layer oral dosage form, preferably a tablet, comprising a matrix core comprising a therapeutically effective amount of a first drug (NSAID), wherein the matrix core allows sustained release of the first drug; a first layer, which is in contact with the matrix core, comprising a first portion of a...

20060127479 - Solvent free taste masked pharmaceutical compositions: A taste masked pharmaceutical composition comprising: (a) a core comprising a bitter tasting drug, such as cetirizine dihydrochloride; and (b) a coating comprising a pharmaceutically acceptable cationic co-polymer based on mono- or dialkylaminoalkyl methacrylate and neutral acrylic or methacrylic esters, wherein the alkyl group independently has 1 to 6 carbon...

20060127480 - Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof: A pharmaceutical excipient comprising a solid, reticulated matrix, wherein the matrix comprises an aggregation of inorganic particles in association with an organic polymeric material, defines a plurality of pores with a mean width in the range of about 0.01-500 m, and has a specific surface area of at least about...

20060127482 - Combination of immuno gene therapy & chemotherapy for treatment of cancer & hyperproliferative diseases: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection....

20060127481 - Ophthalmic drug delivery system using polymer micell: The current situation is such that it is difficult for drugs to reach posterior tissues of eyeball, such as choroid and retina, with the result that treating diseases in such regions is difficult. Thus, how to attain effective delivery of drugs is of importance. It has been found that effective...

20060127483 - Topical drug delivery system: The present invention relates to topical drug compositions and methods for topical drug delivery which promote stability of a drug component and facilitate the penetration of the drug component into the skin of the host. The invention also relates to topical drug compositions containing a suitable vasoactive agent, such as...

20060127487 - Antiviral compositions: The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and...

20060127485 - Bio-degradable colloid particles, in particular for pulmonary applications: The invention concerns a compound formed from a biologically degradable, water-soluble comb polymer based on a polyol backbone with side chains carrying amino groups, and, as a stabilizer, at least one negatively charged organic base, which can be a Lewis or Bronsted base, or its corresponding acid, which can be...

20060127486 - Ceramic structures for prevention of drug diversion: The present invention is directed to compositions that provide drug delivery while resisting methods of diversion. The compositions are combinations of the drug and a ceramic structure. Any suitable drug may be used, but the drug is typically an opioid agonist. The ceramic structures arc usually metal oxides, and are...

20060127484 - Controlled release composition: An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon...

20060127488 - Process of making flowable hemostatic compositions and devices containing such compositions: The present invention includes both sterilized and unsterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid phase, and a discontinuous, biocompatible gaseous phase, each of which...

20060127490 - Liquid core capsules and methods of synthesis thereof through interfacial polymerization: A process for the encapsulation of liquid particles within nanometer thick polymer shells utilizes an interfacial free radical alternating copolymerization process. Encapsulating a liquid material includes providing a mixture comprising the liquid material to be encapsulated, a hydrophobic monomer in a non-polar solution and a hydrophilic monomer in a polar...

20060127489 - Targeted delivery: An encapsulated product comprises a plurality of micro-capsules formed from a plurality of micro-organisms and having a lipophilic active encapsulated and passively retained within said micro-capsules. The lipophilic active is not being a natural constituent of the micro-organisms, and the micro-capsules has: (a) an at least substantially intact cell wall,...

20060127491 - Treatment and prevention of liver disease associated with parenteral nutrition (pn): The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty...

20060127493 - Composition for treating psoriasis: The present invention relates to a composition and methods or uses thereof in the prophylaxis and treatment of psoriasis and related disorders. The composition may be comprised of TGF-βl, TGF-β2, and a large proportion of dairy derived proteins....

20060127492 - Sustained improver of muscular fatigue: A long-acting improver of muscular fatigue characterized by comprising 4 kinds of amino acids made up of leucine, isoleucine, valine and glutamine, and a whey protein component (whey protein and/or decomposition product of whey protein). At least one of a whey protein isolate (WPI), a whey protein concentrate (WPC), β-lactoglobulin,...

20060127494 - Biologically active products: The present invention relates to dehydrated Type II collagen containing cartilage which has retained the collagen in its original crosslinked structure and which contains at least 40% by weight of the Type II collagen of an ionizable edible salt and which has a water content of less than 10%....

20060127495 - Method to treat collagenous connective tissue for implant remodeled by host cells into living tissue: The invention relates to a method of treatment of collagenous connective tissue removed from a donor for implant into a recipient which is re-habited or re-colonized by host cells without an immune rejection and inflammatory reaction. After removal from the donor, the tissue is trimmed and thereafter soaked in a...

20060127496 - L-histidine in ophthalmic solutions: The invention relates to an aqueous ophthalmic solution comprising 0.01 to about 1.0 percent by weight L-histidine; 0.01 to 0.0001 percent by weight hydrogen peroxide; 0.1 to 500 parts per million of a cationic polymeric preservative that provides superior preservative efficacy especially as against fungal microbes. These solutions may be...

20060127497 - Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide: An anti-microbial composition for providing a therapeutic application onto a living being. The composition includes from about 0.001 wt. % to about 0.20 wt. % chlorite compound and from about 0.001 wt. % to about 0.05 wt. % peroxy compound. The anti-microbial composition of the present invention is composed to...

20060127498 - Vitreous antimicrobial agent and antimicrobial product: The present invention relates to a vitreous antimicrobial agent that includes, relative to 100 mass % of total glass components, 0.1 to 2 mass % of Ag2O, 40.5 to 49 mass % of ZnO, 6 to 9.5 mass % of SiO2, 30.5 to 39.5 mass % of B2O3, 2 to...

20060127499 - Vitamin-mineral compositions: This invention provides compositions of vitamins and minerals used in the prevention and treatment of vitamin and mineral deficiency. These compositions provide a minimization of the intake dosage of vitamins and minerals while still meeting the nutritional daily requirements for these vitamins and minerals. At the same time, these compositions...

20060127500 - Zinc oxide in the form of an improved flow powder, method for the production and use thereof in polymers: A method is disclosed for atomizing an aqueous suspension of zinc oxygen compounds using a nozzle in a flow of hot air enabling a powder to be obtained, the Flodex index thereof being less than 15 and the compressibility index thereof being less than 20%. The powder is formed from...

20060127501 - Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs: Metal carbonyls are used to deliver CO to organs to limit post-ischaemic damage. The organ may be extracorporeal, e.g. for use in a transplant, or may be an isolated organ inside or attached to the body but isolated from the blood flow. The carbonyl preferably has one or more other...

20060127502 - Methods for inhibiting stat3 signaling in immune cells: Methods of enhancing antitumor activity of an immune cell comprising contacting the immune cell with a Stat3 inhibitor are described. Also described are methods of killing a tumor cell or inhibiting tumor growth in a subject comprising contacting an immune cell of the subject with a Stat3 inhibitor....

20060127503 - Compositions for treatment of inflammatory diseases: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or...

20060127504 - Medicament for treatment of cancer and other diseases: A medicament for treatment of cancer or other diseases by increasing cellular oxygenation is described wherein a composition of oils is used that provides a ratio of parent omega 6 to parent omega 3 that is greater than 1:1 and preferably within a range from about 1.1:1 to about 5:1....

20060127505 - Anti-inflammatory formulations: The invention features compositions and methods for reducing inflammation of ocular tissue by administering to an individual a mixture of ingredients containing carotenoid and a polyphenol compound....

20060127506 - Compositions of s-adenosyl-l-methionine: Compositions of S-adenosyl-L-methionine with additives are disclosed....

20060127507 - Agent for increasing granulocyte macrophage colony stimulating factor: The provision of a GM-CSF increasing agent or a TNF-α modulator, which is a composition comprising Cucurbita moschata, Carthamus tinctorius, Plantago asiatica and Lonicera japonica; or a health food, nutritional supplementary food, or the like for increase of GM-CSF, and the prevention of Crohn's disease and the like, and the...

20060127508 - Preparation for the relief of disease: A composition including (a) a Platelet Activating Factor (PAF) Inhibitor and (b) an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity. The composition is useful for the treatment or the relief of inflammatory diseases, thrombosis, cardiac problems, and/or conditions caused by platelet induced blood clotting....

20060127509 - Methods of reducing beta-amyloid polypeptides: The invention features methods of reducing the level of a β-amyloid (Aβ) polypeptide using an Cimicifuga extract. The invention also features methods of producing an active fraction from an extract of Cimicifuga. The invention further features a composition containing an active fraction of a Cimicifuga extract and an article of...

20060127510 - Harvesting and pelletizing yew biomass for extraction of taxanes and other natural products: A process for harvesting yew biomass and a process of making Yew pellets from Yew tree material is disclosed herein. The process for harvesting comprising the steps of (i) harvesting the tops or roots of the Yew tree; (ii) washing the harvested material; (iii) drying the harvested material; and (iv)...

20060127511 - Modulation of inflammation by hops fractions and derivatives: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops....

20060127512 - Modulation of inflammation by hops fractions and derivatives: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops....

20060127516 - Modulation of inflammation by hops fractions and derivatives: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops....

20060127513 - Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments...

20060127514 - Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments...

20060127515 - Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments...

20060127517 - Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments...

20060127518 - Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion: This invention relates to a biological preparation, especially Nocardia Rubra cell wall skeleton preparation. After cultivating, collecting thallus, cell fragmentation, purifying enzyme, removing the grease, the final preparation containing Nocardia Rubra cell wall skeleton is obtained by dispensing, lyophilizing and filling. The invented preparation has marked effect to adaptable diseases,...

20060115424 - Combination therapy of oxaliplatin and radioactively doped particles treating cancer: A method of treating cancer in a patient comprising administering to the patient an amount of oxaliplatin in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have a synergistic anticancer effect....

20060115427 - Diagnosis and assessment of skeletal related disease using calcium 41: A method of determining calcium metabolism in a patient comprises the steps of administering radioactive calcium isotope 41Ca to the patient, allowing a period of time to elapse sufficient for dissemination and reaction of the radioactive calcium isotope 41Ca by the patient, obtaining a sample of the radioactive calcium isotope...

20060115426 - Methods of detecting breast cancer, brain cancer, and pancreatic cancer: The present invention discloses methods for detecting breast cancer, brain cancer, and pancreatic cancer via nuclear imaging using certain phospholipid ether analogs....

20060115425 - Substituted amides: The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes...

20060115428 - Identification and characterization of function-blocking anti-ed-b-fibronectin antibodies: The invention relates to recombinant polypeptides, in particular antibodies or antibody fragments that bind Ed-B-isoforms of fibronectin and can block their function. In addition, the diagnostic and pharmaceutical application of the polypeptides according to the invention is disclosed....

20060115429 - Biological systems analysis: Disclosed are methods for the practice of systems pharmacology, systems toxicology, and systems pathology using patterns, such as images, reflective of the biological state of subjects such as humans or experimental mammals. The patterns are generated from data obtained from one or more samples from one or more subjects by...

20060115430 - Calcium challenge test for detecting calcium homeostasis disorders: The invention provides simple methods for detecting disorders of a subject's calcium homeostasis. The methods include administering a calcium salt to the subject and observing the effect of this dose of calcium on calcium levels in the subject's bodily fluids and/or tissues. The methods are useful to detect certain calcium...

20060115431 - Procedures of cellular labelling with paramagnetic complexes for mri applications: The present invention relates to paramagnetic complexes based on lantanides or transition metals administered in the form of particulates internalysed by cells and whose presence in the cells can be detected by MRI techniques....

20060115432 - New powdered inhalants based on modified lactose mixtures as excipient: The invention relates to a new process for preparing modified lactose mixtures, these lactose mixtures per se and compositions of medicaments for powder inhalation consisting of one or more micronised active substances and the modified lactose according to the invention....

20060115434 - Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same: A composition in the form of a chewing gum composition or a confectionery composition containing an encapsulated stain removing agent selected from anionic and non-ionic surfactants and methods of preparing and using the same to remove stains from dental material including teeth....

20060115433 - Compressed chewing gum: The invention relates to a compressed chewing gum tablet including a chewing gum center, the gum center including a compression of gum base granules and chewing gum additives. The chewing gum additives comprise sweeteners and flavors. At least a first part of the gum base granules have granules of flavor...

20060115435 - Dental toothpaste, solution, tablet and system with plaque color indicator and integrated decolorizing compound: Thoroughly cleaning teeth daily is indispensable for keeping human teeth healthy. However, plaque is generally not sufficiently removed because it is difficult to see. Conventional plaque-dyeing agents allow plaque to be seen easily but are complicated to apply and leave traces of dyes. A toothpaste includes an integrated plaque indicator...

20060115436 - Enzyme containing composition, process of producing said composition and its use: The present invention relates to a composition comprising at least one biologically active protease and at least one biologically active glycosidase wherein the proteases and the glycosidases are present in an activity ratio of from 1,000,000:1 to 1:1,000,000 and wherein the composition has a total enzyme activity of at least...

20060115437 - Dental whitening compositions: A whitening system has a de-sensitizing effect as well as re-mineralizing capability. The system may be a one-component or a two-component composition. The system may also be an unfoamed, a foamed or a foamable composition. For a one-component system, a sparingly soluble calcium phosphate salt may be in dry particle...

20060115438 - Cosmetic composition containing microcrystalline cellulose: A sprayable cosmetic composition is disclosed. In one aspect, the composition comprises a sunscreen agent or mixture of sunscreen agents; an emulsifier or mixture of emulsifiers; optionally an emollient or mixture of emollients; a rheology control agent; and water. The rheology control agent is microcrystalline cellulose. When sprayed on the...

20060115439 - Compositions containing at least one silicone resin and glass beads: Compositions containing at least one silicone resin and glass beads and methods of use thereof....

20060115440 - Silver dihydrogen citrate compositions: Personal care and home care compositions are disclosed, which include silver dihydrogen citrate. The inventive compositions advantageously take the form of suspensions, pastes, liquids and gels. The inventive compositions also optionally comprise additional ingredients, and are therefore suitable for a wide variety of personal, home and industrial care purposes....

20060115441 - Underarm cosmetic method and compositions: A method of inhibiting skin darkening whilst inhibiting perspiration in the underarm which comprises incorporating into a antiperspirant composition comprising an astringent salt comprising an aluminium and/or zirconium salt, a triglyceride oil and optionally an active acid comprising an aliphatic dicarboxylic acid, especially C6-C12 such as azelaic acid, an unsaturated...

20060115442 - Facial cleansing composition: A facial cleansing composition is provided which includes the following ingredients: polyolefinic abrasive particles; a cationic surfactant; water; a hydrophobically modified cellulosic thickener; a water-soluble conditioning agent; a water-insoluble conditioning agent; and wherein the composition has a viscosity ranging from about 20,000 to about 200,000 cps....

20060115447 - Hair care formulations: This invention relates to hair conditioning formulations comprising at least one aminofunctional polyorganosiloxane. Furthermore, the invention relates to the use of these formulations for the treatment of keratin-containing fibers, preferably human hair....

20060115443 - Cosmetic composition of two polysaccharides based on fucose and rhamnose: The invention relates to a cosmetic composition of two polysaccharides based on fucose and rhamnose, and to the use of the same especially in topically applied products which are used to act on cutaneous, epithelial and conjunctive tissue, especially for cosmetic anti-ageing effects....

20060115445 - Compositions for treating keratin materials comprising electrophilic monomers and liquid crystal agents: Disclosed herein is a cosmetic composition for treating keratin materials, for example, keratin fibers such as the hair, comprising, in a cosmetically acceptable medium, at least one electrophilic monomer and at least one liquid crystal agent. Also disclosed is a method for cosmetically treating keratin materials comprising applying the cosmetic...

20060115444 - Glossy liquid composition comprising a sequenced polymer: The present invention relates to a liquid cosmetic composition containing a cosmetically acceptable organic liquid medium and a non-elastomeric film-forming linear ethylenic block polymer in a sufficient amount such that the mean gloss of a deposit of the composition, once spread onto a support, is greater than or equal to...

20060115446 - Thickened hair composition comprising at least one high-molecular-weight polyurethane: The present disclosure relates to a hair cosmetic composition, such as a gel, comprising at least one high-molecular-weight polyurethane polymer and at least one thickener. The present disclosure also relates to a hair cosmetic method comprising the application of said composition to the hair and its use to fix and/or...

20060115449 - Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings: This document discloses a family of tyrosine carbonate polymers and polymer mixtures that may contain bioactive or biobeneficial polymers or constituents. Methods of making these polymers and mixtures are disclosed, as well. Also, implantable or partially implantable medical devies constructed with or from these polymers are disclosed....

20060115448 - Amphiphilic polynorbornene derivatives and methods of using the same: Polynorbornene derivatives exhibiting antibacterial activity and low hemolytic activity are described herein. Antimicrobial compositions and pharmaceutical compositions comprising polynorbonene derivatives and methods of using the same are also described. Such compositions, which exhibit substantial antibacterial activity and low hemolytic activity, may be suitable for material applications and therapeutic uses....

20060115450 - Polyalkylene glycol derivative and modified bio-related substance: l

20060115451 - Modified cytokines for use in cancer therapy: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents....

20060115452 - Uses of interleukin-18 for treating skin disorders associated with uv radiations: The present invention relates to uses of interleukin-18....

20060115453 - Methods and compositions for treating cellular proliferative diseases: The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, screening assays for identifying such compounds, and methods for treating such disorders....

20060115456 - Replication-competent adenoviral vectors: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes....

20060115455 - Therapeutic rnai agents for treating psoriasis: The present invention provides compositions and methods suitable for delivering RNAi agents against genetic targets in skin tissues so as to treat psoriasis....

20060115454 - Therapeutic rnai agents for treating restenosis: The present invention provides compositions and methods suitable for delivering RNAi agents against genetic targets in vascular and adjacent tissue in vivo so as to treat restenosis....

20060115461 - Apparatus and system having dry gene silencing compositions: A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least a first siRNA which...

20060115460 - Compositions and methods comprising wnt proteins to promote repair of damaged tissue: Compositions and methods for treating damaged tissue are provided herein....

20060115462 - Direct dna delivery to bone cells: An method is described that enables in vivo delivery of polynucleotides to cells of a mammalian bone limb. The method involves the injection of polynucleotides in a large volume into the lumen of the bone....

20060115463 - Mixed-cell gene therapy: The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been...

20060115464 - Use of cardiotrophin to modulate stem cell proliferation: Methods of promoting stem cell proliferation by contacting the cells with cardiotrophin-1 (CT-1) are provided. The methods may further include contacting the stem cells with one or more stem cell modulators that promote differentiation of the stem cells. Methods of inhibiting stem cell proliferation by contacting the cells with one...

20060115465 - Treatment of gastrointestinal disorders: The present invention relates to the use of a therapeutic or nutraceutical composition for the treatment of a gastrointestinal disorder, namely ulcerative colitis. In addition, the present invention provides methods of treating subjects suffering from gastrointestinal disorders such as ulcerative colitis....

20060115457 - Biocompatible hydrogel compositions: Compositions, instruments, systems, and methods are providing for creating families of materials having diverse therapeutic indications and possessing enhanced biocompatibility. One genus platform for the families includes a biocompatible synthetic electrophilic component mixed with a nucleophilic component. The electrophilic component can include a functionalized electrophilic poly (anhydride ester) material. The...

20060115458 - Material for repairing biological tissues, product for repairing biological tissues, and method of manufacturing material for repairing biological tissues: Osteoblast activity is promoted and a large amount of extracellular substrates are produced so as to promote cell proliferation and/or differentiation. A material for repairing biological tissues, the material comprising a biocompatible material containing at least one of niobium and tantalum, is provided. These metal salts are not toxic even...

20060115459 - Sickle cell anemia treatment: This patent is an evolution of U.S. Pat. No. 4,216,770 named “sickle cell therapeutic treatment”. That patent is one in which blood is taken out of the subject and treated with anti-sickling agents which are then washed out. In this application blood is removed from a subject and instead filtered...

20060115466 - Quenching methods for red blood cell inactivation process: Methods are provided for improved quenching of undesired side reactions upon treating a red blood cell composition with a pathogen inactivating compound comprising a nucleic acid binding ligand and a functional group which is, or which is capable of forming, an electrophilic group. In some embodiments, the improved methods use...

20060115467 - Compositions and methods for the treatment of autism: Compositions that may be usefully employed to alleviate symptoms resulting from deficiencies in carbohydrate enzymes, together with methods for the treatment of disorders that are characterized by such deficiencies, such as autism, are provided. The compositions preferably comprise transglucosidase isolated from A. niger....

20060115468 - Dietary supplement for treating and preventing gastrointestinal disorders: A dietary and vitamin supplement, in capsule or powder form, for enhancing and maintaining digestive health and colon care, and alleviating gastrointestinal disorders, includes a blend of natural ingredients, including acidophilus, digestive enzymes and antioxidants, and which can be taken on an as-needed basis, in either capsule or liquid form,...

20060115469 - Interstitial collagenase molecular motor: A novel interstitial collagenase is disclosed which acts as an ATP-independent molecular motor driven by the proteolysis of substrate collagen. Also disclosed is a method of reacting interstitial collagenase with a collagen fibril to encounter multiple cleavage sites without substantial dissociation of said interstitial collagenase and thereby act as a...

20060115470 - Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders: The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method...

20060115471 - Treatment of disease with antibodies against high molecular weight kininogen domain 5: Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis....

20060115474 - Ligands for use in therapeutic compositions for the treatment of hemostasis disorders: The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is...

20060115473 - Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists: Methods of, and compositions for, treating central nervous system injury with an antagonist of an alpha4 subunit containing integrin are described....

20060115472 - Stabilizing formulations: Formulations are described that are suitable for storage of proteins, such as antibodies, over a relatively broad range of protein concentrations, pH, and buffer types. Also described are methods of storing a protein and methods of identifying a suitable formulation for storage of a specific protein. In general, a formulation...

20060115475 - Toll like receptor 3 antagonists, methods and uses: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed....

20060115476 - Antibodies anti-c5 component of the complement system and their use: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies...

20060115478 - Compositions and methods for treating and preventing type-1 diabetes: The present invention relates generally to the use of compounds, compositions, combinations, kits, and methods for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes....

20060115477 - Neuropilin-1 inhibitors: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or...

20060115480 - Disease treatment via antimicrobial peptide inhibitors: A method of treating a disease in a subject in need thereof is disclosed. The method comprises providing to the subject a therapeutically effective amount of a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the...

20060115479 - Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof: The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence...

20060115484 - Apo-2 receptor: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided....

20060115483 - Fibroblast growth factor receptors and methods for their use: Isolated fibroblast growth factor receptor 5 (FGFR5) polypeptides are provided, together with polynucleotides encoding such polypeptides. Also provided are modulators of FGFR5 gene expression and binding molecules that specifically bind to, and agonize or antagonize, FGFR5 polypeptide function. Binding molecules include antibodies, and functional fragments thereof, as well as scFv...

20060115481 - Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for gvhd in allogeneic antitumor cell therapy: The present invention refers to a method of treating tumor growth and metastasis in a mammal, said treating comprising administering allogenic effector cells together with trifunctional bispecific or trispecific antibodies or a combination thereof having the following properties: a) binding to a T cell b) binding to at least one...

20060115482 - Modifications of histone proteins as indicators of cell proliferation and differentiation: The invention provides a method of a method of characterizing the proliferative state of cells in a biological sample based on detecting transcription factor-mediated phosphorylation of histone H2B (H2B) at residue 36 (numbered according to human H2B). This method optionally includes detection of transcription factor-mediated acetylation of histone H3 (H3)...

20060115485 - Methods of preventing and treating rsv infections and related conditions: The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as...

20060115486 - Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express...

20060115487 - Allogeneic cellular immunotherapy for invasive pulmonary aspergillosis (ipa): A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion....

20060115488 - Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections: The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV...

20060115489 - Influenza immunogen and vaccine: A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (HBc) protein is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza sequence in two to four copies is preferably expressed at or near the N-terminus or in the HBc immunogenic loop...

20060115491 - Method to provide bacterial ghosts with antigens: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a...

20060115490 - Staphylococcus aureus proteins and nucleic acids: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics....

20060115492 - Pharmaceutical composition and health food comprising extract of phellinus sp. pl3 or phellinsin a isolated from the same as an effective component for prevention and treatment of cardiovascular disease: The present invention relates to a pharmaceutical composition and health food comprising Phellinus sp. PL3 extract or phellinsin A isolated from the same as an effective component. More particularly, the present invention relates to a pharmaceutical composition and health food comprising Phellinus sp. PL3 extract or phellinsin A isolated from...

20060115493 - Bacterial packaging strains useful for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof: Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to...

20060115494 - Recombinant bcg strains with attenuated immunosuppressive properties: Strains of Mycobacterium that have decreased immunosuppressive properties are provided. The Mycobacterium strains are genetically engineered to express but not secrete super-oxide dismutase (Sod). The presence of cytosol bound Sod allows replication and growth of the Mycobacterium, but does not result in attenuation of the host immune response. The Mycobacterium...

20060115495 - Protein-noble metal nanoparticles: The present invention is a composition and method of making protein-noble metal nanoparticles and methods for using the same as anti-virals....

20060115496 - Toxoplasma gondii proteins, nucleic acid molecules, and uses thereof: The present invention relates to immunogenic Toxoplasma gondii proteins, to T. gondii nucleic acid molecules, including those that encode such proteins and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules and antibodies. Also included in the present invention are...

20060115497 - Mycobacterium strains with modified erp gene and vaccine composition containing same: The invention concerns Mycobacterium strains whereof the erp gene is modified and a vaccine composition containing same. The modification of the erp gene decreases the virulence and the persistence of the Mycobacterium strains....

20060115498 - Dna encoding an antigenic protein of eimeria apical membrane antigen 1 and use thereof: This invention provides a novel DNA for preventing avian coccidiosis and use thereof. The novel DNA encodes an antigenic protein of Eimeria apical membrane antigen 1, and is used for DNA vaccine and/or for vaccine comprising the recombinant protein deduced from the said DNA sequence as a main ingredient. The...

20060115499 - Liquid allergy vaccine formulation for oromucosal administration: Use of a composition comprising an allergen and an adjuvant selected from the group consisting of oxygen-containing metal salts for the manufacture of a liquid formulation for preventing or treating allergy in a subject by oromucosal administration, and a method of preventing and treating allergy in a subject by oromucosal...

20060115501 - Homogeneously formulating microdosed active principles: A microdose of at least one active principle is essentially homogeneously formulated within at least one excipient therefor, via the following steps: 1. weighing the at least one active principle in a receptacle lined with a petroleum jelly; 2. encapsulating the active principle with additional petroleum jelly; 3. introducing the...

20060115500 - Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent: This invention relates to a semisolid ophthalmic composition, in particular an ointment, comprising (1) an ophthalmic drug, e.g. a staurosporine derivative, (2) an ointment base and (3) an agent for dispersing and/or dissolving said drug in the ointment base, selected from a polyethylene-glycol), a polyethoxylated castor oil, an alcohol having...

20060115503 - Composition, system and method for treatment of skin: A skin care system and method for treating the signs of aging skin and treating, preventing, and controlling acne is described. The skin care system of the present invention can include combinations of a glycolic cleanser, glycolic scrub mask, glycolic lotion, skin lightening agent, corticosteroid cream, sunscreen and finishing product...

20060115502 - Cosmetic composition based on cirsimarin: The invention relates to the use of the active molecule of formula (I), wherein R═H or R=glucose, for the production of a composition used to activate lipolysis....

20060115504 - Cosmetic compositions comprising a fine and porous powder: an apparent specific surface of 1 to 299 m2/g, measured by nitrogen absorption according to the ISO 9277 BET method; a linseed oil absorption of between 45 g/100 g of powder and 160 g/100 g of powder, measured according to ISO 787-5. The mean diameter of the particles of the...

20060115505 - Safe, eco-friendly, health protective herbal colours and aroma useful for cosmaceutical applications: The invention relates to a novel safe and eco-friendly health protective and beauty enhancing herbal compositions having various cosmetic applications such as lipsticks, eye shadows, glow-glitters and rouges, said compositions containing colourants from plants of the family Boraginaceae, the invention also provides a method for preparing the said compositions. The...

20060115506 - Compositions and method of wood preservation: This invention provides a method for preserving wood by treating the wood with a composition comprising a dispersion of colloidal silica or colloidal alumina particles in a solvent and one or more organic biocides....

20060115507 - Synergistic and residual pesticidal compositions containing plant essential oils with enzyme inhibitors: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective...

20060115508 - Synergistic and residual pesticidal compositions containing plant essential oils with enzyme inhibitors: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective...

20060115509 - Synergistic and residual pesticidal compositions containing plant essential oils with enzyme inhibitors: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective...

20060115510 - Synergistic and residual pesticidal compositions containing plant essential oils with enzyme inhibitors: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective...

20060115512 - Metallic structures incorporating bioactive materials and methods for creating the same: Disclosed herein are methods to create medical devices and implantable medical devices with an electrochemically engineered porous surface that contains one or more bioactive materials to form bioactive composite structures. The bioactive composite structures are prepared using electrochemical codeposition methods to create metallic layers with pores that can be loaded...

20060115511 - Porous structures, and methods of use: The present invention provides porous structures that each comprise chitosan, alginate and divalent metal cations, wherein: (a) the chitosan is ionically linked to the alginate; and (b) the structure is porous and has a compressive yield strength of at least 0.35 MPa. The present invention also provides methods for making...

20060115514 - Chelating and binding chemicals to a medical implant, medical device formed, and therapeutic applications: Chelating and binding chemicals to a medical implant, and therapeutic applications. Implantable metal chelated surface and chemical coated medical implant device—drug (or biological moiety) coated or drug eluting stent, prosthesis, or other, includes a medical implant component having metal surface (M) with chemical entity (X) bound via chelator (C) chelated...

20060115513 - Derivatized poly(ester amide) as a biobeneficial coating: A derivatized poly(ester amide) (D-PEA) and coatings and medical devices formed therefrom are provided. The coatings and medical devices may optionally include a biobeneficial material and/or a biocompatible polymer and/or a bioactive agent. The medical devices can be implanted in a patient to treat, prevent, or ameliorate a disorder such...

20060115515 - Biodegradable implant and method for manufacturing one: A biodegradable implant and a method for manufacturing one. The implant comprises a matrix component containing at least one biodegradable polymer or copolymer and a pyrrolidone plasticizer that is adapted to reduce the rigidity of the implant. The plasticizer substantially exits from the implant after coming into contact with tissue...

20060115516 - Copolymerizable methine and anthraquinone compounds and articles containing them: This invention relates to polymerizable ultraviolet light absorbers and yellow colorants and their use in ophthalmic lenses. In particular, this invention relates to polymerizable ultraviolet light absorbing methine compounds and yellow compounds of the methine and anthraquinone classes that block ultraviolet light and/or violet-blue light transmission through ophthalmic lenses....

20060115517 - Liquid seasoning: The present invention provides a liquid seasoning, which brings on a sufficient salty taste although it has a low sodium concentration, and which exhibits for example a pharmacological effect such as an antihypertensive effect at a high level. The present invention relates to a liquid seasoning, which contains the following...

20060115518 - Liquid seasoning: The present invention provides a liquid seasoning, which brings on a sufficient salty taste although it has a low common salt concentration, and which exhibits for example a pharmacological effect such as an antihypertensive effect at a high level. The present invention relates to a liquid seasoning, which contains the...

20060115520 - Fluid application device and method: The present invention provides a device and a method for application of fluids....

20060115519 - Stretch tape: The stretch tape of the present invention for eyelid facelifting is stuck in between eyes and near both inner corners of eyes, or beside and near the outer corner of each eye, enabling facelifting which makes the eyes look slitter and brighter by stretching the skins of eyelids by the...

20060115521 - Materials, methods and apparatus for treating a body cavity: Materials, methods and apparatus for treating a body cavity. The present invention relates to materials, methods and apparatus for treating a body cavity or passageway. In particular, the invention relates to materials, methods and apparatus for treating a body cavity which has been subjected to some sort of trauma, such...

20060115522 - Pharmaceutical composition: A patch, or patch forming composition, comprising at least one immunosuppressant, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, together with a pharmaceutically acceptable carrier or excipient therefor, formulated for delivery of said least one immunosuppressant, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof...

20060115523 - Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal: This invention relates to a composition containing a sterically stabilized liposome and triamcinolone, effective for the treatment of a mammal, with the composition being adapted for administration as an aerosol and with the composition providing effective treatment for a period of time at least 1.5 times as long as the...

20060115524 - Method for preparation of an agglomerate using melt agglomeration: Melt agglomeration for the preparation of an agglomerated material is performed us-ing a vehicle that can be melted at a suitable temperature, an active compound and silicon dioxide as filler. Using silicon dioxide as a filler in melt agglomeration has the benefit that a high ratio of melt to filler...

20060115525 - Pharmaceutical compositions: The present invention provides a solid composition for oral administration comprising: (i) a drug compound; (ii) chitosan or a derivative thereof or a salt of chitosan or salt of a derivative of chitosan; and (iii) an organic acid. Preferably the drug compound is a polar molecule having a molecular weight...

20060115526 - Venlafaxine compositions comprising pellets with double layer coating: This invention provides coated pellets comprising a) a pellet core which comprises venlafaxine hydrochloride; b) a first coating which comprises a lipophilic layer or a sparingly water-soluble layer, and c) a second coating which comprises a water-insoluble polymer or polymer mixture. In another aspect this invention provides compositions which comprises...

20060115527 - Controlled release preparation: Controlled release preparations and capsules are provided. Also provided are emulsions and suspensions, including compositions and methods of manufacturing controlled release capsules, where the fill contains a suspension and/or an emulsion....

20060115529 - Fast-melting tablets having taste-masking and sustained release properties: Fast-melting tablets contain particles of an active ingredient and ion-exchange resin complex to mask unpleasant taste associated with the active ingredient. The resin complex particles can be coated or uncoated to impart sustained release properties to the active ingredient. A fast-melting tablet also comprises a dry binder and bulk diluent...

20060115528 - Rapidly disintegrating tablet: The present invention relates to rapidly disintegrating tablets intended to be used as orodispersible tablets or dispersible tablets. They are ingested either by dispersing directly in the mouth or in water. The tablets include silicified microsrystalline cellulose. They are especially suitable for antibiotics. These tablets are also suitable for use...

20060115530 - Gastric acid secretion inhibiting composition: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in...

20060115531 - Protein-based polymer tissue adhesives for medical use: Tissue adhesives formed by crosslinking albumin and/or gelatin with certain polyamines and/or polycarboxylates using a water-soluble carbodiimide are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; drug...

20060115532 - Bioadhesive delivery system for transmucosal delivery of beneficial agents: Formulations and methods for transmucosal delivery of a beneficial agent are described in which a pH-responsive component and a temperature-responsive component are combined and applied to a mucous membrane. The temperature-responsive component is a component that, in aqueous solutions, is capable of undergoing a temperature-dependent sol to gel phase transition....

20060115533 - Pharmaceutical compositions: A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium....

20060115536 - Glycerin based synthesis of silver nanoparticles and nanowires: The present invention includes compositions and methods for the production of noble metal nanoparticles and nanowires conjugated to polyols or polymers. The present invention allows the incorporation of noble metal nanoparticles to a wide range of products such as body care products to exploit the biocidal properties of silver nanoparticles...

20060115535 - Method for formation of micro-prilled polymers: A method for formation of micro-prilled poloxamer particles is disclosed. The particles find special use in pharmaceutical formulations. The process involves use of atomizing nozzles at higher than normal pressure atomizing gas, high atomizing gas temperature, use of high feed temperatures to reduce the viscosity of the poloxamer and optionally...

20060115537 - Nanoparticles for targeting hepatoma cells: A dual-particle tumor targeting system comprising a first ligand-mediated targeting nanoparticle conjugated with galactosamine and a second EPR-mediated targeting nanoparticle, wherein said first and second nanoparticles are mixed in a solution configured for delivering to a target liver tumor....

20060115534 - Process for the manufacture of powderous preparations of fat-soluble substances: In a process for the manufacture of beadlet preparations of fat-soluble substances in a water-soluble or water-dispersible non-gelling matrix, an aequeous emulsion of the fat-soluble substance(s) and the matrix component are fed through a spray nozzle in the upper section of a vertical spray tower. Through separate inlets powderous starch...

20060115538 - Calcium lactate and whey permeate for lowering the triglyceride level: Disclosed is the combined use of calcium lactate and whey permeate for the prophylaxis or treatment of hypertriglyceridemia and/or symptoms thereof....

20060115539 - Micropellets method for the production thereof, and use thereof: A method for producing micropellets formed of materials that is not easily water soluble, that are provided in the form of a solid dispersion is provided, as well as micropellets which are obtained according to the method, pharmaceutical formulations which contain the micropellets, and the use of micropellets for the...

20060115540 - Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient: (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or its salt shows a potent bladder relaxation effect in “isolated rat bladder smooth muscle relaxation test”, dose-dependently lowers the contraction frequency of rhythmic bladder contractions in “rat rhythmic bladder contraction measurement test” and, moreover, prolongs the urination intervals in “urination functions measurement test on cyclophosphamide-induced overactive...

20060115541 - Treatment of bladder conditions: Treatment of bladder conditions is disclosed...

20060115542 - Therapeutic delivery of carbon monoxide: Metal carbonyls are used to deliver CO having biological activity, for example vasodilatation and inhibition of transplant rejection. The metal of the carbonyl is typically of groups 7 to 10, e.g. Fe and Ru. The carbonyl preferably has one or more ligands other than CO, such as amino acids, to...

20060115543 - Anti-diabetic extract isolated from rauvolfia vomitoria and citrus aurantium, and method of using same: This invention provides a process for extracting a pharmaceutically active fraction from the foliage (leaves and stems) and/or roots of Rauvolfia vomitoria and the fruit of Citrus aurantium. In one aspect, the process requires extracting from a boiled tea of Rauvolfia vomitoria foliage and/or roots and Citrus aurantium fruit an...

20060115544 - Method and composition for the treatment of muscular-skeletal and related afflictions: A method for treating musculoskeletal problems by applying a topical composition to a skin surface adjacent the musculoskeletal problem, the topical composition consisting essentially of herbal extracts in a water based synthetic gel and periodically repeating the step of applying as necessary for treatment of the musculoskeletal problem. The water...

20060115545 - Methods and means for the manufacture of hyaluronan: The present invention relates to plant cells and plants which synthesize hyaluronan and to methods for preparing such plants, and also to methods for preparing hyaluronan with the aid of these plant cells or plants. Furthermore, the present invention relates to the use of plants for preparing hyaluronan and to...